0001731348 Tilray Brands, Inc. false --05-31 Q3 2025 0.0001 0.0001 1,416,000,000 1,416,000,000 983,372,617 983,372,617 831,925,373 831,925,373 0.0001 0.0001 10,000,000 10,000,000 0 0 0 0 9,619,421 0 http://www.tilray.com/20250228#OperatingAndFinanceLeaseLiabilityCurrent http://www.tilray.com/20250228#OperatingAndFinanceLeaseLiabilityCurrent http://www.tilray.com/20250228#OperatingAndFinanceLeaseLiabilityCurrent http://www.tilray.com/20250228#OperatingAndFinanceLeaseLiabilityCurrent http://www.tilray.com/20250228#OperatingAndFinanceLeaseLiabilityNoncurrent http://www.tilray.com/20250228#OperatingAndFinanceLeaseLiabilityNoncurrent http://www.tilray.com/20250228#OperatingAndFinanceLeaseLiabilityNoncurrent http://www.tilray.com/20250228#OperatingAndFinanceLeaseLiabilityNoncurrent 0 570,000 100,000 25,000 4,235 0 8 0 0 4 0 0 0 0 1,000 0 2 7,000 500 7,442 7,500 7,000 500 53,000 53,000 3 3 10 10 February 29, 2028 February 29, 2028 25,000 25,000 1.00 1.00 5 5 15 15 181 181 July 31, 2033 July 31, 2033 25,000 25,000 1.00 1.00 5 5 15 15 196 196 July 31, 2033 July 31, 2033 1,250 1,250 1.50 1.50 5 5 10 10 12 12 August 31, 2026 August 31, 2026 3,750 3,750 1.50 1.50 5 5 20 20 23 23 August 31, 2026 August 31, 2026 1,500 1,500 2.00 2.00 5 5 94 94 April 30, 2025 April 30, 2025 3,500 3,500 4.59 4.59 5 5 52 52 August 31, 2028 August 31, 2028 22,635 22,635 1.5 1.5 10 10 57 57 69 69 October 31, 2030 October 31, 2030 90,000 90,000 5 5 875 875 2,250 2,250 June 30, 2028 June 30, 2028 5.20 5.20 5.25 5.25 5.20 5.20 5.25 6,209,000 5.95 1 1 983,372,617 0 4 4 2,621 0 0 100 4 0 0 0 0 0 0 0 false false false false 00017313482024-06-012025-02-28 xbrli:shares 00017313482025-04-04 thunderdome:item iso4217:USD 00017313482024-12-31 00017313482023-12-31 iso4217:USDxbrli:shares 00017313482024-12-012025-02-28 00017313482023-12-012024-02-29 00017313482023-06-012024-02-29 0001731348us-gaap:CommonStockMember2023-05-31 0001731348us-gaap:TreasuryStockCommonMember2023-05-31 0001731348us-gaap:AdditionalPaidInCapitalMember2023-05-31 0001731348us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-05-31 0001731348us-gaap:RetainedEarningsMember2023-05-31 0001731348us-gaap:NoncontrollingInterestMember2023-05-31 00017313482023-05-31 0001731348tlry:HexoAcquisitionMemberus-gaap:CommonStockMember2023-06-012023-08-31 0001731348tlry:HexoAcquisitionMemberus-gaap:TreasuryStockCommonMember2023-06-012023-08-31 0001731348tlry:HexoAcquisitionMemberus-gaap:AdditionalPaidInCapitalMember2023-06-012023-08-31 0001731348tlry:HexoAcquisitionMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-012023-08-31 0001731348tlry:HexoAcquisitionMemberus-gaap:RetainedEarningsMember2023-06-012023-08-31 0001731348tlry:HexoAcquisitionMemberus-gaap:NoncontrollingInterestMember2023-06-012023-08-31 0001731348tlry:HexoAcquisitionMember2023-06-012023-08-31 0001731348us-gaap:CommonStockMember2023-06-012023-08-31 0001731348us-gaap:TreasuryStockCommonMember2023-06-012023-08-31 0001731348us-gaap:AdditionalPaidInCapitalMember2023-06-012023-08-31 0001731348us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-012023-08-31 0001731348us-gaap:RetainedEarningsMember2023-06-012023-08-31 0001731348us-gaap:NoncontrollingInterestMember2023-06-012023-08-31 00017313482023-06-012023-08-31 0001731348us-gaap:CommonStockMember2023-08-31 0001731348us-gaap:TreasuryStockCommonMember2023-08-31 0001731348us-gaap:AdditionalPaidInCapitalMember2023-08-31 0001731348us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-08-31 0001731348us-gaap:RetainedEarningsMember2023-08-31 0001731348us-gaap:NoncontrollingInterestMember2023-08-31 00017313482023-08-31 0001731348us-gaap:CommonStockMember2023-09-012023-11-30 0001731348us-gaap:TreasuryStockCommonMember2023-09-012023-11-30 0001731348us-gaap:AdditionalPaidInCapitalMember2023-09-012023-11-30 0001731348us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-012023-11-30 0001731348us-gaap:RetainedEarningsMember2023-09-012023-11-30 0001731348us-gaap:NoncontrollingInterestMember2023-09-012023-11-30 00017313482023-09-012023-11-30 0001731348tlry:TilrayBrandsIncMedipharmHexoLitigationSettlementMemberus-gaap:CommonStockMember2023-09-012023-11-30 0001731348tlry:TilrayBrandsIncMedipharmHexoLitigationSettlementMemberus-gaap:TreasuryStockCommonMember2023-09-012023-11-30 0001731348tlry:TilrayBrandsIncMedipharmHexoLitigationSettlementMemberus-gaap:AdditionalPaidInCapitalMember2023-09-012023-11-30 0001731348tlry:TilrayBrandsIncMedipharmHexoLitigationSettlementMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-012023-11-30 0001731348tlry:TilrayBrandsIncMedipharmHexoLitigationSettlementMemberus-gaap:RetainedEarningsMember2023-09-012023-11-30 0001731348tlry:TilrayBrandsIncMedipharmHexoLitigationSettlementMemberus-gaap:NoncontrollingInterestMember2023-09-012023-11-30 0001731348tlry:TilrayBrandsIncMedipharmHexoLitigationSettlementMember2023-09-012023-11-30 0001731348tlry:TLRY23Memberus-gaap:CommonStockMember2023-09-012023-11-30 0001731348tlry:TLRY23Memberus-gaap:TreasuryStockCommonMember2023-09-012023-11-30 0001731348tlry:TLRY23Memberus-gaap:AdditionalPaidInCapitalMember2023-09-012023-11-30 0001731348tlry:TLRY23Memberus-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-012023-11-30 0001731348tlry:TLRY23Memberus-gaap:RetainedEarningsMember2023-09-012023-11-30 0001731348tlry:TLRY23Memberus-gaap:NoncontrollingInterestMember2023-09-012023-11-30 0001731348tlry:TLRY23Member2023-09-012023-11-30 0001731348us-gaap:CommonStockMember2023-11-30 0001731348us-gaap:TreasuryStockCommonMember2023-11-30 0001731348us-gaap:AdditionalPaidInCapitalMember2023-11-30 0001731348us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-11-30 0001731348us-gaap:RetainedEarningsMember2023-11-30 0001731348us-gaap:NoncontrollingInterestMember2023-11-30 00017313482023-11-30 0001731348tlry:APHA24Memberus-gaap:CommonStockMember2023-12-012024-02-29 0001731348tlry:APHA24Memberus-gaap:TreasuryStockCommonMember2023-12-012024-02-29 0001731348tlry:APHA24Memberus-gaap:AdditionalPaidInCapitalMember2023-12-012024-02-29 0001731348tlry:APHA24Memberus-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-012024-02-29 0001731348tlry:APHA24Memberus-gaap:RetainedEarningsMember2023-12-012024-02-29 0001731348tlry:APHA24Memberus-gaap:NoncontrollingInterestMember2023-12-012024-02-29 0001731348tlry:APHA24Member2023-12-012024-02-29 0001731348us-gaap:CommonStockMember2023-12-012024-02-29 0001731348us-gaap:TreasuryStockCommonMember2023-12-012024-02-29 0001731348us-gaap:AdditionalPaidInCapitalMember2023-12-012024-02-29 0001731348us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-012024-02-29 0001731348us-gaap:RetainedEarningsMember2023-12-012024-02-29 0001731348us-gaap:NoncontrollingInterestMember2023-12-012024-02-29 0001731348us-gaap:CommonStockMember2024-02-29 0001731348us-gaap:TreasuryStockCommonMember2024-02-29 0001731348us-gaap:AdditionalPaidInCapitalMember2024-02-29 0001731348us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-02-29 0001731348us-gaap:RetainedEarningsMember2024-02-29 0001731348us-gaap:NoncontrollingInterestMember2024-02-29 00017313482024-02-29 0001731348us-gaap:CommonStockMember2024-05-31 0001731348us-gaap:TreasuryStockCommonMember2024-05-31 0001731348us-gaap:AdditionalPaidInCapitalMember2024-05-31 0001731348us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-05-31 0001731348us-gaap:RetainedEarningsMember2024-05-31 0001731348us-gaap:NoncontrollingInterestMember2024-05-31 00017313482024-05-31 0001731348us-gaap:CommonStockMember2024-06-012024-08-31 0001731348us-gaap:TreasuryStockCommonMember2024-06-012024-08-31 0001731348us-gaap:AdditionalPaidInCapitalMember2024-06-012024-08-31 0001731348us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-012024-08-31 0001731348us-gaap:RetainedEarningsMember2024-06-012024-08-31 0001731348us-gaap:NoncontrollingInterestMember2024-06-012024-08-31 00017313482024-06-012024-08-31 0001731348us-gaap:CommonStockMember2024-08-31 0001731348us-gaap:TreasuryStockCommonMember2024-08-31 0001731348us-gaap:AdditionalPaidInCapitalMember2024-08-31 0001731348us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-08-31 0001731348us-gaap:RetainedEarningsMember2024-08-31 0001731348us-gaap:NoncontrollingInterestMember2024-08-31 00017313482024-08-31 0001731348us-gaap:CommonStockMember2024-09-012024-11-30 0001731348us-gaap:TreasuryStockCommonMember2024-09-012024-11-30 0001731348us-gaap:AdditionalPaidInCapitalMember2024-09-012024-11-30 0001731348us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-012024-11-30 0001731348us-gaap:RetainedEarningsMember2024-09-012024-11-30 0001731348us-gaap:NoncontrollingInterestMember2024-09-012024-11-30 00017313482024-09-012024-11-30 0001731348tlry:TLRY27Memberus-gaap:CommonStockMember2024-09-012024-11-30 0001731348tlry:TLRY27Memberus-gaap:TreasuryStockCommonMember2024-09-012024-11-30 0001731348tlry:TLRY27Memberus-gaap:AdditionalPaidInCapitalMember2024-09-012024-11-30 0001731348tlry:TLRY27Memberus-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-012024-11-30 0001731348tlry:TLRY27Memberus-gaap:RetainedEarningsMember2024-09-012024-11-30 0001731348tlry:TLRY27Memberus-gaap:NoncontrollingInterestMember2024-09-012024-11-30 0001731348tlry:TLRY27Member2024-09-012024-11-30 0001731348us-gaap:CommonStockMember2024-11-30 0001731348us-gaap:TreasuryStockCommonMember2024-11-30 0001731348us-gaap:AdditionalPaidInCapitalMember2024-11-30 0001731348us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-11-30 0001731348us-gaap:RetainedEarningsMember2024-11-30 0001731348us-gaap:NoncontrollingInterestMember2024-11-30 00017313482024-11-30 0001731348us-gaap:CommonStockMember2024-12-012025-02-28 0001731348us-gaap:TreasuryStockCommonMember2024-12-012025-02-28 0001731348us-gaap:AdditionalPaidInCapitalMember2024-12-012025-02-28 0001731348us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-012025-02-28 0001731348us-gaap:RetainedEarningsMember2024-12-012025-02-28 0001731348us-gaap:NoncontrollingInterestMember2024-12-012025-02-28 0001731348tlry:TLRY27Memberus-gaap:CommonStockMember2024-12-012025-02-28 0001731348tlry:TLRY27Memberus-gaap:TreasuryStockCommonMember2024-12-012025-02-28 0001731348tlry:TLRY27Memberus-gaap:AdditionalPaidInCapitalMember2024-12-012025-02-28 0001731348tlry:TLRY27Memberus-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-012025-02-28 0001731348tlry:TLRY27Memberus-gaap:RetainedEarningsMember2024-12-012025-02-28 0001731348tlry:TLRY27Memberus-gaap:NoncontrollingInterestMember2024-12-012025-02-28 0001731348tlry:TLRY27Member2024-12-012025-02-28 0001731348us-gaap:CommonStockMember2025-02-28 0001731348us-gaap:TreasuryStockCommonMember2025-02-28 0001731348us-gaap:AdditionalPaidInCapitalMember2025-02-28 0001731348us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-02-28 0001731348us-gaap:RetainedEarningsMember2025-02-28 0001731348us-gaap:NoncontrollingInterestMember2025-02-28 00017313482025-02-28 0001731348us-gaap:RestrictedStockUnitsRSUMember2024-12-012025-02-28 0001731348us-gaap:RestrictedStockUnitsRSUMember2024-06-012025-02-28 0001731348us-gaap:EmployeeStockOptionMember2024-12-012025-02-28 0001731348us-gaap:EmployeeStockOptionMember2024-06-012025-02-28 0001731348tlry:WarrantsMember2024-12-012025-02-28 0001731348tlry:WarrantsMember2024-06-012025-02-28 0001731348tlry:BeverageInventoryMember2025-02-28 0001731348tlry:BeverageInventoryMember2024-05-31 0001731348tlry:CannabisPlantsMember2025-02-28 0001731348tlry:CannabisPlantsMember2024-05-31 0001731348tlry:DriedCannabisMember2025-02-28 0001731348tlry:DriedCannabisMember2024-05-31 0001731348tlry:CannabisDerivativesMember2025-02-28 0001731348tlry:CannabisDerivativesMember2024-05-31 0001731348tlry:CannabisVapesMember2025-02-28 0001731348tlry:CannabisVapesMember2024-05-31 0001731348tlry:PackagingAndOtherInventoryItemsMember2025-02-28 0001731348tlry:PackagingAndOtherInventoryItemsMember2024-05-31 0001731348tlry:DistributionInventoryMember2025-02-28 0001731348tlry:DistributionInventoryMember2024-05-31 0001731348tlry:WellnessInventoryMember2025-02-28 0001731348tlry:WellnessInventoryMember2024-05-31 0001731348us-gaap:LandMember2025-02-28 0001731348us-gaap:LandMember2024-05-31 0001731348us-gaap:ManufacturingFacilityMember2025-02-28 0001731348us-gaap:ManufacturingFacilityMember2024-05-31 0001731348us-gaap:EquipmentMember2025-02-28 0001731348us-gaap:EquipmentMember2024-05-31 0001731348us-gaap:LeaseholdImprovementsMember2025-02-28 0001731348us-gaap:LeaseholdImprovementsMember2024-05-31 0001731348tlry:RightOfUseAssetsMember2025-02-28 0001731348tlry:RightOfUseAssetsMember2024-05-31 0001731348us-gaap:ConstructionInProgressMember2025-02-28 0001731348us-gaap:ConstructionInProgressMember2024-05-31 0001731348us-gaap:LandMember2025-02-28 0001731348us-gaap:LandMember2024-05-31 0001731348tlry:ProductionFacilitiesMember2025-02-28 0001731348tlry:ProductionFacilitiesMember2024-05-31 0001731348us-gaap:EquipmentMember2025-02-28 0001731348us-gaap:EquipmentMember2024-05-31 0001731348tlry:CustomerRelationshipsAndDistributionChannelMember2025-02-28 0001731348tlry:CustomerRelationshipsAndDistributionChannelMember2024-05-31 0001731348tlry:LicensesPermitsAndApplicationsMember2025-02-28 0001731348tlry:LicensesPermitsAndApplicationsMember2024-05-31 0001731348us-gaap:NoncompeteAgreementsMember2025-02-28 0001731348us-gaap:NoncompeteAgreementsMember2024-05-31 0001731348tlry:IntellectualPropertyTrademarksKnowHowAndBrandsMember2025-02-28 0001731348tlry:IntellectualPropertyTrademarksKnowHowAndBrandsMember2024-05-31 0001731348tlry:MultiperiodSponsorshipRightsMember2025-02-28 0001731348tlry:LicensesPermitsAndApplicationsMember2025-02-28 0001731348tlry:MultiperiodSponsorshipRightsMember2024-05-31 0001731348tlry:LicensesPermitsAndApplicationsMember2024-05-31 0001731348tlry:BeverageSegmentMember2025-02-28 0001731348tlry:CannabisSegmentMember2025-02-28 0001731348tlry:WellnessBusinessMember2025-02-28 0001731348tlry:DistributionBusinessMember2025-02-28 0001731348tlry:BeverageSegmentMember2024-05-31 0001731348tlry:CannabisSegmentMember2024-05-31 0001731348tlry:WellnessBusinessMember2024-05-31 0001731348tlry:DistributionBusinessMember2024-05-31 0001731348tlry:CannabisSegmentMember2024-12-012025-02-28 0001731348tlry:CannabisSegmentMember2024-06-012025-02-28 0001731348tlry:BeverageSegmentMember2024-12-012025-02-28 0001731348tlry:BeverageSegmentMember2024-06-012025-02-28 0001731348tlry:WellnessBusinessMember2024-12-012025-02-28 0001731348tlry:WellnessBusinessMember2024-06-012025-02-28 0001731348tlry:DistributionBusinessMember2024-12-012025-02-28 0001731348tlry:DistributionBusinessMember2024-06-012025-02-28 xbrli:pure 0001731348us-gaap:MeasurementInputDiscountRateMembertlry:CannabisSegmentMember2025-02-28 0001731348tlry:MeasurementInputTerminalGrowthRateMembertlry:CannabisSegmentMember2025-02-28 0001731348tlry:MeasurementInputAverageRevenueGrowthRateMembertlry:CannabisSegmentMember2025-02-28 0001731348us-gaap:MeasurementInputExpectedTermMembertlry:CannabisSegmentMember2025-02-28 0001731348tlry:MeasurementInputProbabilityOfLegalizationMembertlry:CannabisSegmentMemberus-gaap:EuropeanUnionMember2025-02-28 0001731348tlry:MeasurementInputProbabilityOfLegalizationMembertlry:CannabisSegmentMembercountry:US2025-02-28 0001731348tlry:CannabisSegmentMemberus-gaap:EuropeanUnionMember2024-06-012025-02-28 0001731348tlry:CannabisSegmentMembercountry:US2024-06-012025-02-28 0001731348us-gaap:MeasurementInputDiscountRateMembertlry:BeverageSegmentMember2025-02-28 0001731348tlry:MeasurementInputTerminalGrowthRateMembertlry:BeverageSegmentMember2025-02-28 0001731348tlry:MeasurementInputAverageRevenueGrowthRateMembertlry:BeverageSegmentMember2025-02-28 0001731348us-gaap:MeasurementInputExpectedTermMembertlry:BeverageSegmentMember2025-02-28 0001731348us-gaap:MeasurementInputDiscountRateMembertlry:WellnessBusinessMember2025-02-28 0001731348tlry:MeasurementInputTerminalGrowthRateMembertlry:WellnessBusinessMember2025-02-28 0001731348tlry:MeasurementInputAverageRevenueGrowthRateMembertlry:WellnessBusinessMember2025-02-28 0001731348us-gaap:MeasurementInputExpectedTermMembertlry:WellnessBusinessMember2025-02-28 0001731348tlry:CraftBeverageBusinessAcquisitionMember2023-09-292023-09-29 0001731348tlry:CraftBeverageBusinessAcquisitionMember2023-09-29 00017313482023-09-29 0001731348tlry:CraftBeverageBusinessAcquisitionMember2024-12-012025-02-28 0001731348tlry:CraftBeverageBusinessAcquisitionMember2024-06-012025-02-28 0001731348tlry:CraftBeverageBusinessAcquisitionIIMember2024-09-012024-09-01 0001731348tlry:CraftBeverageBusinessAcquisitionIIMember2024-09-01 0001731348tlry:CraftBeverageBusinessAcquisitionIIMember2024-12-012025-02-28 0001731348tlry:CraftBeverageBusinessAcquisitionIIMember2024-06-012025-02-28 0001731348tlry:CraftBeverageBusinessAcquisitionIIMember2023-12-012024-02-29 0001731348tlry:CraftBeverageBusinessAcquisitionIIMember2023-06-012024-02-29 0001731348tlry:MedMenConvertibleNoteMember2025-02-28 0001731348tlry:MedMenConvertibleNoteMember2024-05-31 0001731348tlry:TheMMNotesAndMMWarrantsMember2021-08-312021-08-31 0001731348tlry:SuperheroAcquisitionLPMember2021-08-31 0001731348tlry:MMNotesMember2021-08-31 0001731348tlry:MMNotesMember2021-08-312021-08-31 0001731348tlry:MMNotesMember2024-12-012025-02-28 0001731348tlry:MMNotesMember2024-06-012025-02-28 0001731348tlry:SuperheroAcquisitionLPMembertlry:UponUsFederalCannabisLegalizationMember2025-01-16 0001731348tlry:MMNotesMemberus-gaap:ConvertibleDebtMember2024-12-012025-02-28 0001731348tlry:MMNotesMemberus-gaap:ConvertibleDebtMember2024-06-012025-02-28 0001731348tlry:SuperheroAcquisitionLPMembertlry:UponUsFederalCannabisLegalizationMember2025-02-28 0001731348tlry:SuperheroAcquisitionLPMember2025-02-28 iso4217:CAD 0001731348tlry:AphriaIncMemberus-gaap:LineOfCreditMember2025-02-28 0001731348us-gaap:LineOfCreditMemberus-gaap:PrimeRateMember2024-06-012025-02-28 0001731348tlry:CCPharmaGmbHMemberus-gaap:LineOfCreditMember2025-02-28 iso4217:EUR 0001731348tlry:CCPharmaGmbHMembertlry:OperatingLineOfCreditOneMember2025-02-28 0001731348tlry:CCPharmaGmbHMembertlry:OperatingLineOfCreditTwoMember2025-02-28 0001731348tlry:CCPharmaGmbHMemberus-gaap:LineOfCreditMembertlry:EuroShorttermRateMember2024-06-012025-02-28 0001731348tlry:CCPharmaGmbHMemberus-gaap:LineOfCreditMembertlry:EuroInterbankOfferedRateMember2024-06-012025-02-28 0001731348tlry:AmericanBeverageCraftsGroupIncMemberus-gaap:RevolvingCreditFacilityMember2025-02-28 0001731348tlry:TermLoanDueInFebruary2028Member2025-02-28 0001731348tlry:TermLoanDueInFebruary2028Member2024-05-31 utr:Y 0001731348tlry:TermLoanDueInFebruary2028Member2024-06-012025-02-28 0001731348tlry:TermLoanDueInFebruary2028Member2023-06-012024-05-31 0001731348tlry:TermLoanDueInJuly2033Member2025-02-28 0001731348tlry:TermLoanDueInJuly2033Member2024-05-31 0001731348tlry:TermLoanDueInJuly2033Memberus-gaap:PrimeRateMember2024-06-012025-02-28 0001731348tlry:TermLoanDueInJuly2033Memberus-gaap:PrimeRateMember2023-06-012024-05-31 0001731348tlry:TermLoanDueInJuly2033Member2024-06-012025-02-28 0001731348tlry:TermLoanDueInJuly2033Member2023-06-012024-05-31 0001731348tlry:TermLoanDueInJuly2033TwoMember2025-02-28 0001731348tlry:TermLoanDueInJuly2033TwoMember2024-05-31 0001731348tlry:TermLoanDueInJuly2033TwoMember2024-06-012025-02-28 0001731348tlry:TermLoanDueInJuly2033TwoMember2023-06-012024-05-31 0001731348tlry:TermLoanDueInAugust2026Member2025-02-28 0001731348tlry:TermLoanDueInAugust2026Member2024-05-31 0001731348tlry:TermLoanDueInAugust2026Memberus-gaap:PrimeRateMember2024-06-012025-02-28 0001731348tlry:TermLoanDueInAugust2026Memberus-gaap:PrimeRateMember2023-06-012024-05-31 0001731348tlry:TermLoanDueInAugust2026Member2024-06-012025-02-28 0001731348tlry:TermLoanDueInAugust2026Member2023-06-012024-05-31 0001731348tlry:MortgagePayableDueInAugust2026Member2025-02-28 0001731348tlry:MortgagePayableDueInAugust2026Member2024-05-31 0001731348tlry:MortgagePayableDueInAugust2026Memberus-gaap:PrimeRateMember2024-06-012025-02-28 0001731348tlry:MortgagePayableDueInAugust2026Memberus-gaap:PrimeRateMember2023-06-012024-05-31 0001731348tlry:MortgagePayableDueInAugust2026Member2024-06-012025-02-28 0001731348tlry:MortgagePayableDueInAugust2026Member2023-06-012024-05-31 0001731348tlry:TermLoanDueInApril2025Member2025-02-28 0001731348tlry:TermLoanDueInApril2025Member2024-05-31 0001731348tlry:TermLoanDueInApril2025Member2024-06-012025-02-28 0001731348tlry:TermLoanDueInApril2025Member2023-06-012024-05-31 0001731348tlry:TermLoanDueInAugust2028Member2025-02-28 0001731348tlry:TermLoanDueInAugust2028Member2024-05-31 0001731348tlry:TermLoanDueInAugust2028Member2024-06-012025-02-28 0001731348tlry:TermLoanDueInAugust2028Member2023-06-012024-05-31 0001731348tlry:MortgagePayableDueInOctober2030Member2025-02-28 0001731348tlry:MortgagePayableDueInOctober2030Member2024-05-31 0001731348tlry:MortgagePayableDueInOctober2030Membertlry:EuroInterbankOfferedRateMember2024-06-012025-02-28 0001731348tlry:MortgagePayableDueInOctober2030Membertlry:EuroInterbankOfferedRateMember2023-06-012024-05-31 0001731348tlry:MortgagePayableDueInOctober2030Member2024-06-012025-02-28 0001731348tlry:MortgagePayableDueInOctober2030Member2023-06-012024-05-31 0001731348tlry:MortgagePayableDueInOctober2030Membersrt:MinimumMember2024-06-012025-02-28 0001731348tlry:MortgagePayableDueInOctober2030Membersrt:MinimumMember2023-06-012024-05-31 0001731348tlry:MortgagePayableDueInOctober2030Membersrt:MaximumMember2024-06-012025-02-28 0001731348tlry:MortgagePayableDueInOctober2030Membersrt:MaximumMember2023-06-012024-05-31 0001731348tlry:TermLoanDueInJune2028Member2025-02-28 0001731348tlry:TermLoanDueInJune2028Member2024-05-31 0001731348tlry:TermLoanDueInJune2028Member2024-06-012025-02-28 0001731348tlry:TermLoanDueInJune2028Member2023-06-012024-05-31 0001731348tlry:TermLoanDueInJune2028Membersrt:MinimumMember2024-06-012025-02-28 0001731348tlry:TermLoanDueInJune2028Membersrt:MinimumMember2023-06-012024-05-31 0001731348tlry:TermLoanDueInJune2028Membersrt:MaximumMember2024-06-012025-02-28 0001731348tlry:TermLoanDueInJune2028Membersrt:MaximumMember2023-06-012024-05-31 0001731348tlry:LongtermDebtExcludingConvertibleDebenturesMember2025-02-28 0001731348tlry:LongtermDebtExcludingConvertibleDebenturesMember2024-05-31 0001731348tlry:AphriaDiamondMember2022-11-28 0001731348us-gaap:SecuredDebtMembertlry:CreditFacilityDueInNovember2025Member2024-06-012025-02-28 0001731348tlry:TLRY27Member2025-02-28 0001731348tlry:TLRY27Member2024-05-31 0001731348tlry:APHA24Member2025-02-28 0001731348tlry:APHA24Member2024-05-31 0001731348tlry:ConvertibleDebenturesMember2025-02-28 0001731348tlry:ConvertibleDebenturesMember2024-05-31 0001731348tlry:TLRY27Member2023-05-30 0001731348tlry:TLRY27Member2023-05-302023-05-30 0001731348tlry:TLRY27Member2024-09-122024-09-12 0001731348tlry:TLRY27Member2024-11-042024-11-04 0001731348tlry:TLRY27Member2024-06-012024-11-30 0001731348tlry:TLRY27Member2024-06-012025-02-28 0001731348tlry:TLRY27Member2023-12-012024-02-29 0001731348tlry:TLRY27Member2023-06-012024-02-29 0001731348tlry:APHA24Member2023-06-012024-05-31 0001731348tlry:APHA24Member2019-04-01 0001731348tlry:WarrantsToPurchaseCommonStockMember2025-02-28 0001731348tlry:WarrantsToPurchaseCommonStockMember2024-05-31 0001731348srt:MaximumMember2025-02-28 0001731348us-gaap:FairValueInputsLevel3Member2025-02-28 0001731348us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMember2025-02-28 0001731348us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2025-02-28 0001731348us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMember2025-02-28 0001731348us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputConversionPriceMember2025-02-28 0001731348us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputSharePriceMember2025-02-28 0001731348tlry:AtthemarketProgramMember2024-06-012025-02-28 0001731348tlry:SettlementOfTlry27ConvertibleNoteWithShareIssuanceMemberus-gaap:TreasuryStockCommonMember2024-06-012025-02-28 0001731348tlry:TilrayBrandsIncMedipharmHexoLitigationSettlementMember2024-06-012025-02-28 0001731348tlry:TimebasedRestrictedStockUnitsMember2024-06-012025-02-28 0001731348tlry:PerformancebasedRestrictedStockUnitsMember2024-06-012025-02-28 0001731348tlry:TimebasedRestrictedStockUnitsMember2023-06-012024-02-29 0001731348tlry:PerformancebasedRestrictedStockUnitsMember2023-06-012024-02-29 0001731348us-gaap:RestrictedStockUnitsRSUMember2023-12-012024-02-29 0001731348us-gaap:RestrictedStockUnitsRSUMember2023-06-012024-02-29 0001731348us-gaap:AccumulatedTranslationAdjustmentMember2023-05-31 0001731348us-gaap:AccumulatedTranslationAdjustmentMember2023-06-012023-08-31 0001731348us-gaap:AccumulatedTranslationAdjustmentMember2023-08-31 0001731348us-gaap:AccumulatedTranslationAdjustmentMember2023-09-012023-11-30 0001731348us-gaap:AccumulatedTranslationAdjustmentMember2023-11-30 0001731348us-gaap:AccumulatedTranslationAdjustmentMember2023-12-012024-02-29 0001731348us-gaap:AccumulatedTranslationAdjustmentMember2024-02-29 0001731348us-gaap:AccumulatedTranslationAdjustmentMember2024-05-31 0001731348us-gaap:AccumulatedTranslationAdjustmentMember2024-06-012024-08-31 0001731348us-gaap:AccumulatedTranslationAdjustmentMember2024-08-31 0001731348us-gaap:AccumulatedTranslationAdjustmentMember2024-09-012024-11-30 0001731348us-gaap:AccumulatedTranslationAdjustmentMember2024-11-30 0001731348us-gaap:AccumulatedTranslationAdjustmentMember2024-12-012025-02-28 0001731348us-gaap:AccumulatedTranslationAdjustmentMember2025-02-28 0001731348tlry:AphriaDiamondMember2025-02-28 0001731348tlry:ColCannaSASMember2025-02-28 0001731348tlry:ColCannaSASMember2025-01-07 0001731348tlry:SuperheroAcquisitionLPMember2025-02-28 0001731348tlry:CCPharmaNordicApSMember2025-02-28 0001731348tlry:AphriaDiamondMember2025-02-28 0001731348tlry:ColCannaSASMember2025-02-28 0001731348srt:SubsidiariesMember2025-02-28 0001731348tlry:SuperheroAcquisitionLPMember2024-05-31 0001731348tlry:CCPharmaNordicApSMember2024-05-31 0001731348tlry:AphriaDiamondMember2024-05-31 0001731348tlry:ColCannaSASMember2024-05-31 0001731348srt:SubsidiariesMember2024-05-31 0001731348tlry:SuperheroAcquisitionLPMember2024-06-012025-02-28 0001731348tlry:CCPharmaNordicApSMember2024-06-012025-02-28 0001731348tlry:AphriaDiamondMember2024-06-012025-02-28 0001731348tlry:ColCannaSASMember2024-06-012025-02-28 0001731348srt:SubsidiariesMember2024-06-012025-02-28 0001731348tlry:CCPharmaNordicApSMember2025-02-28 0001731348tlry:SuperheroAcquisitionLPMember2023-06-012024-02-29 0001731348tlry:CCPharmaNordicApSMember2023-06-012024-02-29 0001731348tlry:AphriaDiamondMember2023-06-012024-02-29 0001731348tlry:ColCannaSASMember2023-06-012024-02-29 0001731348srt:SubsidiariesMember2023-06-012024-02-29 0001731348tlry:SuperheroAcquisitionLPMember2024-02-29 0001731348tlry:CCPharmaNordicApSMember2024-02-29 0001731348tlry:AphriaDiamondMember2024-02-29 0001731348tlry:ColCannaSASMember2024-02-29 0001731348tlry:ConvertibleDebenturesMember2025-02-28 0001731348tlry:MaterialPurchaseObligationsMember2025-02-28 0001731348us-gaap:CapitalAdditionsMember2025-02-28 0001731348tlry:AphiraClassActionMemberus-gaap:PendingLitigationMembertlry:DamagesMember2022-09-012022-09-30 0001731348tlry:AphiraClassActionMemberus-gaap:SettledLitigationMember2025-02-052025-02-05 0001731348tlry:AphiraClassActionMemberus-gaap:SettledLitigationMember2025-02-28 0001731348tlry:BeverageAlcoholBusinessMember2024-12-012025-02-28 0001731348tlry:BeverageAlcoholBusinessMember2023-12-012024-02-29 0001731348tlry:BeverageAlcoholBusinessMember2024-06-012025-02-28 0001731348tlry:BeverageAlcoholBusinessMember2023-06-012024-02-29 0001731348tlry:CannabisSegmentMember2023-12-012024-02-29 0001731348tlry:CannabisSegmentMember2023-06-012024-02-29 0001731348tlry:DistributionBusinessMember2023-12-012024-02-29 0001731348tlry:DistributionBusinessMember2023-06-012024-02-29 0001731348tlry:WellnessBusinessMember2023-12-012024-02-29 0001731348tlry:WellnessBusinessMember2023-06-012024-02-29 0001731348tlry:HexoAcquisitionMemberus-gaap:EmployeeSeveranceMembertlry:CannabisSegmentMember2024-06-012025-02-28 0001731348tlry:TrussBeverageCompanyMemberus-gaap:FacilityClosingMembertlry:CannabisSegmentMember2024-06-012025-02-28 0001731348tlry:AvantiFacilityMemberus-gaap:FacilityClosingMembertlry:CannabisSegmentMember2024-06-012025-02-28 0001731348us-gaap:FacilityClosingMembertlry:CannabisSegmentMembercountry:NZ2024-06-012025-02-28 0001731348us-gaap:EmployeeSeveranceMembertlry:BeverageSegmentMember2024-06-012025-02-28 0001731348tlry:CraftAcquisitionAndCraftAcquisitionIIMembertlry:ConsolidationOfProductionSitesMembertlry:BeverageSegmentMember2024-06-012025-02-28 0001731348tlry:CraftAcquisitionAndCraftAcquisitionIIMemberus-gaap:ContractTerminationMembertlry:BeverageSegmentMember2024-06-012025-02-28 0001731348tlry:SuperheroLPMember2024-06-012025-02-28 0001731348tlry:HTIConvertibleNotePayableMember2023-06-012024-02-29 0001731348tlry:CannfectionsGroupIncMember2023-06-012024-02-29 0001731348us-gaap:ConvertibleDebtMember2025-02-28 0001731348us-gaap:ConvertibleDebtMember2024-05-31 0001731348us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-02-28 0001731348us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-02-28 0001731348us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-02-28 0001731348us-gaap:FairValueMeasurementsRecurringMember2025-02-28 0001731348tlry:APHA24Memberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-02-28 0001731348tlry:APHA24Memberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-02-28 0001731348tlry:APHA24Memberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-02-28 0001731348tlry:APHA24Memberus-gaap:FairValueMeasurementsRecurringMember2025-02-28 0001731348us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-05-31 0001731348us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-05-31 0001731348us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-05-31 0001731348us-gaap:FairValueMeasurementsRecurringMember2024-05-31 0001731348tlry:APHA24Memberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-05-31 0001731348tlry:APHA24Memberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-05-31 0001731348tlry:APHA24Memberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-05-31 0001731348tlry:APHA24Memberus-gaap:FairValueMeasurementsRecurringMember2024-05-31 0001731348tlry:SuperheroAcquisitionLPMember2025-01-16 0001731348tlry:SweetwaterMontaukAndTrussMembertlry:MeasurementInputProbabilityOfAchievementMembersrt:MaximumMember2025-02-28 0001731348us-gaap:FairValueInputsLevel3Membertlry:ContingentConsiderationMember2025-02-28 0001731348tlry:SweetwaterMontaukAndTrussMembertlry:MeasurementInputProbabilityOfAchievementMembersrt:MinimumMember2025-02-28 0001731348tlry:ContingentConsiderationMember2024-06-012025-02-28 0001731348tlry:ContingentConsiderationMember2023-06-012024-02-29 0001731348tlry:SweetWaterMembertlry:ContingentConsiderationMember2023-06-012024-02-29 0001731348tlry:TrussBeverageCompanyMembertlry:ContingentConsiderationMember2023-06-012024-02-29 0001731348tlry:AcquisitionOfMontaukBrewingCompanyIncMembertlry:ContingentConsiderationMember2023-06-012024-02-29 0001731348us-gaap:NotesReceivableMemberus-gaap:FairValueInputsLevel3Member2024-05-31 0001731348us-gaap:FairValueInputsLevel3Membertlry:EquityInvestmentsMember2024-05-31 0001731348us-gaap:FairValueInputsLevel3Membertlry:WarrantLiabilityMember2024-05-31 0001731348us-gaap:FairValueInputsLevel3Membertlry:ContingentConsiderationMember2024-05-31 0001731348tlry:APHA24Memberus-gaap:FairValueInputsLevel3Memberus-gaap:LongTermDebtMember2024-05-31 0001731348us-gaap:NotesReceivableMemberus-gaap:FairValueInputsLevel3Member2024-06-012025-02-28 0001731348us-gaap:FairValueInputsLevel3Membertlry:EquityInvestmentsMember2024-06-012025-02-28 0001731348us-gaap:FairValueInputsLevel3Membertlry:WarrantLiabilityMember2024-06-012025-02-28 0001731348us-gaap:FairValueInputsLevel3Membertlry:ContingentConsiderationMember2024-06-012025-02-28 0001731348tlry:APHA24Memberus-gaap:FairValueInputsLevel3Memberus-gaap:LongTermDebtMember2024-06-012025-02-28 0001731348us-gaap:NotesReceivableMemberus-gaap:FairValueInputsLevel3Member2025-02-28 0001731348us-gaap:FairValueInputsLevel3Membertlry:EquityInvestmentsMember2025-02-28 0001731348us-gaap:FairValueInputsLevel3Membertlry:WarrantLiabilityMember2025-02-28 0001731348tlry:APHA24Memberus-gaap:FairValueInputsLevel3Memberus-gaap:LongTermDebtMember2025-02-28 0001731348us-gaap:NotesReceivableMemberus-gaap:FairValueInputsLevel3Member2023-05-31 0001731348us-gaap:FairValueInputsLevel3Membertlry:EquityInvestmentsMember2023-05-31 0001731348us-gaap:FairValueInputsLevel3Membertlry:WarrantLiabilityMember2023-05-31 0001731348us-gaap:FairValueInputsLevel3Membertlry:ContingentConsiderationMember2023-05-31 0001731348tlry:APHA24Memberus-gaap:FairValueInputsLevel3Memberus-gaap:LongTermDebtMember2023-05-31 0001731348us-gaap:NotesReceivableMemberus-gaap:FairValueInputsLevel3Member2023-06-012024-02-29 0001731348us-gaap:FairValueInputsLevel3Membertlry:EquityInvestmentsMember2023-06-012024-02-29 0001731348us-gaap:FairValueInputsLevel3Membertlry:WarrantLiabilityMember2023-06-012024-02-29 0001731348us-gaap:FairValueInputsLevel3Membertlry:ContingentConsiderationMember2023-06-012024-02-29 0001731348tlry:APHA24Memberus-gaap:FairValueInputsLevel3Memberus-gaap:LongTermDebtMember2023-06-012024-02-29 0001731348us-gaap:NotesReceivableMemberus-gaap:FairValueInputsLevel3Member2024-02-29 0001731348us-gaap:FairValueInputsLevel3Membertlry:EquityInvestmentsMember2024-02-29 0001731348us-gaap:FairValueInputsLevel3Membertlry:WarrantLiabilityMember2024-02-29 0001731348us-gaap:FairValueInputsLevel3Membertlry:ContingentConsiderationMember2024-02-29 0001731348tlry:APHA24Memberus-gaap:FairValueInputsLevel3Memberus-gaap:LongTermDebtMember2024-02-29 0001731348tlry:MeasurementInputConversionRateMembersrt:MinimumMemberus-gaap:ValuationTechniqueOptionPricingModelMember2025-02-28 0001731348us-gaap:MeasurementInputPriceVolatilityMembersrt:MinimumMemberus-gaap:ValuationTechniqueOptionPricingModelMember2025-02-28 0001731348us-gaap:MeasurementInputExpectedTermMembersrt:MinimumMemberus-gaap:ValuationTechniqueOptionPricingModelMember2025-02-28 0001731348us-gaap:MeasurementInputDiscountRateMembersrt:MinimumMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2025-02-28 0001731348tlry:MeasurementInputConversionRateMembersrt:MaximumMemberus-gaap:ValuationTechniqueOptionPricingModelMember2025-02-28 0001731348tlry:MeasurementInputProbabilityOfAchievementMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2025-02-28 0001731348tlry:MedicalCannabisProductsMembertlry:CannabisSegmentMember2024-12-012025-02-28 0001731348tlry:MedicalCannabisProductsMembertlry:CannabisSegmentMember2023-12-012024-02-29 0001731348tlry:MedicalCannabisProductsMembertlry:CannabisSegmentMember2024-06-012025-02-28 0001731348tlry:MedicalCannabisProductsMembertlry:CannabisSegmentMember2023-06-012024-02-29 0001731348tlry:AdultuseCannabisProductsMembertlry:CannabisSegmentMember2024-12-012025-02-28 0001731348tlry:AdultuseCannabisProductsMembertlry:CannabisSegmentMember2023-12-012024-02-29 0001731348tlry:AdultuseCannabisProductsMembertlry:CannabisSegmentMember2024-06-012025-02-28 0001731348tlry:AdultuseCannabisProductsMembertlry:CannabisSegmentMember2023-06-012024-02-29 0001731348tlry:WholesaleCannabisProductsMembertlry:CannabisSegmentMember2024-12-012025-02-28 0001731348tlry:WholesaleCannabisProductsMembertlry:CannabisSegmentMember2023-12-012024-02-29 0001731348tlry:WholesaleCannabisProductsMembertlry:CannabisSegmentMember2024-06-012025-02-28 0001731348tlry:WholesaleCannabisProductsMembertlry:CannabisSegmentMember2023-06-012024-02-29 0001731348tlry:InternationalCannabisProductsMembertlry:CannabisSegmentMember2024-12-012025-02-28 0001731348tlry:InternationalCannabisProductsMembertlry:CannabisSegmentMember2023-12-012024-02-29 0001731348tlry:InternationalCannabisProductsMembertlry:CannabisSegmentMember2024-06-012025-02-28 0001731348tlry:InternationalCannabisProductsMembertlry:CannabisSegmentMember2023-06-012024-02-29 0001731348tlry:AdvisoryServicesRevenueMembertlry:AdvisoryServicesAgreementWithHEXOMember2024-12-012025-02-28 0001731348tlry:AdvisoryServicesRevenueMembertlry:AdvisoryServicesAgreementWithHEXOMember2024-06-012025-02-28 0001731348tlry:AdvisoryServicesRevenueMembertlry:AdvisoryServicesAgreementWithHEXOMember2023-12-012024-02-29 0001731348tlry:AdvisoryServicesRevenueMembertlry:AdvisoryServicesAgreementWithHEXOMember2023-06-012024-02-29 0001731348country:US2024-12-012025-02-28 0001731348country:US2023-12-012024-02-29 0001731348country:US2024-06-012025-02-28 0001731348country:US2023-06-012024-02-29 0001731348country:CA2024-12-012025-02-28 0001731348country:CA2023-12-012024-02-29 0001731348country:CA2024-06-012025-02-28 0001731348country:CA2023-06-012024-02-29 0001731348us-gaap:EMEAMember2024-12-012025-02-28 0001731348us-gaap:EMEAMember2023-12-012024-02-29 0001731348us-gaap:EMEAMember2024-06-012025-02-28 0001731348us-gaap:EMEAMember2023-06-012024-02-29 0001731348tlry:RestOfWorldMember2024-12-012025-02-28 0001731348tlry:RestOfWorldMember2023-12-012024-02-29 0001731348tlry:RestOfWorldMember2024-06-012025-02-28 0001731348tlry:RestOfWorldMember2023-06-012024-02-29 0001731348country:US2025-02-28 0001731348country:US2024-05-31 0001731348country:CA2025-02-28 0001731348country:CA2024-05-31 0001731348us-gaap:EMEAMember2025-02-28 0001731348us-gaap:EMEAMember2024-05-31 0001731348tlry:RestOfWorldMember2025-02-28 0001731348tlry:RestOfWorldMember2024-05-31 0001731348us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembertlry:MajorCustomersMember2024-12-012025-02-28 0001731348us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembertlry:MajorCustomersMember2024-06-012025-02-28 0001731348us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembertlry:MajorCustomersMember2023-12-012024-02-29 0001731348us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembertlry:MajorCustomersMember2023-06-012024-02-29 0001731348tlry:TLRY27Memberus-gaap:SubsequentEventMember2025-03-052025-03-17 0001731348tlry:TLRY27Memberus-gaap:SubsequentEventMember2025-03-17

0001731348 Tilray Brands, Inc. false --05-31 Q1 2026 0.0001 0.0001 1,416,000,000 1,416,000,000 1,118,291,159 1,118,291,159 1,060,678,745 1,060,678,745 3,213,914 2,004,218 0.0001 0.0001 10,000,000 10,000,000 0 0 0 0 http://www.tilray.com/20250831#OperatingAndFinanceLeaseLiabilityCurrent http://www.tilray.com/20250831#OperatingAndFinanceLeaseLiabilityCurrent http://www.tilray.com/20250831#OperatingAndFinanceLeaseLiabilityCurrent http://www.tilray.com/20250831#OperatingAndFinanceLeaseLiabilityCurrent http://www.tilray.com/20250831#OperatingAndFinanceLeaseLiabilityNoncurrent http://www.tilray.com/20250831#OperatingAndFinanceLeaseLiabilityNoncurrent http://www.tilray.com/20250831#OperatingAndFinanceLeaseLiabilityNoncurrent http://www.tilray.com/20250831#OperatingAndFinanceLeaseLiabilityNoncurrent 4 0 0 68 1.00 8,160 1,000 0 2 7,000 500 7,459 7,500 7,000 500 0 53,000 53,000 3 3 10 10 February 29, 2028 February 29, 2028 25,000 25,000 1.00 1.00 5 5 15 15 181 181 July 31, 2033 July 31, 2033 25,000 25,000 1.00 1.00 5 5 15 15 196 196 July 31, 2033 July 31, 2033 1,250 1,250 1.50 1.50 5 5 10 10 12 12 August 31, 2026 August 31, 2026 3,750 3,750 1.50 1.50 5 5 20 20 23 23 August 31, 2026 August 31, 2026 3,500 3,500 4.59 4.59 5 5 52 52 August 31, 2028 August 31, 2028 22,635 22,635 1.5 1.5 10 10 57 57 69 69 October 31, 2030 October 31, 2030 90,000 90,000 5 5 875 875 2,250 2,250 June 30, 2028 June 30, 2028 5.20 5.20 6,209,000 5.95 1 1 1,118,291,159 0 0 4 4 0 4 0 2,108 false false false false 00017313482025-06-012025-08-31 xbrli:shares 00017313482025-10-07 thunderdome:item iso4217:USD 00017313482025-08-31 00017313482025-05-31 iso4217:USDxbrli:shares 00017313482024-06-012024-08-31 0001731348us-gaap:CommonStockMember2024-05-31 0001731348us-gaap:TreasuryStockCommonMember2024-05-31 0001731348us-gaap:AdditionalPaidInCapitalMember2024-05-31 0001731348us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-05-31 0001731348us-gaap:RetainedEarningsMember2024-05-31 0001731348us-gaap:NoncontrollingInterestMember2024-05-31 00017313482024-05-31 0001731348us-gaap:CommonStockMember2024-06-012024-08-31 0001731348us-gaap:TreasuryStockCommonMember2024-06-012024-08-31 0001731348us-gaap:AdditionalPaidInCapitalMember2024-06-012024-08-31 0001731348us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-012024-08-31 0001731348us-gaap:RetainedEarningsMember2024-06-012024-08-31 0001731348us-gaap:NoncontrollingInterestMember2024-06-012024-08-31 0001731348us-gaap:CommonStockMember2024-08-31 0001731348us-gaap:TreasuryStockCommonMember2024-08-31 0001731348us-gaap:AdditionalPaidInCapitalMember2024-08-31 0001731348us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-08-31 0001731348us-gaap:RetainedEarningsMember2024-08-31 0001731348us-gaap:NoncontrollingInterestMember2024-08-31 00017313482024-08-31 0001731348us-gaap:CommonStockMember2025-05-31 0001731348us-gaap:TreasuryStockCommonMember2025-05-31 0001731348us-gaap:AdditionalPaidInCapitalMember2025-05-31 0001731348us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-05-31 0001731348us-gaap:RetainedEarningsMember2025-05-31 0001731348us-gaap:NoncontrollingInterestMember2025-05-31 0001731348us-gaap:CommonStockMember2025-06-012025-08-31 0001731348us-gaap:TreasuryStockCommonMember2025-06-012025-08-31 0001731348us-gaap:AdditionalPaidInCapitalMember2025-06-012025-08-31 0001731348us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-012025-08-31 0001731348us-gaap:RetainedEarningsMember2025-06-012025-08-31 0001731348us-gaap:NoncontrollingInterestMember2025-06-012025-08-31 0001731348tlry:TLRY23Memberus-gaap:CommonStockMember2025-06-012025-08-31 0001731348tlry:TLRY23Memberus-gaap:TreasuryStockCommonMember2025-06-012025-08-31 0001731348tlry:TLRY23Memberus-gaap:AdditionalPaidInCapitalMember2025-06-012025-08-31 0001731348tlry:TLRY23Memberus-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-012025-08-31 0001731348tlry:TLRY23Memberus-gaap:RetainedEarningsMember2025-06-012025-08-31 0001731348tlry:TLRY23Memberus-gaap:NoncontrollingInterestMember2025-06-012025-08-31 0001731348tlry:TLRY23Member2025-06-012025-08-31 0001731348us-gaap:CommonStockMember2025-08-31 0001731348us-gaap:TreasuryStockCommonMember2025-08-31 0001731348us-gaap:AdditionalPaidInCapitalMember2025-08-31 0001731348us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-08-31 0001731348us-gaap:RetainedEarningsMember2025-08-31 0001731348us-gaap:NoncontrollingInterestMember2025-08-31 0001731348us-gaap:RestrictedStockUnitsRSUMember2025-06-012025-08-31 0001731348us-gaap:RestrictedStockUnitsRSUMember2024-06-012024-08-31 0001731348us-gaap:EmployeeStockOptionMember2025-06-012025-08-31 0001731348us-gaap:EmployeeStockOptionMember2024-06-012024-08-31 0001731348tlry:WarrantsMember2025-06-012025-08-31 0001731348tlry:WarrantsMember2024-06-012024-08-31 0001731348tlry:BeverageInventoryMember2025-08-31 0001731348tlry:BeverageInventoryMember2025-05-31 0001731348tlry:CannabisPlantsMember2025-08-31 0001731348tlry:CannabisPlantsMember2025-05-31 0001731348tlry:DriedCannabisMember2025-08-31 0001731348tlry:DriedCannabisMember2025-05-31 0001731348tlry:CannabisDerivativesMember2025-08-31 0001731348tlry:CannabisDerivativesMember2025-05-31 0001731348tlry:CannabisVapesMember2025-08-31 0001731348tlry:CannabisVapesMember2025-05-31 0001731348tlry:PackagingAndOtherInventoryItemsMember2025-08-31 0001731348tlry:PackagingAndOtherInventoryItemsMember2025-05-31 0001731348tlry:DistributionInventoryMember2025-08-31 0001731348tlry:DistributionInventoryMember2025-05-31 0001731348tlry:WellnessInventoryMember2025-08-31 0001731348tlry:WellnessInventoryMember2025-05-31 0001731348us-gaap:LandMember2025-08-31 0001731348us-gaap:LandMember2025-05-31 0001731348us-gaap:ManufacturingFacilityMember2025-08-31 0001731348us-gaap:ManufacturingFacilityMember2025-05-31 0001731348us-gaap:EquipmentMember2025-08-31 0001731348us-gaap:EquipmentMember2025-05-31 0001731348us-gaap:LeaseholdImprovementsMember2025-08-31 0001731348us-gaap:LeaseholdImprovementsMember2025-05-31 0001731348tlry:RightOfUseAssetsMember2025-08-31 0001731348tlry:RightOfUseAssetsMember2025-05-31 0001731348us-gaap:ConstructionInProgressMember2025-08-31 0001731348us-gaap:ConstructionInProgressMember2025-05-31 0001731348tlry:ProductionFacilitiesMember2025-08-31 0001731348tlry:ProductionFacilitiesMember2025-05-31 0001731348tlry:CustomerRelationshipsAndDistributionChannelMember2025-08-31 0001731348tlry:LicensesPermitsAndApplicationsMember2025-08-31 0001731348tlry:IntellectualPropertyTrademarksKnowHowAndBrandsMember2025-08-31 0001731348tlry:CustomerRelationshipsAndDistributionChannelMember2025-05-31 0001731348tlry:LicensesPermitsAndApplicationsMember2025-05-31 0001731348us-gaap:NoncompeteAgreementsMember2025-05-31 0001731348tlry:IntellectualPropertyTrademarksKnowHowAndBrandsMember2025-05-31 0001731348tlry:BeverageSegmentMember2025-08-31 0001731348tlry:BeverageSegmentMember2025-05-31 0001731348tlry:CannabisSegmentMember2025-05-31 0001731348tlry:WellnessBusinessMember2025-05-31 0001731348tlry:DistributionBusinessMember2025-05-31 xbrli:pure 0001731348tlry:CraftBeverageBusinessAcquisitionIIMember2024-09-012024-09-01 0001731348tlry:CraftBeverageBusinessAcquisitionMember2024-09-012024-09-01 0001731348tlry:CraftBeverageBusinessAcquisitionMember2024-09-01 00017313482024-09-01 0001731348tlry:CraftBeverageBusinessAcquisitionIIMember2025-06-012025-08-31 0001731348tlry:CraftBeverageBusinessAcquisitionIIMember2024-06-012024-08-31 0001731348tlry:CraftBeverageBusinessAcquisitionIIMember2025-06-012025-08-31 0001731348tlry:CraftBeverageBusinessAcquisitionIIMember2024-06-012024-08-31 0001731348tlry:SuperheroAcquisitionLPMembertlry:UponUsFederalCannabisLegalizationMember2025-08-31 0001731348tlry:SuperheroAcquisitionLPMembertlry:UponUsFederalCannabisLegalizationMember2024-05-31 0001731348tlry:SuperheroAcquisitionLPMember2025-08-31 0001731348tlry:SuperheroAcquisitionLPMember2024-05-31 iso4217:CAD 0001731348tlry:AphriaIncMemberus-gaap:LineOfCreditMember2025-08-31 0001731348us-gaap:LineOfCreditMemberus-gaap:PrimeRateMember2025-06-012025-08-31 0001731348tlry:CCPharmaGmbHMemberus-gaap:LineOfCreditMember2025-08-31 iso4217:EUR 0001731348tlry:CCPharmaGmbHMembertlry:OperatingLineOfCreditOneMember2025-08-31 0001731348tlry:CCPharmaGmbHMembertlry:OperatingLineOfCreditTwoMember2025-08-31 0001731348tlry:CCPharmaGmbHMemberus-gaap:LineOfCreditMembertlry:EuroShorttermRateMember2025-06-012025-08-31 0001731348tlry:CCPharmaGmbHMemberus-gaap:LineOfCreditMembertlry:EuroInterbankOfferedRateMember2025-06-012025-08-31 0001731348tlry:AmericanBeverageCraftsGroupIncMemberus-gaap:RevolvingCreditFacilityMember2025-07-25 0001731348tlry:TermLoanDueInFebruary2028Member2025-08-31 0001731348tlry:TermLoanDueInFebruary2028Member2025-05-31 utr:Y 0001731348tlry:TermLoanDueInFebruary2028Member2025-06-012025-08-31 0001731348tlry:TermLoanDueInFebruary2028Member2024-06-012025-05-31 0001731348tlry:TermLoanDueInJuly2033Member2025-08-31 0001731348tlry:TermLoanDueInJuly2033Member2025-05-31 0001731348tlry:TermLoanDueInJuly2033Memberus-gaap:PrimeRateMember2025-06-012025-08-31 0001731348tlry:TermLoanDueInJuly2033Memberus-gaap:PrimeRateMember2024-06-012025-05-31 0001731348tlry:TermLoanDueInJuly2033Member2025-06-012025-08-31 0001731348tlry:TermLoanDueInJuly2033Member2024-06-012025-05-31 0001731348tlry:TermLoanDueInJuly2033TwoMember2025-08-31 0001731348tlry:TermLoanDueInJuly2033TwoMember2025-05-31 0001731348tlry:TermLoanDueInJuly2033TwoMember2025-06-012025-08-31 0001731348tlry:TermLoanDueInJuly2033TwoMember2024-06-012025-05-31 0001731348tlry:TermLoanDueInAugust2026Member2025-08-31 0001731348tlry:TermLoanDueInAugust2026Member2025-05-31 0001731348tlry:TermLoanDueInAugust2026Memberus-gaap:PrimeRateMember2025-06-012025-08-31 0001731348tlry:TermLoanDueInAugust2026Memberus-gaap:PrimeRateMember2024-06-012025-05-31 0001731348tlry:TermLoanDueInAugust2026Member2025-06-012025-08-31 0001731348tlry:TermLoanDueInAugust2026Member2024-06-012025-05-31 0001731348tlry:MortgagePayableDueInAugust2026Member2025-08-31 0001731348tlry:MortgagePayableDueInAugust2026Member2025-05-31 0001731348tlry:MortgagePayableDueInAugust2026Memberus-gaap:PrimeRateMember2025-06-012025-08-31 0001731348tlry:MortgagePayableDueInAugust2026Memberus-gaap:PrimeRateMember2024-06-012025-05-31 0001731348tlry:MortgagePayableDueInAugust2026Member2025-06-012025-08-31 0001731348tlry:MortgagePayableDueInAugust2026Member2024-06-012025-05-31 0001731348tlry:TermLoanDueInAugust2028Member2025-08-31 0001731348tlry:TermLoanDueInAugust2028Member2025-05-31 0001731348tlry:TermLoanDueInAugust2028Member2025-06-012025-08-31 0001731348tlry:TermLoanDueInAugust2028Member2024-06-012025-05-31 0001731348tlry:MortgagePayableDueInOctober2030Member2025-08-31 0001731348tlry:MortgagePayableDueInOctober2030Member2025-05-31 0001731348tlry:MortgagePayableDueInOctober2030Membertlry:EuroInterbankOfferedRateMember2025-06-012025-08-31 0001731348tlry:MortgagePayableDueInOctober2030Membertlry:EuroInterbankOfferedRateMember2024-06-012025-05-31 0001731348tlry:MortgagePayableDueInOctober2030Member2025-06-012025-08-31 0001731348tlry:MortgagePayableDueInOctober2030Member2024-06-012025-05-31 0001731348tlry:MortgagePayableDueInOctober2030Membersrt:MinimumMember2025-06-012025-08-31 0001731348tlry:MortgagePayableDueInOctober2030Membersrt:MinimumMember2024-06-012025-05-31 0001731348tlry:MortgagePayableDueInOctober2030Membersrt:MaximumMember2025-06-012025-08-31 0001731348tlry:MortgagePayableDueInOctober2030Membersrt:MaximumMember2024-06-012025-05-31 0001731348tlry:TermLoanDueInJune2028Member2025-08-31 0001731348tlry:TermLoanDueInJune2028Member2025-05-31 0001731348tlry:TermLoanDueInJune2028Member2025-06-012025-08-31 0001731348tlry:TermLoanDueInJune2028Member2024-06-012025-05-31 0001731348tlry:TermLoanDueInJune2028Membersrt:MinimumMember2025-06-012025-08-31 0001731348tlry:TermLoanDueInJune2028Membersrt:MinimumMember2024-06-012025-05-31 0001731348tlry:TermLoanDueInJune2028Membersrt:MaximumMember2025-06-012025-08-31 0001731348tlry:TermLoanDueInJune2028Membersrt:MaximumMember2024-06-012025-05-31 0001731348tlry:LongtermDebtExcludingConvertibleDebenturesMember2025-08-31 0001731348tlry:LongtermDebtExcludingConvertibleDebenturesMember2025-05-31 0001731348tlry:TLRY27Member2025-08-31 0001731348tlry:TLRY27Member2025-05-31 0001731348tlry:TLRY27Member2023-05-30 0001731348tlry:TLRY27Member2023-05-302023-05-30 0001731348tlry:ConversionOfTlry27NotesToSharesMember2025-06-012025-08-31 0001731348tlry:TLRY27Member2025-06-012025-08-31 0001731348tlry:TLRY27Member2024-06-012024-08-31 0001731348tlry:WarrantsToPurchaseCommonStockMember2025-08-31 0001731348tlry:WarrantsToPurchaseCommonStockMember2025-05-31 0001731348srt:MaximumMember2025-08-31 0001731348us-gaap:FairValueInputsLevel3Member2025-08-31 0001731348us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMember2025-08-31 0001731348us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2025-08-31 0001731348us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMember2025-08-31 0001731348us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputConversionPriceMember2025-08-31 0001731348us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputSharePriceMember2025-08-31 0001731348tlry:AtthemarketProgramMember2025-06-012025-08-31 0001731348tlry:TimebasedRestrictedStockUnitsMember2025-06-012025-08-31 0001731348tlry:PerformancebasedRestrictedStockUnitsMember2025-06-012025-08-31 0001731348tlry:PerformancebasedRestrictedStockUnitsMember2023-06-012024-05-31 0001731348us-gaap:AccumulatedTranslationAdjustmentMember2024-05-31 0001731348us-gaap:AccumulatedTranslationAdjustmentMember2024-06-012024-08-31 0001731348us-gaap:AccumulatedTranslationAdjustmentMember2024-08-31 0001731348us-gaap:AccumulatedTranslationAdjustmentMember2025-05-31 0001731348us-gaap:AccumulatedTranslationAdjustmentMember2025-06-012025-08-31 0001731348us-gaap:AccumulatedTranslationAdjustmentMember2025-08-31 0001731348tlry:AphriaDiamondMember2025-08-31 0001731348tlry:ColCannaSASMember2025-08-31 0001731348tlry:AphriaDiamondMember2025-08-31 0001731348tlry:ColCannaSASMember2025-08-31 0001731348srt:SubsidiariesMember2025-08-31 0001731348tlry:SuperheroAcquisitionLPMember2025-05-31 0001731348tlry:CCPharmaNordicApSMember2025-05-31 0001731348tlry:AphriaDiamondMember2025-05-31 0001731348tlry:ColCannaSASMember2025-05-31 0001731348srt:SubsidiariesMember2025-05-31 0001731348tlry:AphriaDiamondMember2025-06-012025-08-31 0001731348tlry:ColCannaSASMember2025-06-012025-08-31 0001731348srt:SubsidiariesMember2025-06-012025-08-31 0001731348tlry:SuperheroAcquisitionLPMember2024-06-012024-08-31 0001731348tlry:CCPharmaNordicApSMember2024-06-012024-08-31 0001731348tlry:AphriaDiamondMember2024-06-012024-08-31 0001731348tlry:ColCannaSASMember2024-06-012024-08-31 0001731348srt:SubsidiariesMember2024-06-012024-08-31 0001731348tlry:SuperheroAcquisitionLPMember2024-08-31 0001731348tlry:CCPharmaNordicApSMember2024-08-31 0001731348tlry:AphriaDiamondMember2024-08-31 0001731348tlry:ColCannaSASMember2024-08-31 0001731348tlry:ConvertibleDebenturesMember2025-08-31 0001731348tlry:MaterialPurchaseObligationsMember2025-08-31 0001731348us-gaap:CapitalAdditionsMember2025-08-31 0001731348tlry:BeverageAlcoholBusinessMember2025-06-012025-08-31 0001731348tlry:BeverageAlcoholBusinessMember2024-06-012024-08-31 0001731348tlry:CannabisSegmentMember2025-06-012025-08-31 0001731348tlry:CannabisSegmentMember2024-06-012024-08-31 0001731348tlry:DistributionBusinessMember2025-06-012025-08-31 0001731348tlry:DistributionBusinessMember2024-06-012024-08-31 0001731348tlry:WellnessBusinessMember2025-06-012025-08-31 0001731348tlry:WellnessBusinessMember2024-06-012024-08-31 0001731348us-gaap:EmployeeSeveranceMembertlry:CannabisSegmentMember2025-06-012025-08-31 0001731348us-gaap:FacilityClosingMembertlry:CannabisSegmentMembercountry:NZ2025-06-012025-08-31 0001731348tlry:HopValleyMemberus-gaap:FacilityClosingMembertlry:CannabisSegmentMember2024-06-012025-05-31 0001731348tlry:HopValleyMemberus-gaap:FacilityClosingMembertlry:CannabisSegmentMember2025-06-012025-08-31 0001731348tlry:LongtermDebtExcludingConvertibleDebenturesMember2024-05-31 0001731348us-gaap:ConvertibleDebtMember2025-08-31 0001731348us-gaap:ConvertibleDebtMember2024-05-31 0001731348us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-08-31 0001731348us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-08-31 0001731348us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-08-31 0001731348us-gaap:FairValueMeasurementsRecurringMember2025-08-31 0001731348us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-05-31 0001731348us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-05-31 0001731348us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-05-31 0001731348us-gaap:FairValueMeasurementsRecurringMember2025-05-31 0001731348tlry:BitcoinMember2025-08-31 0001731348tlry:SweetwaterMontaukAndTrussMembertlry:MeasurementInputProbabilityOfAchievementMembersrt:MaximumMember2025-08-31 0001731348tlry:SweetwaterMontaukAndTrussMembertlry:MeasurementInputProbabilityOfAchievementMembersrt:MinimumMember2025-08-31 0001731348us-gaap:FairValueInputsLevel3Membertlry:ContingentConsiderationMember2025-06-012025-08-31 0001731348tlry:SweetwaterMontaukAndTrussMembertlry:MeasurementInputProbabilityOfAchievementMembersrt:MinimumMember2024-08-31 0001731348us-gaap:FairValueInputsLevel3Membertlry:ContingentConsiderationMember2024-08-31 0001731348us-gaap:FairValueInputsLevel3Membertlry:EquityInvestmentsMember2025-05-31 0001731348us-gaap:FairValueInputsLevel3Membertlry:WarrantLiabilityMember2025-05-31 0001731348us-gaap:FairValueInputsLevel3Membertlry:ContingentConsiderationMember2025-05-31 0001731348us-gaap:FairValueInputsLevel3Membertlry:EquityInvestmentsMember2025-06-012025-08-31 0001731348us-gaap:FairValueInputsLevel3Membertlry:WarrantLiabilityMember2025-06-012025-08-31 0001731348us-gaap:FairValueInputsLevel3Membertlry:EquityInvestmentsMember2025-08-31 0001731348us-gaap:FairValueInputsLevel3Membertlry:WarrantLiabilityMember2025-08-31 0001731348us-gaap:FairValueInputsLevel3Membertlry:ContingentConsiderationMember2025-08-31 0001731348us-gaap:NotesReceivableMemberus-gaap:FairValueInputsLevel3Member2024-05-31 0001731348us-gaap:FairValueInputsLevel3Membertlry:EquityInvestmentsMember2024-05-31 0001731348us-gaap:FairValueInputsLevel3Membertlry:WarrantLiabilityMember2024-05-31 0001731348us-gaap:FairValueInputsLevel3Membertlry:ContingentConsiderationMember2024-05-31 0001731348tlry:APHA24Memberus-gaap:FairValueInputsLevel3Memberus-gaap:LongTermDebtMember2024-05-31 0001731348us-gaap:NotesReceivableMemberus-gaap:FairValueInputsLevel3Member2024-06-012024-08-31 0001731348us-gaap:FairValueInputsLevel3Membertlry:EquityInvestmentsMember2024-06-012024-08-31 0001731348us-gaap:FairValueInputsLevel3Membertlry:WarrantLiabilityMember2024-06-012024-08-31 0001731348us-gaap:FairValueInputsLevel3Membertlry:ContingentConsiderationMember2024-06-012024-08-31 0001731348tlry:APHA24Memberus-gaap:FairValueInputsLevel3Memberus-gaap:LongTermDebtMember2024-06-012024-08-31 0001731348us-gaap:NotesReceivableMemberus-gaap:FairValueInputsLevel3Member2024-08-31 0001731348us-gaap:FairValueInputsLevel3Membertlry:EquityInvestmentsMember2024-08-31 0001731348us-gaap:FairValueInputsLevel3Membertlry:WarrantLiabilityMember2024-08-31 0001731348tlry:APHA24Memberus-gaap:FairValueInputsLevel3Memberus-gaap:LongTermDebtMember2024-08-31 0001731348tlry:MeasurementInputConversionRateMembersrt:MinimumMemberus-gaap:ValuationTechniqueOptionPricingModelMember2025-08-31 0001731348us-gaap:MeasurementInputPriceVolatilityMembersrt:MinimumMemberus-gaap:ValuationTechniqueOptionPricingModelMember2025-08-31 0001731348us-gaap:MeasurementInputExpectedTermMembersrt:MinimumMemberus-gaap:ValuationTechniqueOptionPricingModelMember2025-08-31 0001731348us-gaap:MeasurementInputDiscountRateMembersrt:MinimumMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2025-08-31 0001731348tlry:MeasurementInputProbabilityOfAchievementMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2025-08-31 0001731348tlry:MedicalCannabisProductsMembertlry:CannabisSegmentMember2025-06-012025-08-31 0001731348tlry:MedicalCannabisProductsMembertlry:CannabisSegmentMember2024-06-012024-08-31 0001731348tlry:AdultuseCannabisProductsMembertlry:CannabisSegmentMember2025-06-012025-08-31 0001731348tlry:AdultuseCannabisProductsMembertlry:CannabisSegmentMember2024-06-012024-08-31 0001731348tlry:WholesaleCannabisProductsMembertlry:CannabisSegmentMember2025-06-012025-08-31 0001731348tlry:WholesaleCannabisProductsMembertlry:CannabisSegmentMember2024-06-012024-08-31 0001731348tlry:InternationalCannabisProductsMembertlry:CannabisSegmentMember2025-06-012025-08-31 0001731348tlry:InternationalCannabisProductsMembertlry:CannabisSegmentMember2024-06-012024-08-31 0001731348country:US2025-06-012025-08-31 0001731348country:US2024-06-012024-08-31 0001731348country:CA2025-06-012025-08-31 0001731348country:CA2024-06-012024-08-31 0001731348us-gaap:EMEAMember2025-06-012025-08-31 0001731348us-gaap:EMEAMember2024-06-012024-08-31 0001731348tlry:RestOfWorldMember2025-06-012025-08-31 0001731348tlry:RestOfWorldMember2024-06-012024-08-31 0001731348country:US2025-08-31 0001731348country:US2025-05-31 0001731348country:CA2025-08-31 0001731348country:CA2025-05-31 0001731348us-gaap:EMEAMember2025-08-31 0001731348us-gaap:EMEAMember2025-05-31 0001731348tlry:RestOfWorldMember2025-08-31 0001731348tlry:RestOfWorldMember2025-05-31 0001731348us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembertlry:MajorCustomersMember2025-06-012025-08-31 0001731348tlry:WarrantsMemberus-gaap:SubsequentEventMember2025-09-052025-09-15 0001731348tlry:PromissoryNoteMembertlry:AphriaDiamondMemberus-gaap:SubsequentEventMember2025-10-09 0001731348tlry:DoubleDiamondHoldingsLtdMemberus-gaap:SubsequentEventMember2025-10-092025-10-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~February~~August 2831, 2025

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-38594

TILRAY BRANDS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	82-4310622
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
265 Talbot Street West, Leamington, ON	N8H 5L4
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (844) 845-7291

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

TLRY

The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒	Accelerated filer	☐

Non-accelerated filer	☐	Smaller reporting company	☐

Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☒ No ☐

As of ~~April~~October 47, 2025, the registrant had 1,~~006~~122,~~495~~863,~~926~~ 166 shares of Common Stock, $0.0001 par value per share issued and outstanding.

Table of Contents

		Page
PART I.	FINANCIAL INFORMATION	1
Item 1.	Financial Statements (Unaudited)	1
	Consolidated Statements of Financial Position (Unaudited)	1
	Consolidated Statements of Loss and Comprehensive Loss (Unaudited)	2
	Consolidated Statements of Stockholders' Equity (Unaudited)	3
	Consolidated Statements of Cash Flows (Unaudited)	4
	Notes to Condensed Interim Consolidated Financial Statements (Unaudited)	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	25
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	46
Item 4.	Controls and Procedures	46
PART II.	OTHER INFORMATION	47
Item 1.	Legal Proceedings	47
Item 1A.	Risk Factors	48
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	49
Item 3.	Defaults Upon Senior Securities	49
Item 4.	Mine Safety Disclosures	49
Item 5.	Other Information	49
Item 6.	Exhibits	50
Signatures		52

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q for the fiscal quarter ended ~~February~~August 2831, 2025 (the “Form 10-Q”) contains forward-looking statements under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Such statements involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward-looking statements under the Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “project,” “will,” “would,” “seek,” or “should,” or the negative or plural of these words or similar expressions or variations are intended to identify such forward-looking statements. Forward-looking statements include, among other things, our beliefs or expectations relating to our future performance, results of operations and financial condition ~~and liquidity~~; our intentions ~~or expectations~~ regarding our cost savings initiatives; our strategic initiatives, business strategy, supply chain, brand portfolio, product performance and expansion efforts; our intentions regarding the use of net proceeds from our ATM Program; our intentions regarding our capital structure and TLRY 27 Notes; current or future macroeconomic trends; ~~our~~ ~~expectations~~current ~~and potential impacts of regulatory~~ or ~~industry~~future ~~developments;~~macroeconomic ~~our~~trends ~~expectations for our positioning~~ and ~~cannabis~~industry ~~market~~or ~~share~~regulatory ~~in Europe and other markets~~trends; our statements regarding the consolidation of the Canadian cannabis industry; our expectations ~~regarding~~for ~~any future tax developments, tariffs or other trade restrictions;~~ our ~~expectations~~positioning ~~regarding~~and ~~our~~cannabis ~~ability~~market toshare ~~regain~~in ~~compliance~~Europe ~~with~~and ~~Nasdaq~~other ~~listing standards~~markets; future corporate acquisitions and strategic transactions; and our synergies, cash savings and efficiencies anticipated from the integration of our completed acquisitions and strategic transactions.

Risks and uncertainties that may cause actual results to differ materially from forward-looking statements include, but are not limited to, those identified in this Form 10-Q and other risks and matters described in our most recent Annual Report on Form 10-K for the fiscal year ended May 31, ~~2024~~2025 as well as our other filings made from time to time with the U.S. Securities and Exchange Commission and in our Canadian securities filings.

Forward looking statements are based on information available to us as of the date of this Form 10-Q and, while we believe that information provides a reasonable basis for these statements, these statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. You should not rely upon forward-looking statements or forward-looking information as predictions of future events.

We undertake no obligation to update forward-looking statements to reflect actual results or changes in assumptions or circumstances, except as required by applicable law.

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited).

TILRAY BRANDS, INC.

Consolidated Statements of Financial Position

(in thousands of United States dollars, unaudited)

	February 28,			May 31,
	August 31,			May 31,
	2025			~~2024~~2025
Assets
Current assets
Cash and cash equivalents	$	~~199~~264,~~956~~828		$	~~228~~221,~~340~~666
Marketable securities		~~48,458~~—			3234,~~182~~697
Accounts receivable, net		~~103~~107,~~367~~075			~~101~~121,~~695~~489
Inventory		~~263~~282,~~398~~787			~~252~~270,~~087~~882
Prepaids and other current assets		40,~~138~~650			3134,~~332~~092
Assets held for sale		305,~~972~~800			325,~~074~~800
Total current assets		~~686~~701,~~289~~140			~~677~~688,~~710~~626
Capital assets		~~537~~560,~~800~~157			~~558~~568,~~247~~433
Operating lease, right-of-use assets		1621,~~994~~003			1622,~~101~~279
Intangible assets		847,215			915,469
Digital assets		992			—
Goodwill		1,299,781			2,008,884
Intangible assets		25,173			21,423
Long-term investments		10,035			7,859
Goodwill		752,350			752,350
Convertible notes receivable		—			32,000
Long-term investments		10,172			10,132
Other assets		511,~~032~~659			511,~~395~~084
Total assets	$	32,~~403~~082,~~146~~646		$	42,~~221~~074,~~665~~327
Liabilities
Current liabilities
Bank indebtedness	$	108,~~740~~185		$	187,~~033~~181
Accounts payable and accrued liabilities		~~216~~230,~~567~~913			~~241~~235,~~957~~322
Contingent consideration		~~15,000~~—			15,000
Warrant liability		~~357~~4,762			31,~~253~~092
Current portion of lease liabilities		67,~~606~~477			56,~~091~~941
Current portion of long-term debt		1216,~~904~~295			1514,~~506~~767
Current portion of convertible debentures payable		—			330
Total current liabilities		267,632			280,303
Total current liabilities		262,174			299,170
Long - term liabilities
Lease liabilities		6063,~~188~~345			6064,~~422~~925
Long-term debt		~~149~~144,~~401~~175			~~158~~148,~~352~~493
Convertible debentures payable		~~104~~84,~~071~~267			~~129~~86,~~583~~428
Deferred tax liabilities, net		~~123~~1,~~938~~943			~~130~~3,~~870~~748
Other liabilities		~~1,271~~626			90855
Total liabilities		~~701~~561,~~043~~988			~~778~~584,~~487~~752
Commitments and contingencies (refer to Note 19)
Stockholders' equity
Common stock ($0.0001 par value; 1,416,000,000 common shares authorized; 983,372,617 and 831,925,373 common shares issued and outstanding, respectively)		99			83
Common stock ($0.0001 par value; 1,416,000,000 common shares authorized; 1,118,291,159 and 1,060,678,745 common shares issued and outstanding, respectively)		111			106
Treasury Stock (3,213,914 and 2,004,218 treasury shares issued and outstanding, respectively)		—			—
Preferred shares ($0.0001 par value; 10,000,000 preferred shares authorized; nil and nil preferred shares issued and outstanding, respectively)		—			—
Treasury Stock (9,619,421 and nil treasury shares issued and outstanding, respectively)		—			—
Additional paid-in capital		6,431,410			6,401,657
Additional paid-in capital		6,357,039			6,146,810
Accumulated other comprehensive loss		(43,230	)		(43,063	)
Accumulated other comprehensive loss		(52,935	)		(43,499	)
Accumulated deficit		(4,847,548	)		(4,847,226	)
Accumulated deficit		(3,574,431	)		(2,660,488	)
Total Tilray Brands, Inc. stockholders' equity		1,540,743			1,511,474
Total Tilray Brands, Inc. stockholders' equity		2,729,772			3,442,906
Non-controlling interests		(20,085	)		(21,899	)
Non-controlling interests		(27,669	)		272
Total stockholders' equity		1,520,658			1,489,575
Total stockholders' equity		2,702,103			3,443,178
Total liabilities and stockholders' equity	$	2,082,646		$	2,074,327
Total liabilities and stockholders' equity	$	3,403,146		$	4,221,665

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

TILRAY BRANDS, INC.

Consolidated Statements of Income (Loss ) and Comprehensive Income (Loss)

(in thousands of United States dollars, except for share and per share data, unaudited)

	Three months ended						~~Nine months ended~~
		February 28,			February 29,			February 28,			February 29,
	August 31,			August 31,
	2025			2024			~~2025~~			~~2024~~
Net revenue	$	~~185~~209,~~780~~501		$	~~188~~200,~~340~~044		$	~~596,774~~		$	~~559,060~~
Cost of goods sold		~~133~~152,~~769~~032			~~138~~140,~~944~~338			~~423,837~~			~~418,059~~
Gross profit		5257,~~011~~469			4959,~~396~~706			~~172,937~~			~~141,001~~
Operating expenses:
General and administrative		3941,~~246~~053			3944,~~940~~113			~~129,356~~			~~123,769~~
Selling		1312,~~905~~923			911,~~995~~690			~~41,757~~			~~24,437~~
Amortization		233,~~182~~929			21,~~558~~804			~~67,913~~			~~65,700~~
Marketing and promotion		610,~~793~~155			11,~~191~~566			~~28,079~~			~~28,934~~
Research and development		8541			~~106~~105			~~250~~			~~241~~
Change in fair value of contingent consideration		—(15,000	)		~~(5,983~~—	)		—			~~(16,790~~	)
Impairments		699,235			—			699,235			—
Litigation costs, net of recoveries		1,007			1,595
Other than temporary change in fair value of convertible notes receivable		20,000			42,681			20,000			42,681
Restructuring costs		869			4,247
Litigation costs, net of recoveries		2,758			3,363			5,254			8,439
Transaction costs (income), net		400			1,156
Restructuring costs		6,133			5,178			17,249			8,748
Total operating expenses		55,377			96,276
Transaction costs (income), net		605			3,465			2,563			13,061
Operating income (loss)		2,092			(36,570	)
Total operating expenses		811,942			131,494			1,011,656			299,220
Interest expense, net		(6,696	)		(9,842	)
Operating loss		(759,931	)		(82,098	)		(838,719	)		(158,219	)
Non-operating income (expense), net		3,832			12,646
Interest expense, net		(8,378	)		(8,517	)		(25,986	)		(26,977	)
Loss before income taxes		(772	)		(33,766	)
Non-operating income (expense), net		(24,022	)		(17,239	)		(44,631	)		(20,820	)
Income tax expense (recovery), net		(2,285	)		886
Loss before income taxes		(792,331	)		(107,854	)		(909,336	)		(206,016	)
Net income (loss)	$	1,513		$	(34,652	)
Income tax expense (recovery), net		1,203			(2,871	)		4,125			1,013
Total net income (loss) attributable to:
Net loss	$	(793,534	)	$	(104,983	)	$	(913,461	)	$	(207,029	)
Stockholders of Tilray Brands, Inc.		(322	)		(39,165	)
Total net (loss) income attributable to:
Non-controlling interests		1,835			4,513
Stockholders of Tilray Brands, Inc.		(789,436	)		(92,701	)		(913,943	)		(213,234	)
Other comprehensive gain (loss), net of tax
Non-controlling interests		(4,098	)		(12,282	)		482			6,205
Foreign currency translation gain (loss)		(188	)		4,160
Other comprehensive gain (loss), net of tax
Comprehensive income (loss)	$	1,325		$	(30,492	)
Foreign currency translation gain (loss)		(5,389	)		(4,696	)		(10,195	)		3,716
Total comprehensive income (loss) attributable to:
Total other comprehensive gain (loss), net of tax		(5,389	)		(4,696	)		(10,195	)		3,716
Stockholders of Tilray Brands, Inc.		(489	)		(35,543	)
Comprehensive loss	$	(798,923	)	$	(109,679	)	$	(923,656	)	$	(203,313	)
Non-controlling interests		1,814			5,051
Total comprehensive (loss) income attributable to:
Weighted average number of common shares - basic		1,060,271,899			875,444,828
Stockholders of Tilray Brands, Inc.		(794,414	)		(97,521	)		(923,379	)		(209,811	)
Weighted average number of common shares - diluted		1,060,271,899			875,444,828
Non-controlling interests		(4,509	)		(12,158	)		(277	)		6,498
Net loss per share - basic	$	(0.00	)	$	(0.04	)
Weighted average number of common shares - basic		908,342,792			754,439,331			860,793,723			725,346,952
Net loss per share - diluted	$	(0.00	)	$	(0.04	)
Weighted average number of common shares - diluted		908,342,792			754,439,331			860,793,723			725,346,952
Net loss per share - basic	$	(0.87	)	$	(0.12	)	$	(1.06	)	$	(0.29	)
Net loss per share - diluted	$	(0.87	)	$	(0.12	)	$	(1.06	)	$	(0.29	)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

TILRAY BRANDS, INC.

Consolidated Statements of Stockholders’ Equity

(in thousands of United States dollars, except for share data, unaudited)

													Accumulated
	Number of				Number of					Additional			other						Non-
	common		Common		treasury			Treasury		paid-in			comprehensive			Accumulated			controlling
	shares		Stock		shares			stock		capital			loss			Deficit			interests			Total
Balance at May 31, 2023		656,655,455	$	66		—		$	—	$	5,777,743		$	(46,610	)	$	(2,415,507	)	$	14,251		$	3,329,943
Balance at May 31, 2024		831,925,373	$	83		—		$	—	$	6,146,810		$	(43,499	)	$	(2,660,488	)	$	272		$	3,443,178
Share issuance - HEXO acquisition		39,705,962		4		—			—		65,158			—			—			—			65,162
Share issuance - settlement of contractual change of control severance incurred from HEXO acquisition		865,426		—		—			—		1,500			—			—			—			1,500
Share issuance - Double Diamond Holdings dividend settlement		5,004,735		—		—			—		8,146			—			—			—			8,146
Share issuance - HTI convertible note		17,148,541		2		—			—		49,998			—			—			—			50,000
Share issuance - RSUs exercised		3,912,481		—		—			—		—			—			—			—			—
Shares effectively repurchased for employee withholding tax		—		—		—			—		(4,860	)		—			—			—			(4,860	)
Equity component related to issuance of convertible debt, net of issuance costs		—		—		—			—		3,953			—			—			—			3,953
Stock-based compensation		—		—		—			—		8,257			—			—			—			8,257
Dividends declared to non-controlling interests				—		—			—		—			—			—			(7,891	)		(7,891	)
Comprehensive income (loss) for the period		—		—		—			—		—			3,049			(71,525	)		15,822			(52,654	)
Balance at August 31, 2023		723,292,600		72		—			—		5,909,895			(43,561	)		(2,487,032	)		22,182			3,401,556
Share issuance - HTI convertible note		1,032,616		—		—			—		2,313			—			—			—			2,313
Share issuance - Settlement of litigation claims from MediPharm Labs Inc		1,573,152		—		—			—		3,477			—			—			—			3,477
Share issuance - Repurchase of TLRY 23 convertible note		7,000,000		1		—			—		20,457			—			—			—			20,458
Share issuance - Settlement of equity component of TLRY 23 convertible note		—		—		—			—		(1,672	)		—			—			—			(1,672	)
Share issuance - RSUs exercised		9,184		—		—			—		—			—			—			—			—
Stock-based compensation		—		—		—			—		8,201			—			—			—			8,201
Comprehensive income (loss) for the period		—		—		—			—		—			5,194			(49,008	)		2,834			(40,980	)
Balance at November 30, 2023		732,907,552		73		—			—		5,942,671			(38,367	)		(2,536,040	)		25,016			3,393,353
Share issuance - Repurchase of APHA 24 convertible note		27,228,252		3		—			—		51,380			—			—			—			51,383
Share issuance -Double Diamond Holdings dividend settlement		13,627,391		1		—			—		28,599			—			—			(26,217	)		2,383
Share issuance - RSUs exercised		260,567		—		—			—		—			—			—			—			—
Share issuance - options exercised		4,291		—		—			—		—			—			—			—			—
Stock-based compensation		—		—		—			—		8,059			—			—			—			8,059
Dividends declared to non-controlling interests		—		—		—			—		—			—			—			(2,458	)		(2,458	)
Comprehensive income (loss) for the period		—		—		—			—		—			(4,820	)		(92,701	)		(12,158	)		(109,679	)
Balance at February 29, 2024		774,028,053		77		—			—		6,030,709			(43,187	)		(2,628,741	)		(15,817	)		3,343,041
Balance at May 31, 2024		831,925,373		83		—			—		6,146,810			(43,499	)		(2,660,488	)		272			3,443,178
Share issuance - At-the-Market (“ATM”) program		36,693,307		4		—			—		66,468			—			—			—			66,472
Share issuance - RSUs exercised		6,823,140		1		—			—		(1	)		—			—			—			—
Share issuance - options exercised		3,008		—		—			—		—			—			—			—			—
Shares effectively repurchased for employee withholding tax		—		—		—			—		(2,661	)		—			—			—			(2,661	)
Stock-based compensation		—		—		—			—		6,917			—			—			—			6,917
Comprehensive income (loss) for the period		—		—		—			—		—			3,622			(39,165	)		5,051			(30,492	)
Balance at August 31, 2024		875,444,828	$	88		—		$	—	$	6,217,533		$	(39,877	)	$	(2,699,653	)	$	5,323		$	3,483,414
Share issuance - At-the-Market (“ATM”) program		30,517,557		3		—			—		45,041			—			—			—			45,044
Balance at May 31, 2025		1,060,678,745	$	106		(2,004,218	)	$	—	$	6,401,657		$	(43,063	)	$	(4,847,226	)	$	(21,899	)	$	1,489,575
Share issuance - Repurchase of TLRY 27 convertible note		10,034,635		1		(3,682,609	)		—		17,084			—			—			—			17,085
Share issuance - At-the-Market (“ATM”) program		34,443,799		3		—			—		22,488			—			—			—			22,491
Share issuance - Settlement of equity component of TLRY 27 convertible note		—		—		—			—		(4,931	)		—			—			—			(4,931	)
Share issuance - Repurchase of TLRY 27 convertible note		12,591,816		1		(1,209,696	)		—		4,799			—			—			—			4,800
Share issuance - Double Diamond Holdings dividend settlement		13,217,588		1		—			—		23,823			—			—			(23,824	)		—
Share issuance - Settlement of equity component of TLRY 27 convertible note		—		—		—			—		(1,158	)		—			—			—			(1,158	)
Share issuance - RSUs exercised		3510,~~983~~576,799		—1		—			—		—(1	)		—			—			—			—
Share issuance - options exercised		7,354		—		—			—		—			—			—			—			—
Shares effectively repurchased for employee withholding tax		—		—		—			—		(1,427	)		—			—			—			(1,427	)
Stock-based compensation		—		—		—			—		75,~~237~~052			—			—			—			75,~~237~~052
Comprehensive income (loss) for the period		—		—		—			—		—			(~~8,080~~167	)		(~~85,342~~322	)		~~(819~~1,814	)		~~(94~~1,~~241~~325	)
Balance at November 30, 2024		929,257,945	$	93		(3,682,609	)	$	—	$	6,305,787		$	(47,957	)	$	(2,784,995	)	$	(19,320	)	$	3,453,608
Balance at August 31, 2025		1,118,291,159	$	111		(3,213,914	)	$	—	$	6,431,410		$	(43,230	)	$	(4,847,548	)	$	(20,085	)	$	1,520,658
Share issuance - At-the-Market (“ATM”) program		26,399,937		3		—			—		28,219			—			—			—			28,222
Share issuance - Repurchase of TLRY 27 convertible note		27,136,770		3		(5,936,812	)		—		26,440			—			—			—			26,443
Share issuance - Settlement of equity component of TLRY 27 convertible note		—		—		—			—		(7,442	)		—			—			—			(7,442	)
Share issuance - RSUs exercised		577,965		—		—			—		—			—			—			—			—
Stock-based compensation		—		—		—			—		4,035			—			—			—			4,035
Disposal of SH Acquisition non-controlling interests		—		—		—			—		—			—			—			(3,840	)		(3,840	)
Comprehensive income (loss) for the period		—		—		—			—		—			(4,978	)		(789,436	)		(4,509	)		(798,923	)
Balance at February 28, 2025		983,372,617	$	99		(9,619,421	)	$	—	$	6,357,039		$	(52,935	)	$	(3,574,431	)	$	(27,669	)	$	2,702,103

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

TILRAY BRANDS, INC.

Consolidated Statements of Cash Flows

(in thousands of United States dollars, unaudited)

	For the nine months ended
	For the three months ended
	February 28,			February 29,
	August 31,			August 31,
	2025			2024
Cash provided by (used in) operating activities:
Net loss	$	(913,461	)	$	(207,029	)
Net income (loss)	$	1,513		$	(34,652	)
Adjustments for:
Deferred income tax expense (recovery), net		2,686			(7,399	)
Deferred income tax (recovery) expense, net		(2,285	)		382
Unrealized foreign exchange loss (gain)		30,725			(6,622	)
Unrealized foreign exchange gain		(2,328	)		(5,602	)
Amortization		9915,~~410~~561			9531,~~183~~814
Accretion of convertible debt discount		81,~~751~~976			113,~~463~~067
Impairments		699,235			—
Unrealized loss on digital assets		8			—
Other than temporary change in fair value of convertible notes receivable		20,000			42,681
Other non-cash items		282			729
Other non-cash items		1,503			13,297
Stock-based compensation		5,052			6,917
Stock-based compensation		18,189			24,517
Gain on long-term investments		(39	)		(499	)
Loss (gain) on long-term investments & equity investments		5,540			4,255
Loss (gain) on derivative instruments		3,670			(696	)
(Gain) loss on derivative instruments		(2,896	)		13,717
Change in fair value of contingent consideration		(15,000	)		—
Change in fair value of contingent consideration		—			(16,790	)
Change in non-cash working capital:
Accounts receivable		~~321~~14,414			5(2,~~578~~342	)
Prepaids and other current assets		(87,~~258~~133	)		1(13,~~148~~570	)
Inventory		(511,~~577~~905	)		(412,~~629~~383	)
Accounts payable and accrued liabilities		(375,~~960~~127	)		(308,~~982~~472	)
Net cash used in operating activities		(811,~~792~~341	)		(6135,~~612~~307	)
Cash provided by (used in) investing activities:
Investment in capital and intangible assets		(269,~~586~~523	)		(196,~~539~~736	)
Proceeds from disposal of capital and intangible assets		~~833~~293			~~1,166~~28
(Purchase) disposal of marketable securities, net		(16,276	)		162,292
Investment in digital assets		(1,000	)		—
Business acquisitions, net of cash acquired		(18,210	)		(60,626	)
Disposal (purchase) of marketable securities, net		34,697			(42,687	)
Net cash (used in) provided by investing activities		(60,239	)		83,293
Net cash provided by (used in) investing activities		24,467			(49,395	)
Cash provided by (used in) financing activities:
Share capital issued, net of cash issuance costs		~~139~~22,~~738~~491			—66,472
Proceeds from long-term debt		3,450			32,621
Repayment of long-term debt		(2,653	)		(4,791	)
Repayment of long-term debt		(16,115	)		(17,978	)
Repayment of convertible debt		—			(330	)
Proceeds from convertible debt		—			21,553
Repayment of lease liabilities		(994	)		(862	)
Repayment of convertible debt		(330	)		(107,330	)
Net decrease in bank indebtedness		1,004			101
Repayment of lease liabilities		(2,586	)		(2,771	)
Net cash provided by financing activities		19,848			60,590
Net decrease in bank indebtedness		(7,293	)		(8,352	)
Effect of foreign exchange on cash and cash equivalents		188			958
Net cash provided by (used in) financing activities		116,864			(82,257	)
Net increase (decrease) in cash and cash equivalents		43,162			(23,154	)
Effect of foreign exchange on cash and cash equivalents		(3,217	)		197
Cash and cash equivalents, beginning of period		221,666			228,340
Net decrease in cash and cash equivalents		(28,384	)		(60,379	)
Cash and cash equivalents, end of period	$	264,828		$	205,186
Cash and cash equivalents, beginning of period		228,340			206,632
Cash and cash equivalents, end of period	$	199,956		$	146,253

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

TILRAY BRANDS, INC.

Notes to Consolidated Financial Statements

Note 1. Basis of presentation and summary of significant accounting policies

The accompanying unaudited interim consolidated financial statements reflect the accounts of the Company for the quarterly period ended ~~February~~August 2831, 2025 (the “Financial Statements”). The Financial Statements were prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and notes required by U.S. GAAP and should be read in conjunction with the audited consolidated financial statements (the “Annual Financial Statements”) included in the Company’s Annual Report on Form 10-K for the fiscal year ended May 31, ~~2024~~2025 (the “Annual Report”). These Financial Statements reflect all adjustments, which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full fiscal year.

These Financial Statements have been prepared on a going concern basis, which assumes that the Company will continue in operation for the foreseeable future and, accordingly, will be able to realize its assets and discharge its liabilities in the normal course of operations as they come due, under the historical cost convention except for certain financial instruments that are measured at fair value, as detailed in the Company’s accounting policies.

All amounts in the Financial Statements, and the accompanying notes and tables have been rounded to the nearest thousand, except par values and per share amounts, and unless otherwise indicated.

Certain items of the comparative figures have been changed to conform to the presentation adopted in the current period. In limited cases, certain line items that were previously aggregated have been disaggregated within the Consolidated Statements of Cash Flows for the periods presented.

Basis of consolidation

Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of all subsidiaries are included in the Financial Statements from the date that control commences until the date that control ceases. All intercompany balances and transactions have been eliminated on consolidation. A complete list of our subsidiaries that existed as of our most recent fiscal year end is included in the Annual Report.

Impairment of goodwill and indefinite-lived intangible assets

Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently when events or circumstances indicate that impairment may have occurred. As part of the impairment evaluation, we may elect to perform an assessment of qualitative factors. If this qualitative assessment indicates that it is more likely than not that the fair value of the indefinite-lived intangible asset or the reporting unit (for goodwill) is less than its carrying value, a quantitative impairment test to compare the fair value to the carrying value is performed. An impairment charge is recorded if the carrying value exceeds the fair value. The assessment of whether an indication of impairment exists is performed at the end of each reporting period and requires the application of judgment, historical experience, and external and internal sources of information. We make estimates in determining the future cash flows and discount rates in the quantitative impairment test to compare the fair value to the carrying value.

During the period ended February 28, 2025, the Company identified an indicator of impairment with respect to its reporting units and performed an interim impairment test, and determined that the fair value of certain reporting units was not greater than their carrying amounts, resulting in an impairment expense of $699,235, see Note 6 (Goodwill).

Convertible notes receivable

Convertible notes receivable includes various investments in which the Company has the right, or potential right to convert the indenture into Common Stock of the investee and are classified as available-for-sale and are recorded at fair value. Unrealized gains and losses during the year, net of the related tax effect, are excluded from income and reflected in other comprehensive income (loss), and the cumulative effect is reported as a separate component of shareholders' equity until realized. We use judgement to assess convertible notes receivables for impairment at each measurement date. Convertible notes receivables are impaired when a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in the consolidated statements of loss and comprehensive loss and a new cost basis for the investment is established. We also evaluate whether there is a plan to sell the security, or it is more likely than not that we will be required to sell the security before recovery. If neither of the conditions exist, then only the portion of the impairment loss attributable to credit loss is recorded in the statements of loss and the remaining amount is recorded in other comprehensive income (loss).

Earnings (loss) per share

Basic earnings (loss) per share is computed by dividing reported net income (loss) attributable to stockholders of Tilray Brands, Inc. by the weighted average number of common shares outstanding during the ~~year~~period. Diluted earnings (loss) per share is computed by dividing reported net income (loss) attributable to stockholders of Tilray Brands, Inc. by the sum of the weighted average number of common shares and the number of dilutive potential common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options, warrants, and RSUs and the incremental shares issuable upon conversion of the convertible debentures and similar instruments. Shares of Common Stock outstanding under the share lending arrangement entered into in conjunction with the TLRY 27 Notes, see Note 1312 (Convertible debentures payable) are excluded from the calculation of basic and diluted earnings per share because the borrower of the shares is required under the share lending arrangement to refund any dividends paid on the shares lent.

In computing diluted earnings (loss) per share, common share equivalents are not considered in periods in which a net loss attributable to Tilray shareholders is reported, as the inclusion of the common share equivalents would be anti-dilutive. For the three ~~and nine~~ months ended ~~February~~August 2831, 2025 and ~~February~~August 2931, 2024, the dilutive potential common share equivalents outstanding consisted of the following: 2152,~~896~~107,~~120~~218 and 2023,~~652~~411,~~315~~577 common shares from RSUs, 3,032,~~559~~011 and 53,~~744~~359,~~302~~144 common shares from share options, 6,209,000 and 6,209,000 common shares for warrants and 4837,~~738~~664,~~225~~780 and 7264,~~653~~971,~~364~~746 common shares for convertible debentures, respectively.

~~Recently~~New ~~issued~~ accounting pronouncements not yet adopted

In August 2023, the Financial Accounting Standards Board ("“FASB"”) issued Accounting Standards Update ("“ASU"”) 2023-05, Business Combination - Joint Venture Formations (Subtopic 805-60) Recognition and Initial Measurement (“ASU 2023-05”), which is intended to address the accounting for contributions made to a joint venture. ASU 2023-05 is effective for the Company beginning June 1, 2026. This update will be applied prospectively and the Company is currently evaluating the effect of adopting this ASU.

In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative, which amends the disclosure or presentation requirements related to various subtopics in the FASB Accounting Standards Codification (the “Codification”). The effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. If by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective for any entity. The Company is currently evaluating the effect of adopting this ASU.

In ~~November~~ December 2023, the FASB issued ASU 2023-0709, ~~Segment~~Income ~~Reporting~~Taxes (Topic ~~280~~ 740) Improvements to ~~Reportable~~Income ~~Segment~~Tax Disclosures, which requires public entities to disclose specific categories in the rate reconciliation and provide additional information ~~about~~for ~~their~~reconciling ~~reportable~~items ~~segments,~~that ~~including segments'~~meet ~~significant~~a ~~expenses~~quantitative threshold on an ~~interim and~~ annual basis. ~~ASU~~ ASU 2023-07 09 is effective for the Company beginning with its fiscal year ended May 31, ~~2025~~ 2026 and will be disclosed ~~retrospectively~~ in the Financial Statements reported in our Annual Report on Form 10-K filed with the SEC for such period. The Company is in the process of evaluating the impact of the financial statement disclosure ~~requirements~~requirement.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) Improvements to Income Tax Disclosures, which requires public entities to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis. ASU 2023-09 is effective for the Company beginning June 1, 2025. The Company is currently evaluating the effect of adopting this ASU.

In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires disaggregated disclosure of income statement expenses for public business entities. ASU 2024-03 is effective for the Company beginning June 1, 2026. The Company is currently evaluating the effect of adopting this ASU.

~~In November~~New ~~2024,~~accounting ~~the~~pronouncements ~~FASB~~recently issued ASU 2024-04, Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments, which seeks to clarify the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. ASU 2024-04 is effective for the Company beginning June 1, 2025. The Company is currently evaluating the effect of adopting this ASU.adopted

In November 2024, the FASB issued ASU 2024-04, Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments, which seeks to clarify the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. The Company adopted ASU 2024-04 beginning June 1, 2025, however, it did not have any impact on our unaudited interim consolidated financial statements.

Digital Assets

In December 2023, FASB issued ASU 2023-08, Intangibles—Goodwill and Other—Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets. ASU 2023-08 requires certain crypto assets to be measured at fair value separately on the balance sheet with gains and losses from changes in the fair value reported as unrealized gains or losses in the consolidated statement of income (loss) and comprehensive income (loss) each reporting period. ASU 2023-08 also enhances the other intangible asset disclosure requirements by requiring the name, cost basis, fair value, and number of units for each significant crypto asset holding. In conjunction with the acquisition of digital assets during the fiscal quarter ended August 31, 2025, the Company adopted and applied ASU-2023-08 henceforth.

The Company's digital assets are initially recorded at cost, and are subsequently measured at fair value as of each reporting period. The Company determines the fair value of its digital assets in accordance with ASC 820, Fair Value Measurement, based on quoted prices in its principal market for Bitcoin (Level 1). Changes in fair value are recognized as incurred in the Company's consolidated statement of income (loss) and comprehensive income (loss), as “Unrealized (gain) loss on digital assets,” within non-operating (income) and expenses, net.

Note 2. Inventory

Inventory consisted of the following:

	February 28,		May 31,
	August 31,		May 31,
	2025		~~2024~~2025
Beverage inventory	$	7270,~~313~~622	$	5263,~~831~~965
Cannabis plants		1827,~~086~~033		1324,~~828~~045
Dried cannabis		95106,~~846~~653		~~108~~103,~~721~~507
Cannabis derivatives		94,~~127~~481		47,~~504~~877
Cannabis vapes		21,~~583~~892		41,~~132~~860
Packaging and other inventory items		14,~~550~~508		2215,~~115~~366
Distribution inventory		3744,~~846~~450		3538,~~645~~735
Wellness inventory		13,~~047~~148		1015,~~311~~527
Total	$	~~263~~282,~~398~~787	$	~~252~~270,~~087~~882

Note 3. Capital assets

Capital assets consisted of the following:

	February 28,			May 31,
	August 31,			May 31,
	2025			~~2024~~2025
Land	$	4345,~~599~~122		$	4544,~~577~~529
Production facilities		~~377~~416,~~214~~605			~~369~~407,~~630~~650
Equipment		~~260~~278,~~875~~584			~~258~~280,~~532~~585
Leasehold improvements		20,~~166~~415			1920,~~377~~415
Finance lease, right-of-use assets		40,~~691~~019			4340,~~993~~308
Construction in progress		1211,~~276~~190			1011,~~713~~241
	$	~~754~~811,~~821~~935		$	~~747~~804,~~822~~728
Less: accumulated amortization		(~~217~~251,~~021~~778	)		(~~189~~236,~~575~~295	)
Total	$	~~537~~560,~~800~~157		$	~~558~~568,~~247~~433

Assets held for sale consisted of the following:

	February 28,		May 31,
	August 31,		May 31,
	2025		~~2024~~2025
Land	$	912	$	954
Production facilities	$	5,800	$	5,800
Production facilities		23,876		24,682
Total	$	5,800	$	5,800
Equipment		6,184		6,438
	$	30,972	$	32,074

~~Beginning~~As inof August ~~the fiscal year ended May~~ 31, ~~2024~~2025, the Company classified the ~~following assets from its Cannabis reporting segment as held for sale, including its Quebec cultivation facility, the~~ Fort Collins, CO partially vacant warehouse facility, ~~and~~from ~~the~~its ~~Broken~~Cannabis ~~Coast former~~reporting ~~cultivation~~segment ~~facility~~as ~~located in Duncan, B.C. Following an assessment of facility capacity utilization, it was determined that these facilities would be exited and~~ held for sale. It isThe ~~expected~~Company ~~that~~expects the sale of ~~these assets will be completed within twelve months from~~ the ~~period~~asset ~~in which they were classified as held for sale. Assets held for sale are measured at the lower of carrying amount and their fair value less costs~~ to ~~sell and~~be ~~are no longer~~completed ~~depreciated.~~during ~~Disposition of assets held for sale are recorded in~~ the ~~consolidated~~fiscal ~~statement~~year ~~of loss~~ended May ~~and comprehensive loss~~31, ~~within the line, “Non-operating income (expense), net”~~2026.

Note 4. Leases

The table below presents the lease-related assets and liabilities recorded on the balance sheet.

		February 28,		May 31,
		August 31,		May 31,
	Classification on Balance Sheet	2025		~~2024~~2025
Assets
Finance lease, right-of-use assets	Capital assets	$	40,~~691~~019	$	4340,~~993~~308
Operating lease, right-of-use assets	Operating lease, right-of-use assets		1621,~~994~~003		1622,~~101~~279
Total right-of-use assets		$	5761,~~685~~022	$	6062,~~094~~587
Liabilities
Current:
Current portion of finance lease liabilities	Current portion of lease liabilities	$	1,~~527~~582	$	1,~~092~~560
Current portion of operating lease liabilities	Current portion of lease liabilities		5,~~079~~895		35,~~999~~381
Non-current:
Finance lease liabilities	Lease liabilities		4443,~~615~~965		4344,~~948~~295
Operating lease liabilities	Lease liabilities		1519,~~573~~380		1620,~~474~~630
Total lease liabilities		$	6670,~~794~~822	$	6571,~~513~~866

The following table presents the future undiscounted payments associated with lease liabilities as of ~~February~~August 2831, 2025:

	Operating			Finance
	leases			leases
2025 (remaining three months)	$	1,744		$	1,128
2026 (remaining nine months)	$	5,902		$	3,388
2026		6,759			4,511
2027		6,931			4,518
2027		5,788			4,511
2028		5,916			4,518
2028		4,776			4,511
2029		2,941			4,370
Thereafter		610,~~528~~647			7066,~~801~~694
Total minimum lease payments	$	2532,~~595~~337		$	8583,~~462~~488
Imputed interest		(47,~~943~~062	)		(3937,~~320~~941	)
Obligations recognized	$	2025,~~652~~275		$	4645,~~142~~547

Note 5. Intangible Assets

Intangible assets consisted of the following items:

	February 28,			May 31,
	Customer relationships & distribution channel			Licenses, permits & applications			Intellectual property, trademarks, knowhow & brands			August 31,
	~~2025~~			~~2024~~						2025
Customer relationships & distribution channels	$	589,595		$	603,939
Cost	$	2,409		$	15,047		$	16,381		$	33,837
Licenses, permits & applications		374,914			368,057
Costs of impaired assets		444,208			367,022			452,530			1,263,760
Non-compete agreements		12,289			12,403
Gross carrying amounts		446,617			382,069			468,911			1,297,597
Intellectual property, trademarks, knowhow & brands		593,212			608,672
Accumulated amortization		(41	)		(5,544	)		(3,079	)		(8,664	)
	$	1,570,010		$	1,593,071
Accumulated impairment losses		(444,208	)		(367,022	)		(452,530	)		(1,263,760	)
Less: accumulated amortization		(306,951	)		(261,758	)
Total	$	2,368		$	9,503		$	13,302		$	25,173
Less: impairments		(415,844	)		(415,844	)
Total	$	847,215		$	915,469

Included in licenses, permits & applications are multi-period sponsorship rights of $15,047 and indefinite-lived intangible assets of $173,707 as of February 28, 2025, compared to $nil and $182,851 as of May 31, 2024, respectively.

	Customer relationships & distribution channel			Licenses, permits & applications			Non-compete agreements			Intellectual property, trademarks, knowhow & brands			May 31,
													2025
Cost	$	610,240		$	387,238		$	12,449		$	618,514		$	1,628,441
Accumulated amortization		(166,032	)		(9,693	)		(12,449	)		(155,084	)		(343,258	)
Accumulated impairment losses		(444,208	)		(367,022	)		—			(452,530	)		(1,263,760	)
Total	$	—		$	10,523		$	—		$	10,900		$	21,423

~~Expected~~Licenses, ~~future~~permits ~~amortization~~& ~~expense~~applications ~~for~~are ~~intangible~~predominantly ~~assets~~comprised as of ~~February~~ ~~28, 2025~~multi-period ~~is as~~sponsorship ~~follows:~~rights.

	Amortization
2025 (remaining three months)	$	17,880
2026		71,520
2027		71,520
2028		71,520
2029		71,520
Thereafter		358,533
Total	$	662,493

Expected future amortization expense for intangible assets as of August 31, 2025 is as follows:

	*Amortization*
2026 (remaining nine months)	$	5,737
2027		7,649
2028		4,085
2029		2,897
2030		2,897
Thereafter		1,908
Total	$	25,173

Note 6. Goodwill

The following table shows the carrying amount of goodwill by reporting units:

	Reporting Unit												February 28,
	August 31,
	Beverage			Cannabis			Wellness			Distribution			2025
	2025
Goodwill	$	120,802		$	2,640,669		$	77,470		$	4,458		$	2,843,399
Cannabis Goodwill	$	2,640,669
Accumulated impairment losses		(~~100~~1,~~000~~897,431	)		~~(1,397,431~~	)		~~(40,000~~	)		~~(4,235~~	)		~~(1,541,666~~	)
Effect of foreign exchange		—9,112			~~9,112~~			~~(10,841~~	)		~~(223~~	)		~~(1,952~~	)
Total	$	20752,~~802~~350		$	~~1,252,350~~		$	~~26,629~~		$	—		$	~~1,299,781~~

	Reporting Unit												May 31,
	Beverage			Cannabis			Wellness			Distribution			~~2024~~2025
Goodwill	$	120,802		$	2,640,669		$	77,470		$	4,458		$	2,843,399
Accumulated impairment losses		—(120,802	)		(~~827~~1,897,431	)		(1568,~~000~~186	)		—(4,235	)		(~~842~~2,~~431~~090,654	)
Effect of foreign exchange		—			159,~~823~~112			(79,~~847~~284	)		(60223	)		~~7,916~~(395	)
Total	$	~~120,802~~—		$	1752,~~829,061~~350		$	~~54,623~~—		$	~~4,398~~—		$	2752,~~008,884~~350

Based upon a combination of factors including a sustained decline in the Company’s market capitalization stemming from the uncertainty resulting from certain changes in U.S. global economic policy, including slower than anticipated progress in global cannabis legalization and overall declines in the craft beer industry sector, the Company concluded that it is more likely than not, that the fair value of our reporting units were less than their carrying amounts as of February 28, 2025. Accordingly, the Company utilized the income approach, which uses future discounted cash flows, to determine the fair value of each reporting unit. As a result, the Company recorded non-cash impairment charges of $570,000 of cannabis goodwill, $100,000 of beverage goodwill, $25,000 of wellness goodwill and $4,235 of distribution goodwill for the three and nine months ended February 28, 2025. The non-cash charge had no impact on the Company’s compliance with debt covenants at February 28, 2025, its cash flows or available liquidity.

In the Company's cannabis goodwill assessment, the Company used a discount rate of 12.00%, a terminal growth rate of 5%, and an average revenue growth rate of 34% over 5 years, based on an 88% and 40% average probability of anticipated EU and U.S. cannabis legalization, respectively and/or changes in drug policy in various countries within the next 5 years. A 1% increase in the discount rate would result in an additional $285,000 in impairment, a 1% decrease in the terminal growth rate would result in an additional $210,000 in impairment, a 5% decrease in the average growth rate would result in an additional $170,000 in impairment, a 5% decrease in the probability of EU cannabis legalization would result in an additional $80,000 in impairment and a 5% decrease in the probability of US cannabis legalization would result in an additional $7,000 in impairment. Changes to those probabilities resulting in continued delays in or cessation of legalization of cannabis within the United States and internationally, or adverse regulatory changes to existing legislation, could have an unfavorable impact on the estimated future cash flows, and ultimately, the fair value of the cannabis reporting unit, which may result in a material impairment expense recognized in future reporting periods.

In the Company's beverage goodwill assessment, the Company used a discount rate of 9.25%, a terminal growth rate of 2%, and an average revenue growth rate of 12% over 5 years. A 1% increase in the discount rate would result in an additional $70,000 in impairment, a 1% decrease in the terminal growth rate would result in an additional $50,000 in impairment and a 1% decrease in the average growth rate would result in an additional $40,000 in impairment.

In the Company's wellness goodwill assessment, the Company used a discount rate of 10.50%, a terminal growth rate of 2%, and an average revenue growth rate of 7% over 5 years. A 1% increase in the discount rate would result in an additional $5,000 in impairment, a 1% decrease in the terminal growth rate would result in an additional $3,000 in impairment and a 1% decrease in the average growth rate would result in an additional $2,000 in impairment.

In the Company's distribution goodwill assessment, the Company recorded $4,235 of impairments which brought the remaining distribution goodwill balance to $nil.

Note 7. Business acquisitions

Acquisition of Craft Beverage Business Portfolio

On September 29, 2023, Tilray acquired a portfolio of beverage brands, assets and businesses comprising eight craft beer and beverage brands from Anheuser-Busch Companies, LLC, (“AB”) including breweries and brewpubs associated with them (the “Craft Acquisition”). The acquired businesses/brands include Shock Top, Breckenridge Brewery, Blue Point Brewing Company, 10 Barrel Brewing Company, Redhook Brewery, Widmer Brothers Brewing, Square Mile Cider Company, and HiBall Energy. The Company paid a total purchase price of $83,658 in cash, net of a working capital adjustment at closing of $1,342.

The table below summarizes the fair value of the assets acquired and liabilities assumed at the acquisition date:

	Amount
Consideration
Cash consideration	$	83,658
Net assets acquired
Current assets
Cash and cash equivalents		77
Inventory		20,993
Prepaids and other current assets		573
Long-term assets
Capital assets		82,913
Finance lease, right-of-use assets		42,497
Operating lease, right-of-use assets		7,677
Other assets		108
Total assets		154,838
Current liabilities
Accounts payable and accrued liabilities		18,006
Current portion of finance lease liabilities		1,031
Current portion of operating lease liabilities		1,408
Long - term liabilities
Finance lease liabilities		44,465
Operating lease liabilities		6,270
Total liabilities		71,180
Total net assets acquired		83,658

In the event that the Craft Acquisition had occurred on June 1, 2023, the Company would have had, on an unaudited proforma basis, additional net revenue of approximately $nil and $55,000 for the three and nine months ended February 29, 2024, respectively, and its consolidated net loss and comprehensive net loss would have increased by approximately $nil and $5,000 for the three and nine months ended February 29, 2024, respectively. This unaudited pro forma financial information does not reflect the realization of any expected ongoing synergies relating to the integration of the Craft Acquisition.

Acquisition of Craft Beverage Business Portfolio II

Effective September 1, 2024, the Company acquired four craft beer brands and breweries from Molson Coors Beverage Company (“Molson”) including Atwater Brewery, Hop Valley Brewing Company, Terrapin Beer Co., and Revolver Brewing (the “Craft Acquisition II”). The purpose of the acquisition was to continue broadening Tilray's beverage brand strategy. In consideration for the acquisition, the Company paid a total purchase price of $2322,~~079~~979 in cash, which iswas subject to certain customary post-closing working capital adjustments.

The Company is in the process of assessing the fair value of the net assets acquired and, as a result, the fair value may be subject to adjustments pending completion of final valuations and post-closing adjustments. The table below summarizes the ~~preliminary estimated~~ fair value of the assets acquired and the liabilities assumed for the Craft Acquisition II at the effective acquisition date as follows:

	Amount
Consideration
Cash consideration	$	2322,~~079~~979
Net assets acquired
Current assets
Cash and cash equivalents		4,869
Accounts receivable		1,993
Inventory		76,~~344~~844
Prepaids and other current assets		185
Long-term assets
Capital assets		1720,~~366~~916
Finance lease, right-of-use assets		1,869
Operating lease, right-of-use assets		1,884
Total assets		3538,~~510~~560
Current liabilities
Accounts payable and accrued liabilities		811,~~678~~828
Current portion of finance lease liabilities		354
Current portion of operating lease liabilities		564
Long - term liabilities
Finance lease liabilities		1,515
Operating lease liabilities		1,320
Total liabilities		1215,~~431~~581
Total net assets acquired		2322,~~079~~979

In the event that the Craft Acquisition II had occurred on June 1, ~~2023~~2024, the Company would have had, on an unaudited proforma basis, additional net revenue of approximately $nil ~~and $13,700~~ for the three ~~and nine~~ months ended ~~February~~August 2831, 2025 and approximately $1113,~~000~~700 ~~and $42,000~~ for the three ~~and nine~~ months ended ~~February~~August 2931, 2024, respectively, and its consolidated net ~~loss~~income and comprehensive net ~~loss~~ income would have increased by approximately $nil ~~and $4,000~~ for the three ~~and nine~~ months ended ~~February~~August 2831, 2025 and approximately $64,~~600 and~~000 ~~$16,200~~ for the three ~~and nine~~ months ended ~~February~~August 2931, 2024, respectively. This unaudited pro forma financial information does not reflect the realization of any expected ongoing synergies relating to the integration of the Craft Acquisition II.

Note 8. Convertible notes receivable

Convertible notes receivable is comprised of the following:

	February 28,		May 31,
	2025		2024
MedMen Convertible Note	$	—	$	32,000
Deduct - current portion		—		—
Total convertible notes receivable, non current portion	$	—	$	32,000

~~MedMen~~Note ~~Convertible~~8. ~~Note~~Long term investments

On August 31, 2021, the Company issued 9,817,061 shares valued at $117,804 to acquire a 68% interest in Superhero Acquisition L.P. (“SH Acquisition”), which purchased a senior secured convertible note issued by MedMen (the “MedMen Convertible Note”), together with certain associated warrants to acquire Class B subordinate voting shares of MedMen, in the principal amount of $165,799. The MedMen Convertible Note bears interest at the Secured Overnight Financing Rate (“SOFR”) plus 6%, with a SOFR floor of 2.5% with any accrued interest being added to the outstanding principal amount. The outstanding principal amount, together with accrued interest is to be paid on August 17, 2028, the maturity date of the MedMen Convertible Note. SH Acquisition was also granted “top-up” rights enabling it (and its limited partners) to maintain its percentage ownership (on an “as-converted” basis) in the event that MedMen issues equity securities. SH Acquisition’s ability to convert the MedMen Convertible Note and exercise the Warrants is dependent upon U.S. federal legalization of cannabis or Tilray’s waiver of such requirement as well as any additional regulatory approvals.

During the three and nine months ended February 28, 2025, the company recognized an other-than-temporary change in fair value, which resulted in a non-cash expense of $20,000 compared to $42,681 for the three and nine months ended February 29, 2024. The MedMen Convertible Note was valued based upon the fair value of the collateral assets net of disposal costs and has been reduced to reflect recent developments in restructuring efforts.

As previously disclosed, MedMen and certain of its subsidiaries commenced insolvency actions in April 2024. On January 16, 2025, MedMen exited receivership and substantially all of its remaining assets were transferred to a new entity owned by MedMen’s secured creditors, including SH Acquisition. In connection with the foregoing, the Company disposed of its MedMen Convertible Note in exchange for an option to acquire a 68% membership interest in SH Acquisition for $1.00 upon U.S. federal cannabis legalization. See Note 9 (Long-term investments). As a result, the Company no longer controls SH Acquisition and thus no longer consolidates this entity for accounting purposes. See Note 17 (Non-controlling interests).

The Company did not derive any revenue or cash from MedMen's operations, and fully complies with all limitations imposed by applicable U.S. law and regulations in connection with its ownership of the MedMen Convertible Note and/or its option to acquire SH Acquisition. In addition, since the fiscal year ended May 31, 2024, the Company has not recognized any interest income on the MedMen Convertible Note, nor did the Company recognize any interest income for the three and nine months ended February 28, 2025, which would have increased its value.

Note 9. Long term investments

Long term investments consisted of the following:

	February 28,		May 31,
	August 31,		May 31,
	2025		~~2024~~2025
Equity investments measured at fair value	$	12,~~875~~012	$	21,~~359~~972
Equity investments under measurement alternative		8,160		58,~~500~~160
Total	$	10,~~035~~172	$	710,~~859~~132

As of ~~February~~August 2831, 2025 and May 31, 2025, included within equity investment under measurement alternative is an option to acquire a 68% membership interest in SH Acquisition for $1.00 upon U.S. federal cannabis legalization valued at $8,160. See Note 2524 (~~Fair~~Financial ~~value~~risk ~~measurements~~management and financial instruments).

Note 109. Bank indebtedness

Aphria Inc., a subsidiary of the Company, has an operating line of credit in the amount of C$1,000, which bears interest at the lender’s prime rate plus 75 basis points. As of ~~February~~August 2831, 2025, the Company has not drawn on the line of credit. The operating line of credit is secured by a security interest on certain real property located at 265 Talbot St. West, Leamington, Ontario.

CC Pharma GmbH, a subsidiary of the Company, has two operating lines of credit in the amounts of €7,000 and €500. These lines bear interest at Euro Short-Term Rate (“ESTR”) plus 2.50% and Euro Interbank Offered Rate (“EURIBOR”) plus 4.00%, respectively. As of ~~February~~August 2831, 2025, a total of €7,~~442~~ 459 ($78,~~740~~185) was drawn down from the total available credit of €7,500. The operating line of credit for €7,000 is secured by an interest in the inventory of CC Pharma GmbH as well as the Densborn, Germany production facility and underlying real property. The operating line of credit for €500 is unsecured.

On July 25, 2025, the Company’s wholly-owned subsidiary, American Beverage Crafts Group Inc. (“ABC Group”), formerly known as aFour ~~subsidiary~~Twenty ofCorporation, finalized its fifth amendment (the ~~Company,~~“Amendment”) ~~has~~to athat ~~revolving~~certain ~~credit~~Credit ~~facility~~Agreement dated as of June $30,~~000,~~ ~~which~~2023 ~~bears~~(the ~~interest~~“ABC atGroup ~~SOFR~~Credit ~~plus~~Agreement”) anby ~~applicable~~and ~~margin.~~among Asthe Borrower, Bank of ~~February~~ 28America, ~~2025~~N.A., ~~the~~in ~~Company~~its ~~had drawn~~capacity ~~down~~as $3Administrative Agent,~~000~~ onand ~~the~~certain ~~revolving~~other ~~line~~guarantors ofand ~~credit~~lenders party thereto. ~~The~~Specifically, ~~revolving~~the ~~credit~~Amendment ~~facility~~amended isand ~~secured~~restated bythe ABC Group's ~~assets~~Credit Agreement to provide for the contribution of the Manitoba Harvest entities’ equity to the Borrower as additional collateral. Additionally, the Amendment added financial covenants for (i) minimum consolidated trailing-twelve-months EBITDA for each of the four quarters, beginning May 31, 2025 and ~~includes~~(ii) aminimum ~~corporate~~liquidity. ABC ~~guarantee~~Group byhas a ~~subsidiary~~revolving credit facility of $25,000, which bears interest at SOFR plus an applicable margin. As of August 31, 2025, the Company has drawn $nil on the revolving line of credit.

Note 1110. Accounts payable and accrued liabilities

Accounts payable and accrued liabilities are comprised of:

	February 28,		May 31,
	August 31,		May 31,
	2025		~~2024~~2025
Trade payables	$	98110,~~914~~802	$	~~105~~107,~~392~~348
Accrued liabilities		8891,~~870~~993		92103,~~424~~260
Litigation accruals		1412,~~787~~021		2412,~~378~~431
Accrued payroll and employment related taxes		52,~~060~~796		61,~~154~~436
Income taxes payable		1,~~495~~038		~~4,092~~58
Accrued interest		32,~~211~~677		4,~~217~~193
Sales taxes payable		49,~~230~~586		56,~~300~~596
Total	$	~~216~~230,~~567~~913	$	~~241~~235,~~957~~322

Note 1211. Long-term debt

The following table sets forth the net carrying amount of long-term debt instruments:

	February 28,			May 31,
	August 31,			May 31,
	2025			~~2024~~2025
Term loan - C$53,000 - Canadian prime plus an applicable margin, 3-year term, with a 10-year amortization, repayable in equal quarterly payments due in February 2028	$	3638,~~570~~690		$	3938,~~420~~690
Term loan - C$25,000 - Canadian prime plus 1.00%, compounded monthly, 5-year term, with a 15-year amortization, repayable in equal monthly installments of C$181 including interest, due in July 2033		911,~~053~~222			1011,~~212~~501
Term loan - C$25,000 - Canadian prime plus 1.00%, compounded monthly, 5-year term, with a 15-year amortization, repayable in equal monthly installments of C$196 including interest, due in July 2033		119,~~130~~127			129,~~422~~354
Term loan - C$1,250 - Canadian prime plus 1.50%, 5-year term, with a 10-year amortization, repayable in equal monthly installments of C$12 including interest, due in August 2026		~~179~~125			~~263~~157
Mortgage payable - C$3,750 - Canadian prime plus 1.50%, 5-year term, with a 20-year amortization, repayable in equal monthly installments of C$23 including interest, due in August 2026		1,~~940~~988			2,~~089~~020
Term loan ‐ €1,500 ‐ at 2.00%, 5‐year term, repayable in quarterly installments of €94 plus interest, due in April 2025		101			417
Term loan ‐ €3,500 ‐ at 4.59%, 5‐year term, repayable in monthly installments of €52 plus interest, due in August 2028		2,437			2,546
Term loan ‐ €3,500 ‐ at 4.59%, 5‐year term, repayable in monthly installments of €52 plus interest, due in August 2028		2,520			3,151
Mortgage payable - $22,635 - EURIBOR rate plus 1.5%, 10-year term, repayable in monthly installments of $57 to $69, due in October 2030		19,233			19,418
Mortgage payable - $22,635 - EURIBOR rate plus 1.5%, 10-year term, repayable in monthly installments of $57 to $69, due in October 2030		19,603			20,066
Term loan - $90,000 - SOFR plus an applicable margin, 5-year term, repayable in quarterly installments of $875 to $2,250 due in June 2028		78,750			80,438
Term loan - $90,000 - SOFR plus an applicable margin, 5-year term, repayable in quarterly installments of $875 to $2,250 due in June 2028		82,124			86,626
Carrying amount of long-term debt		161,572			164,124
Carrying amount of long-term debt		163,220			174,666
Unamortized financing fees		(1,102	)		(864	)
Unamortized financing fees		(915	)		(808	)
Net carrying amount		160,470			163,260
Net carrying amount		162,305			173,858
Less principal portion included in current liabilities		(16,295	)		(14,767	)
Less principal portion included in current liabilities		(12,904	)		(15,506	)
Total non-current portion of long-term debt	$	144,175		$	148,493
Total non-current portion of long-term debt	$	149,401		$	158,352

The Company, entered into a secured credit agreement on November 28, 2022, for a credit facility through its 51% owned subsidiary Aphria Diamond Inc. (“Aphria Diamond”). The principal amount of loans outstanding is secured by the property at 620 Country Road 14, Leamington, Ontario, owned by Aphria Diamond and a guarantee from Aphria Inc. During the period ended February 28, 2025, the Company refinanced this debt by entering into a new Credit Agreement. The Credit Agreement provides for a term loan equal to CAD $53,000 with a maturity date of February 21, 2028. The Company used CAD $48,171 of the proceeds from the Credit Agreement to repay in full all outstanding obligations under the prior credit facility.

Note 1312. Convertible debentures payable

The following table sets forth the net carrying amount of the convertible debentures payable:

	February 28,		May 31,
	August 31,		May 31,
	2025		~~2024~~2025
5.20% Convertible Notes ("TLRY 27")	$	~~104~~84,~~071~~267	$	~~129~~86,~~583~~428
5.25% Convertible Notes ("APHA 24")		—		330
Deduct - current portion		—		—
Total		104,071		129,913
Total convertible debentures payable, non current portion	$	84,267	$	86,428
Deduct - current portion		—		330
Total convertible debentures payable, non current portion	$	104,071	$	129,583

TLRY 27 Notes

	February 28,			May 31,
	August 31,			May 31,
	2025			~~2024~~2025
5.20% Contractual debenture	$	172,500		$	172,500
Debt settlement		(4372,~~100~~500	)		—(67,500	)
Unamortized discount		(2515,~~329~~733	)		(4218,~~917~~572	)
Net carrying amount	$	~~104~~84,~~071~~267		$	~~129~~86,~~583~~428

The TLRY 27 convertible debentures were issued on May 30, 2023 and on June 9, 2023 by way of overallotment, in the principal amount of $172,500 (the “TLRY 27 Notes”). The TLRY 27 Notes bear interest at a rate of 5.20% per annum, payable semi-annually in arrears on June 15 and December 15 of each year, and mature on June 15, 2027, unless earlier converted. The TLRY 27 Notes are Tilray’s general unsecured obligations and rank senior in right of payment to all of Tilray’s indebtedness that is expressly subordinated in right of payment to the notes; equal in right of payment with any of Tilray’s unsecured indebtedness that is not so subordinated, effectively junior in right of payment to any of Tilray’s secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables but excluding intercompany obligations) of Tilray’s current or future subsidiaries. Noteholders have the right to convert their TLRY 27 Notes into shares of Tilray’s Common Stock at their option, at any time, until the close of business on the second scheduled trading day immediately before June 15, 2027. The initial conversion rate is 376.6478 shares per $1,000 principal amount of TLRY 27 Notes, which represents a conversion price of approximately $2.66 per share. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events.

The TLRY 27 Notes ~~will~~are be now redeemable, in whole and not in part, at Tilray’s option at any time on or after June 20, 2025 at a cash redemption price equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, but only if the last reported sale price of Tilray’s Common Stock exceeds 130% of the conversion price for a specified period of time. If certain corporate events that constitute a fundamental change occur, then, subject to a limited exception, noteholders may require Tilray to repurchase their TLRY 27 Notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date. In connection with the Company’s offering of the TLRY 27 Notes, the Company entered into a share lending agreement with an affiliate of Jefferies LLC (the “Share Borrower”), pursuant to which it lent to the Share Borrower 38,500,000 shares of the Company’s Common Stock (the “Borrowed Shares”). The Borrowed Shares were newly-issued shares, will be held as treasury shares until the expiration or early termination of the share lending agreement and may be used by purchasers of the TLRY 27 Notes to sell up to 38,500,000 shares of the Company’s Common Stock. The fair value of the share lending agreement has been recorded as part of the unamortized discount on the debenture. The Company expects that the selling stockholders will use their position created by such sales to establish their initial hedge with respect to their investments in the TLRY 27 Notes. The Company did not receive any proceeds from the sale of the Borrowed Shares.

~~On September~~During ~~12,~~the ~~2024~~three ~~and~~months ended ~~November~~August 431, ~~2024~~2025, the Company exchanged ~~$7,500~~an ~~and~~aggregate $95,000 of its TLRY 27 Notes for cancellation, ~~respectively,~~ by issuing 10 12,~~034~~591,~~635~~816 shares of Common Stock and paying $~~290~~6 in cash to settle ~~both principal~~ ~~and~~ accrued interest. Upon exchanging the TLRY 27 Notes, a portion of the settlement consideration was allocated to the equity component of the instrument and was recognized as a $41,~~931~~ 158 reduction of additional paid-in capital in the Consolidated Statements of Stockholders’ Equity. Additionally, this repurchase resulted in a gain of $~~679~~495 which was recorded in other non-operating (losses) gains, net as shown in Note 2423 (Non-operating income (expense)). Following consummation of the exchange, the number of outstanding Borrowed Shares of Common Stock was reduced by 31,~~682~~209,~~609~~696 shares which were then returned as Treasury Stock. As of August 31, 2025 and May 31, 2025, a total of 22,318,841 and 23,434,783 shares remained outstanding under the share lending arrangement, respectively.

During the three months ended ~~February~~August 2831, 2025, the Company ~~exchanged~~recognized aninterest ~~aggregate $26,600~~expense of ~~its TLRY 27 Notes for cancellation~~$1,367 byand ~~issuing~~accretion ~~27,136,770 shares~~ of ~~Common~~amortized ~~Stock~~discount ~~and paying $212 in cash to settle both principal and accrued~~ interest. ~~Upon exchanging the TLRY 27 Notes, a portion~~ of ~~the settlement consideration was allocated to the equity component of the instrument and was recognized as a~~ $71,~~442~~976. ~~reduction~~During ~~of additional paid-in capital in~~ the ~~Consolidated~~three ~~Statements~~months ofended August ~~Stockholders’ Equity. Additionally~~31, ~~this repurchase resulted in a gain~~ ~~of $2~~2024,~~432~~ ~~which~~the ~~was~~Company ~~recorded~~recognized ininterest ~~other non-operating (losses) gains, net as shown in Note 24 (Non-operating income (~~expense~~)). Following~~ ~~consummation~~ of ~~the exchange~~$2,243 ~~the~~and ~~number~~accretion of ~~outstanding~~amortized ~~Borrowed~~discount ~~Shares~~interest of ~~Common Stock was reduced by 5~~$3,~~936,812 shares which were then returned as Treasury Stock~~067. ~~As of February 28, 2025 and May 31, 2024, a total of 28,880,580 and 38,500,000 shares remained outstanding under the share lending arrangement, respectively.~~

~~During~~As ~~the~~of August ~~three and nine months ended February 28~~31, 2025, ~~the~~there ~~Company~~was ~~recognized interest expense of~~ $1100,~~957~~000 ~~and~~principal ~~$6,332 and~~outstanding ~~accretion~~compared ofto ~~amortized discount interest of~~ $2105,~~766 and $8,751,~~000 ~~respectively.~~principal ~~During~~outstanding ~~the~~as ~~three and nine months ended February 29, 2024, the Company recognized interest expense~~ of May $231,~~243~~ ~~and~~2025 ~~$6,728~~under ~~and~~the ~~accretion~~TLRY of27 ~~amortized discount interest of $2,896 and $8,520, respectively~~Notes.

As at February 28, 2025, there was $129,400 principal outstanding compared to $172,500 principal outstanding as at May 31, 2024 under the TLRY 27 Notes.

APHA 24 Notes

	February 28,		May 31,
	2025		2024
5.25% Contractual debenture	$	—	$	350,000
Debt settlement		—		(349,670	)
Fair value adjustment		—		—
Net carrying amount	$	—	$	330

The APHA 24 convertible debentures, were entered into in April 2019, in the principal amount of $350,000, bore interest at a rate of 5.25% per annum, and were payable semi-annually in arrears on June 1 and December 1 of each year, and matured on June 1, 2024 (the "APHA 24 Notes"). On June 1, 2024, the Company repaid the remaining principal of the APHA 24 Notes in cash upon maturity.

Note 1413. Warrant liability

As of ~~February~~August 2831, 2025 and May 31, ~~2024~~2025, there were 6,209,000 warrants outstanding, with an original exercise price of $5.95 per warrant, expiring September 17, 2025. Each warrant is exercisable for one share of Common Stock of the Company.

The warrants contain anti-dilution price protection features, which adjust the exercise price of the warrants if the Company subsequently issues Common Stock at a price lower than the exercise price of the warrants. In the event additional warrants or convertible debt are issued with a lower and/or variable exercise price, the exercise price of the warrants will be adjusted accordingly. During the ~~nine~~ three months ended ~~February~~August 2831, 2025, the Company issued shares of its Common Stock which triggered the anti-dilution price protection feature and, accordingly, lowered the exercise price of each warrant to $0.9038. These warrants are classified as liabilities as they are to be settled in registered shares, and the registration statement is required to be active, unless such shares may be subject to an applicable exemption from registration requirements. The holders, at their sole discretion, may elect to affect a cashless exercise, and be issued exempt securities in accordance with Section 3(a)(9) of the Securities Act of 1933, as amended. In the event the Company does not maintain an effective registration statement, the Company may be required to pay a daily cash penalty equal to 1% of the number of shares of Common Stock due to be issued multiplied by any trading price of the Common Stock between the exercise date and the share delivery date, as selected by the holder. Alternatively, the Company may deliver registered Common Stock purchased by the Company in the open market. The Company may also be required to pay cash if it does not have sufficient authorized shares to deliver to the holders upon exercise.

Using the Black Scholes pricing model (Level 3), the Company has estimated the fair value of the warrants outstanding as of ~~February~~August 2831, 2025 to be $01.0600 per warrant. In applying the Black Scholes pricing model (Level 3), the Company utilized the following assumptions: a risk-free interest rate of 2.5564%, an expected volatility of 50%, an expected term of 0.55 05 years, strike price of $0.90 38 and fair value of Common Stock of $01.7438. See Note 26 (Subsequent events) as all outstanding warrants were exercised after the period.

~~The~~Expected ~~expected~~ volatility ~~assumption~~is ~~utilized~~based inon ~~the Black Scholes pricing model (Level 3) was calculated using~~ both ~~the~~ historical and implied volatility of the Company’s ~~Common~~common ~~Stock~~stock.

Note 1514. Stockholders' equity

Issued and outstanding

Pursuant to its Fifth Amended and Restated Certificate of Incorporation, the total number of shares that the Company is authorized to issue is 1,426,000,000 shares, of which 1,416,000,000 shares are Common Stock (the “Common Stock”), and 10,000,000 shares of which are Preferred Stock (the “Preferred Stock”). As of ~~February~~August 2831, 2025, the Company had issued and outstanding ~~983~~ 1,~~372~~118,~~617~~ 291,159 shares of Common Stock, 93,~~619~~213,~~421~~914 shares of Treasury Stock (the “Treasury Stock”) and no Preferred Stock. Historically, the Company has issued shares of its Common Stock in consideration for acquisitions and other strategic transactions, settlement of convertible notes, settlement of litigation claims, in connection with public offerings and as payment of dividends to non-controlling interests for profit distributions.

During the ~~nine~~three months ended ~~February~~August 2831, 2025, the Company issued the following shares of Common Stock:

a) 9334,~~610~~443,~~801~~799 shares of Common Stock pursuant to its At-the-Market (“ATM”) program, which generated gross proceeds of $~~143~~23,~~466~~044 and net proceeds of $~~139~~22,~~738~~491, after deducting $~~3,728~~553 in commissions and other fees associated with these issuances.

b) 3712,~~171~~591,~~405~~816 shares of Common Stock in the amount of $434,~~528~~800 to exchange the aggregate principal of $435,~~100~~000 of its TLRY 27 Notes for cancellation. Upon exchanging the TLRY 27 Notes, a portion of the settlement consideration was allocated to the equity component of the instrument and was recognized as a $121,~~373~~158 reduction of additional paid-in capital. Following consummation of the exchange, the number of outstanding Borrowed Shares of Common Stock was reduced by approximately 91,~~619~~209,~~421~~696 shares which were then returned as Treasury Stock, see Note 1312 (Convertible debentures payable).

c) 1310,~~217~~576,~~588~~799 shares of Common Stock toin ~~settle~~connection ~~dividends~~with ~~payable to~~ the ~~non-controlling~~exercise ~~shareholders~~ of ~~Aphria~~previously ~~Diamond~~awarded instock-based ~~the~~compensation ~~amount of $23,824~~awards.

d)During ~~7,447,450~~the ~~shares~~three ofmonths ~~Common~~ended August ~~Stock~~31, in2025, ~~connection~~the ~~with~~Company ~~the~~granted ~~exercise~~44,802,378 oftime-based ~~previously~~Restricted ~~awarded~~Stock ~~stock~~Units (“RSUs”), and nil performance-based ~~compensation awards~~RSUs.

During the ~~nine~~fiscal ~~months~~year ended ~~February~~May 2831, ~~2025~~2024, the Company ~~granted 13,505,127 time-based Restricted Stock Units (“RSUs”),~~ ~~and~~issued ~~no performance-based RSUs. During the nine months ended February 29, 2024, the Company granted 11,665,159 time-based RSUs and~~ 7,566,146 performance-based RSUs. InThese ~~connection with the 7,566,146 performance-based~~ RSUs ~~that~~ were ~~issued,~~not ~~the~~considered ~~performance~~granted ~~conditions~~for ~~associated~~accounting ~~with~~purposes ~~such~~at ~~awards~~the ~~will~~time ~~not~~of ~~be determined and adopted until a future date and~~issuance, ~~therefore,~~as the ~~grant~~performance ~~date~~conditions ~~has~~had not yet been ~~met~~established ~~for~~or ~~accounting purposes~~ approved and no amounts have been recorded within the Consolidated Statement of Income (Loss). The Company's total stock-based compensation expense from RSUs incurred for the three and nine months ended February 28, 2025 was $4,035 and $18,189, respectively, compared to $8,059 and $24,517 for the three and nine months ended February 29, 2024, respectively.

The Company's total stock-based compensation expense from RSUs incurred for the three months ended August 31, 2025 was $5,052, compared to $6,917 for the three months ended August 31, 2024, respectively.

Note 1615. Accumulated other comprehensive income (loss)

Accumulated other comprehensive income (loss) is comprised of foreign currency translation gain (loss) as follows:

	Total
Balance May 31, 2023	$	(46,610	)
	Foreign
Other comprehensive income (loss)		3,049
	currency
Balance August 31, 2023	$	(43,561	)
	translation
Other comprehensive income (loss)		5,194
	gain (loss)
Balance November 30, 2023	$	(38,367	)
Other comprehensive income (loss)		(4,820	)
Balance February 29, 2024	$	(43,187	)
Balance May 31, 2024	$	(43,499	)
Other comprehensive income (loss)		3,622
Balance August 31, 2024	$	(39,877	)
Other comprehensive income (loss)		(8,080	)
Balance May 31, 2025	$	(43,063	)
Balance November 30, 2024	$	(47,957	)
Other comprehensive income (loss)		(167	)
Other comprehensive income (loss)		(4,978	)
Balance August 31, 2025	$	(43,230	)
Balance February 28, 2025	$	(52,935	)

Note 1716. Non-controlling interests

The following are majority-owned subsidiaries of the Company and the percentage of ownership interest maintained by the Company is set forth in the parenthetical: Aphria Diamond (51%), and Colcanna S.A.S. (90%).

~~On January~~The 7,following ~~2025,~~table ~~the~~provides ~~Company~~a ~~dissolved~~summary ~~its~~of ~~75%~~certain ~~ownership~~balance ~~interest~~sheet ininformation CCbefore ~~Pharma~~intercompany ~~Nordic~~eliminations relating ~~ApS.,~~to ~~and~~the asabove-referenced amajority-owned ~~result,~~subsidiaries of the Company in nowhich ~~longer~~there ~~controls~~was CCa ~~Pharma~~non-controlling ~~Nordic~~interest ~~ApS.~~as ~~and~~of August ~~thus~~31, ~~no longer consolidates this entity.~~2025:

On January 16, 2025, MedMen exited receivership and substantially all of its remaining assets were transferred to a new entity owned by MedMen’s secured creditors, including SH Acquisition. In connection with this restructuring, the Company disposed of its MedMen Convertible Note in exchange for on option to acquire a 68% membership interest in SH Acquisition for $1.00 upon U.S. federal cannabis legalization. See Note 8 (Convertible notes receivable). As a result, the Company no longer controls SH Acquisition and thus no longer consolidates this entity.

	*Aphria*			*ColCanna*			*August 31,*
	*Diamond*			*S.A.S.*			*2025*
Current assets	$	90,684		$	5		$	90,689
Non-current assets		112,250			3,485			115,735
Current liabilities		(128,471	)		(7,036	)		(135,507	)
Non-current liabilities		(31,408	)		(1,442	)		(32,850	)
Net assets	$	43,055		$	(4,988	)	$	38,067

The following table provides a summary of certain balance sheet information before intercompany eliminations relating to the above -referenced majority-owned subsidiaries of the Company in which there was a non-controlling interest as of ~~February~~May 2831, 2025:

	SH		CC Pharma		Aphria			ColCanna			~~February~~May 2831,
	Acquisition		Nordic ApS		Diamond			S.A.S.			2025
Current assets	$	—	$	—	$	6783,~~340~~390		$	1620		$	6783,~~356~~410
Non-current assets		—		—		~~110~~114,~~634~~677			3,~~350~~348			~~113~~118,~~984~~025
Current liabilities		—		—		(~~117~~126,~~229~~986	)		(6,~~574~~953	)		(~~123~~133,~~803~~939	)
Non-current liabilities		—		—		(31,~~354~~720	)		(1,~~452~~442	)		(3233,~~806~~162	)
Net assets	$	—	$	—	$	2939,~~391~~361		$	(45,~~660~~027	)	$	2434,~~731~~334

The following table provides a summary of certain balance sheet information before intercompany eliminations relating to the above referenced majority-owned subsidiaries of the Company in which there was a non-controlling interest as of May 31, 2024:

	SH		CC Pharma			Aphria			ColCanna			May 31,
	Acquisition		Nordic ApS			Diamond			S.A.S.			2024
Current assets	$	—	$	12		$	95,720		$	3		$	95,735
Non-current assets		32,000		—			124,675			3,637			160,312
Current liabilities		—		(9	)		(130,945	)		(6,913	)		(137,867	)
Non-current liabilities		—		—			(24,482	)		(1,452	)		(25,934	)
Net assets	$	32,000	$	3		$	64,968		$	(4,725	)	$	92,246

The following table provides a summary of certain income statement information before intercompany eliminations relating to the above referenced majority-owned subsidiaries of the Company in which there was a non-controlling interest for the ~~nine~~three months ended ~~February~~August 2831, 2025:

	SH			CC Pharma			Aphria			ColCanna			February 28,
	Aphria			ColCanna			August 31,
	Acquisition			Nordic ApS			Diamond			S.A.S.			2025
	Diamond			S.A.S.			2025
Revenue	$	—18,102		$	—		$	5318,~~608~~102		$	—		$	~~53,608~~
Total expenses		2013,~~000~~497			6(186	)		3913,~~557~~311			62			~~59,625~~
Net (loss) income		~~(20~~4,~~000~~605	)		(6186	)		144,~~051~~791			~~(62~~	)		~~(6,017~~	)
Other comprehensive (loss) income		—(911	)		3(147	)		(1,~~568~~058	)		~~127~~			~~(1,438~~	)
Net comprehensive (loss) income	$	~~(20~~3,~~000~~694	)	$	(339	)	$	123,~~483~~733		$	65		$	~~(7,455~~	)
Non-controlling interest %		3249	%		2510	%	NA	49	%		10	%	NA
Comprehensive (loss) income attributable to NCI		(61,~~400~~810	)		(14	)		61,~~117~~814			7			~~(277~~	)
Net comprehensive (loss) income attributable to NCI	$	(61,~~400~~810	)	$	(14	)	$	61,~~117~~814		$	7		$	~~(277~~	)

	SH			CC Pharma			Aphria			ColCanna			~~February~~August 2931,
	Acquisition			Nordic ApS			Diamond			S.A.S.			2024
Revenue	$	—		$	—		$	7618,~~541~~558		$	—		$	7618,~~541~~558
Total expenses		~~42,681~~—			~~(1,078~~5	)		479,~~541~~216			~~(594~~630	)		889,~~550~~851
Net (loss) income		~~(42,681~~—	)		~~1,078~~(5	)		299,~~000~~342			~~594~~(630	)		~~(12~~8,~~009~~707	)
Other comprehensive (loss) income		—			(91	)		~~646~~1,041			~~(334~~277	)		~~303~~1,317
Net comprehensive (loss) income	$	~~(42,681~~—	)	$	~~1,069~~(6	)	$	2910,~~646~~383		$	~~260~~(353	)	$	~~(11~~10,~~706~~024	)
Non-controlling interest %		32	%		25	%		49	%		10	%	NA
Comprehensive (loss) income attributable to NCI		~~(13,658~~—	)		~~267~~(2	)		145,~~527~~088			26(35	)		15,~~162~~051
Additional income attributable to NCI		—			—			5,336			—			5,336
Net comprehensive (loss) income attributable to NCI	$	—		$	(2	)	$	5,088		$	(35	)	$	5,051
Net comprehensive (loss) income attributable to NCI	$	(13,658	)	$	267		$	19,863		$	26		$	6,498

Note 1817. Income taxes

The determination of the Company’s overall effective tax rate requires significant judgment, the use of estimates, and the interpretation and application of complex tax laws. The effective tax rate reflects the income earned and taxed in various United States federal, state, and foreign jurisdictions. Tax law changes, increases, and decreases in temporary and permanent differences between book and tax items, valuation allowances against the deferred tax assets, stock compensation, and the Company’s change in income in each jurisdiction all affect the overall effective tax rate. It is the Company’s practice to recognize interest and penalties related to uncertain tax positions in income tax expense.

The Company reported income tax ~~expense~~ recovery of $12,~~203~~285 ~~and $4,125~~ for the three ~~and nine~~ months ended ~~February~~August 2831, 2025, and income tax ~~(recovery)~~ expense of $~~(2,871)~~886 ~~and $1,013~~ for the three ~~and nine~~ months ended ~~February~~August 2931, 2024. The income tax benefit in the current period varies from the US statutory income tax rate and prior year period primarily due to the geographical mix of earnings and losses with no tax benefit resulting from valuation allowances in certain jurisdictions.

Note 1918. Commitments and contingencies

Purchase and other commitments

The Company has financial commitments on long-term debt, refer to Note 1211 (Long-term debt), convertible notes, refer to Note 1312 (Convertible debentures payable), material purchase commitments inclusive of multi-period sponsorship rights and construction commitments as follows:

	Total		2026		2027		2028		2029		Thereafter
Long-term debt repayment	$	~~163~~161,~~220~~572	$	1216,~~904~~295	$	16,~~275~~241	$	1896,~~248~~436	$	853,~~198~~531	$	3029,~~595~~069
Convertible debentures payable		~~129~~100,~~400~~000		—		—		~~129~~100,~~400~~000		—		—
Material purchase obligations		7173,~~520~~691		2941,~~830~~073		3526,~~652~~580		6,038		—		—
Construction commitments		~~835~~888		~~835~~888		—		—		—		—
Total	$	~~364~~336,~~975~~151	$	4358,~~569~~256	$	5142,~~927~~821	$	~~153~~202,~~686~~474	$	853,~~198~~531	$	3029,~~595~~069

Legal proceedings

In the ordinary course of business, we are at times subject to various legal proceedings and disputes, including the proceedings specifically discussed below. We assess our liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that we will incur a loss and the amount of the loss can be reasonably estimated, we record a liability in our consolidated financial statements. These legal reserves may be increased or decreased to reflect any relevant developments on a quarterly basis. Where a loss is not probable or the amount of loss is not estimable, we do not accrue legal reserves. While the outcome of legal proceedings is inherently uncertain, based on information currently available and available insurance coverage, our management believes that it has established appropriate legal reserves. Any incremental liabilities arising from pending legal proceedings are not expected to have a material adverse effect on our consolidated financial position, consolidated results of operations, or consolidated cash flows. However, it is possible that the ultimate resolution of these matters, if unfavorable, may be material to our consolidated financial position, consolidated results of operations, or consolidated cash flows.

There have been no material changes in the legal proceedings since our Annual Report on Form 10-K for the fiscal year ended May 31, ~~2024 or subsequent Quarterly Reports on Form 10-Q, except with respect to the legal proceedings disclosed below:~~2025.

Aphria Securities Class Action (Canada)

In February 2019, a putative securities class action was commenced in the Ontario Superior Court of Justice against Tilray’s wholly-owned subsidiary, Aphria, Inc. (“Aphria”), and certain of its former officers and directors (the “Aphria Canadian Class Action”). The Aphria Canadian Class Action was subsequently amended in September 2022 to proceed only against Aphria and two of its former officers and directors as named defendants.

The class plaintiff sought damages in the amount of CAD $875,000 pursuant to Ontario securities legislation on behalf of all class members who acquired Aphria’s common shares between January 29, 2018 and December 3, 2018. The Aphria Canadian Class Action stemmed from Aphria’s acquisition of Nuuvera Inc. and LATAM Holdings Inc. in March and September 2018, respectively, alleging that the value of the acquired assets was misrepresented as being significantly higher than their actual worth, and that insiders at Aphria personally benefitted from the acquisitions at the expense of investors. Aphria and the individual defendants denied the allegations made in the Aphria Canadian Class Action and vigorously defended against them. Trial was scheduled to begin in January 2025.

On February 5, 2025, Aphria and the individual defendants successfully reached an agreement with the class plaintiff to settle the Aphria Canadian Class Action. The settlement agreement provides for the complete dismissal of the Aphria Canadian Class Action, with prejudice, in exchange for an aggregate payment from all defendants equal to CAD $30,000, or approximately US $21,000, (the “Settlement Amount”). The settlement agreement also provides for the dismissal, with prejudice, of the four individual Canadian lawsuits pursuing the same allegations of wrongdoing against Aphria and former and current officers and directors. The settlement does not constitute an admission of liability or wrongdoing by Aphria or the other defendants.

The Settlement Amount will be primarily funded by the outstanding balance under Aphria’s D&O Insurance Policy and by the individual defendants. Aphria will fund the remaining unpaid portion of the Settlement Amount, currently estimated to equal approximately CAD $8,300 (or approximately US $5,800). The settlement agreement was approved by the Court on March 27, 2025.

Summary of litigation accruals

As described in Note 1110 (Accounts payable and accrued liabilities), the total estimated litigation expense accrual included in accrued liabilities as of ~~February~~August 2831, 2025 and May 31, ~~2024~~ 2025 was $1412,~~787~~021 and $2412,~~378~~431, respectively. This estimated accrual is intended to cover various ongoing litigation matters with probable losses that can be reasonably estimated.

Note 2019. Net revenue

The Company reports Net revenue in four reporting segments: beverage, cannabis, distribution, and wellness. Net revenue for the three ~~and nine~~ months ended ~~February~~August 2831, 2025 and ~~February~~August 2931, 2024 were as follows:

For the three months ended

~~For the nine months ended~~

February 28,

February 29,

February 28,

February 29,

August 31,

2025

2024

~~2025~~

~~2024~~

Beverage revenue

58,~~009~~512

5859,~~247~~163

~~184,033~~

~~133,237~~

Beverage excise taxes

(2,~~088~~773

)

(3,~~559~~191

)

~~(9,059~~

)

~~(7,882~~

)

Net beverage revenue

55,~~921~~739

5455,~~688~~972

~~174,974~~

~~125,355~~

Cannabis revenue

7287,~~982~~735

8581,~~236~~194

~~241,384~~

~~276,676~~

Cannabis excise taxes

(1823,~~708~~224

)

(2119,~~804~~945

)

~~(60,209~~

)

~~(75,797~~

)

Net cannabis revenue

5464,~~274~~511

6361,~~432~~249

~~181,175~~

~~200,879~~

Distribution revenue

6174,~~493~~007

5668,~~794~~071

~~197,175~~

~~193,174~~

Wellness revenue

1415,~~092~~244

1314,~~426~~752

~~43,450~~

~~39,652~~

Total

~~185~~209,~~780~~501

~~188~~200,~~340~~044

~~596,774~~

~~559,060~~

Note 2120. Cost of goods sold

The Company reports Cost of goods sold in four reporting segments: beverage, cannabis, distribution, and wellness. Cost of goods sold for the three ~~and nine~~ months ended ~~February~~August 2831, 2025 and ~~February~~August 2931, 2024 were as follows:

For the three months ended

~~For the nine months ended~~

February 28,

February 29,

February 28,

February 29,

August 31,

2025

2024

~~2025~~

~~2024~~

Beverage costs

3534,~~986~~413

3533,~~836~~050

~~106,961~~

~~77,615~~

Cannabis costs

3241,~~275~~241

4237,~~518~~054

~~111,804~~

~~139,507~~

Distribution costs

5566,~~936~~008

5160,~~231~~138

~~175,281~~

~~172,846~~

Wellness costs

910,~~572~~370

910,~~359~~096

~~29,791~~

~~28,091~~

Total

~~133~~152,~~769~~032

~~138~~140,~~944~~338

~~423,837~~

~~418,059~~

Note 2221. General and administrative expenses

General and administrative expenses for the three ~~and nine~~ months ended ~~February~~August 2831, 2025 and ~~February~~August 2931, 2024 were as follows:

For the three months ended

~~For the nine months ended~~

February 28,

February 29,

February 28,

February 29,

August 31,

2025

2024

~~2025~~

~~2024~~

Salaries and wages

21,~~908~~736

21,~~173~~567

~~66,201~~

~~57,067~~

Office and general

78,~~385~~697

49,~~190~~260

~~26,103~~

~~20,423~~

Stock-based compensation

45,~~035~~052

86,~~059~~917

~~18,189~~

~~24,517~~

Insurance

2,~~942~~393

32,~~569~~455

~~8,552~~

~~9,917~~

Professional fees

1,~~352~~218

~~656~~1,178

~~3,656~~

~~4,658~~

(Gain) loss on sale of capital assets

(202

)

(733

)

Gain on sale of capital assets

(241

)

(26

)

Travel and accommodation

1,~~100~~312

1,~~246~~493

~~4,347~~

~~3,727~~

Rent

~~726~~886

1,~~024~~269

~~3,041~~

~~3,457~~

Total

3941,~~246~~053

3944,~~940~~113

~~129,356~~

~~123,769~~

Note 2322. Restructuring charges

In connection with the ~~execution~~integration of ~~our~~certain ~~acquisition~~acquisitions ~~strategy~~ and strategic transactions, the Company has incurred restructuring and exit costs ~~associated~~in ~~with~~ the ~~integration~~amount ~~efforts~~ of ~~these transactions. In connection with these efforts, the Company recognized $6,133~~ ~~and~~ $~~17,249 of restructuring charges~~ 869 for the three ~~and nine~~ months ended ~~February~~August 2831, 2025 , compared to $54,~~178~~247 ~~and $8,748~~ for the prior year period. All restructuring plans are approved at the executive level, and their associated expenses are recognized in the period in which the plan is committed. ~~All~~or ~~amounts~~otherwise incurred ~~as of February 28, 2025 have been paid~~.

Within the Cannabis segment, ~~our restructuring costs predominantly related to~~ ~~the~~during ~~HEXO acquisition, which are expected to be completed within 24 months from~~ the ~~original~~three ~~acquisition, which occurred June 2023. In the nine~~ months ended ~~February~~August 2831, 2025, we the Company recognized $~~7,872~~ 692 of expenses related to employee termination severance and benefits and other costs related to the conversion of the HEXO Quebec cultivation facility from cannabis to produce (which is currently held for sale), the optimization of our Redecan facilities, and $771 of restructuring charges related to the remaining costs of exiting the Truss Beverage Co. (“Truss”) facility following its sale to a third party in the fiscal year ended May 31, 2024. Additionally, the Company recognized $1,133 of cost associated with the ~~winding~~reorganization ~~down~~ of ~~our Avanti facility,~~ the ~~closure~~Canadian ofcannabis ~~which~~commercial ~~was announced during the quarter ended November 30, 2024~~function. ~~Lastly~~Additionally, the Company recognized $~~351~~177 of restructuring charges related to our decision to exit the New Zealand medical cannabis market announced during the ~~quarter~~fiscal year ended ~~February~~May 2831, 2025.

~~Within~~During the ~~Beverage segment,~~fiscal ~~the~~year ~~Company~~ended May ~~recognized $1~~31,~~089~~ of2025, ~~expenses~~the ~~related~~Company toaccrued ~~employee termination severance and benefits and~~ $28,~~765~~500 of ~~costs associated with the consolidation~~restructuring ofcharges ~~production~~related ~~sites through~~to the ~~integration~~closure of ~~the~~Hop ~~Craft~~Valley ~~Acquisition~~ and ~~the~~other ~~Craft~~Project ~~Acquisition~~420 initiatives ~~II.~~within ~~Additionally,~~ the ~~Company~~Beverage ~~recognized~~segment, ~~$800~~ of ~~restructuring~~which ~~charges related to terminating a legacy storage~~$1,249 ~~agreement~~was ~~from~~recognized in the ~~Craft~~three ~~Acquisition.~~months Weended August ~~expect~~31, to2025 ~~transition~~thereby, toreducing ~~a new storage facility in~~ the ~~fourth~~accrual ~~quarter~~to ~~of our fiscal year ending May 31~~$7, ~~2025~~251.

~~Within~~Note ~~the~~23. ~~Distribution~~Non-operating ~~segment~~income (expense), ~~the Company recognized $374 of restructuring charges related to the divestiture of its retail pharmacy location in Argentina.~~ net

~~Lastly~~Non-operating income (expense), net for the ~~nine~~three months ended ~~February~~August 2831, 2025, and August ~~the Company recognized $2~~31,~~094~~ ~~of costs associated with the investment held in Superhero Acquisition Corp.~~2024 were as ~~a result of MedMen’s ongoing restructuring and liquidation undertakings.~~follows:

Note 24. Non-operating income (expense), net

	*For the three months ended*
	*August 31,*			*August 31,*
	*2025*			*2024*
Change in fair value of warrant liability		(3,670	)		696
Foreign exchange gain (loss)		6,928			11,881
(Loss) gain on long-term investments		39			(39	)
Unrealized loss on digital assets		(8	)		—
Other non-operating (losses) gains, net		543			108
Total	$	3,832		$	12,646

~~Non~~The other non-operating ~~income~~ losses (~~expense~~gains), net for the three ~~and nine~~ months ended ~~February~~August 2831, 2025, were losses of $543 ~~and February~~which ~~29,~~was mainly comprised ~~2024~~of ~~were~~the $495 gain resulting from the exchange transaction of the TLRY 27 Note, as ~~follows:~~described in Note 12 (Convertible debentures payable).

	For the three months ended						For the nine months ended
	February 28,			February 29,			February 28,			February 29,
	2025			2024			2025			2024
Change in fair value of convertible debenture payable	$	—		$	(6,311	)	$	—		$	(12,352	)
Change in fair value of warrant liability		1,338			586			2,896			(1,365	)
Foreign exchange gain (loss)		(22,290	)		(3,302	)		(44,206	)		1,941
(Loss) gain on long-term investments		(5,474	)		33			(5,540	)		383
Other non-operating (losses) gains, net		2,404			(8,245	)		2,219			(9,427	)
Total	$	(24,022	)	$	(17,239	)	$	(44,631	)	$	(20,820	)

Note 24. Financial risk management and financial instruments

The other non-operating (losses) gains, net for the three and nine months ended February 28, 2025, were gains of $2,404 and $2,219, respectively, and were mainly comprised of a $3,111 gain resulting from the exchange transaction of the TLRY 27 Note. Included in other non-operating (losses) gains, net for the three and nine months ended February 29, 2024, are losses of $(8,245) and $(9,427) which is comprised of $2,313 from the downside protection share issuance relating to the HTI note, $2,458 of amounts to settle outstanding notes with non-controlling interest shareholders, and $4,638 for a decrease in value of equity investee, Cannfections.

Note 25. Fair value measurements

Financial instruments

The Company's classification of its financial instruments is described in Note 3 (Significant accounting policies) in the Notes to our Annual Financial Statements.

The carrying values of marketable securities, accounts receivable, bank indebtedness and accounts payable and accrued liabilities approximate their fair values due to their short periods to maturity.

On ~~February~~August 2831, 2025 and May 31, ~~2024~~2025, the Company had long-term debt of $2,~~621~~437 and $32,~~568~~546, respectively, and the principal portion of convertible debentures payable of $~~129~~100,~~400~~000 and $~~172~~105,~~830~~000, respectively, subject to fixed interest rates. The Company’s long-term debt is valued based on discounting the future cash outflows associated with the long-term debt. The discount rate is based on the incremental premium above market rates for the U.S. Department of the Treasury securities of similar duration. In each period thereafter, the incremental premium is held constant while the U.S. Department of the Treasury security is based on the then current market value to derive the discount rate.

The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of ~~February~~August 2831, 2025 and May 31, ~~2024~~2025 and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:

								February 28,
								August 31,
	Level 1		Level 2		Level 3			2025
Financial assets
Cash and cash equivalents	$	~~199~~264,~~956~~828	$	—	$	—		$	~~199~~264,~~956~~828
Marketable securities		48,458		—		—			48,458
Equity investments measured at fair value		995		1,017		8,160			10,172
Convertible notes receivable		—		—		—			—
Digital assets		992		—		—			992
Equity investments measured at fair value		922		953		8,160			10,035
Financial liabilities
Warrant liability		—		—		(~~357~~4,762	)		(~~357~~4,762	)
Contingent consideration		—		—		~~(15,000~~—	)		~~(15,000~~—	)
APHA 24 Convertible debenture		—		—		—			—
Total recurring fair value measurements	$	266,815	$	1,017	$	3,398		$	271,230
Total recurring fair value measurements	$	249,336	$	953	$	(7,197	)	$	243,092

								May 31,
	Level 1		Level 2		Level 3			~~2024~~2025
Financial assets
Cash and cash equivalents	$	~~228~~221,~~340~~666	$	—	$	—		$	~~228~~221,~~340~~666
Marketable securities		3234,~~182~~697		—		—			3234,~~182~~697
Convertible notes receivable		—		—		32,000			32,000
Equity investments measured at fair value		909		1,063		8,160			10,132
Equity investments measured at fair value		919		1,440		5,500			7,859
Financial liabilities
Warrant liability		—		—		(31,~~253~~092	)		(31,~~253~~092	)
Contingent consideration		—		—		(15,000	)		(15,000	)
APHA 24 Convertible debenture		—		—		(330	)		(330	)
Total recurring fair value measurements	$	257,272	$	1,063	$	(7,932	)	$	250,403
Total recurring fair value measurements	$	261,441	$	1,440	$	18,917		$	281,798

The Company’s financial assets and liabilities required to be measured on a recurring basis are its ~~convertible notes receivable,~~ equity investments measured at fair value, ~~convertible~~digital ~~debentures measured at fair value~~assets, acquisition-related contingent consideration, and warrant liability.

~~Convertible~~During ~~notes receivable and long-term investments are recorded at fair value. The estimated fair value is determined by assessing~~ the ~~collateral entitlement from the asset and is classified as Level~~ 3.three ~~During the nine~~ months ended ~~February~~August 2831, 2025, ~~an impairment~~ tothe ~~convertible~~Company ~~notes~~purchased 9.16 ~~receivable~~units of ~~$20,000 was~~Bitcoin. ~~recognized,~~Digital ~~compared~~assets ~~to an impairment of $42,681~~recorded inat ~~the~~fair ~~period~~value ~~ended February~~have ~~29,~~quoted ~~2024.~~prices ~~Subsequent to which~~ in ~~January~~ ~~2025, MedMen~~active ~~exited~~markets ~~receivership~~for ~~and~~identical ~~substantially all of its remaining~~ assets ~~were~~and ~~transferred~~are toclassified aas ~~new entity owned by MedMen’s secured creditors, including SH Acquisition~~Level 1. InThe ~~connection~~following ~~with~~table ~~the~~presents ~~foregoing,~~ the Company ~~disposed~~’s ofdigital ~~its~~asset ~~MedMen~~holdings Convertible Note in exchange for on option to acquire a 68% membership interest in SH Acquisition for $1.00 upon U.S. federal cannabis legalization. See Note 9 (Long-term investments). This option was recorded as ~~a Level 3 equity investment measured at fair value~~ of $8 August 31,~~160~~ ~~by assessing the discounted cash flows of SH Acquisition.~~ 2025:

Convertible debentures payable are recorded at fair value when elected or required under US GAAP. Specifically, the APHA 24 instrument's estimated fair value was determined using the Black-Scholes option pricing model and was classified as Level 3.

	*Quantity*		*Cost Basis*		*Fair Value*		*Cumulative Unrealized Gain (Loss)*
Bitcoin		9.16	$	1,000	$	992	$	(8	)
Total digital assets		9.16	$	1,000	$	992	$	(8	)

Certain equity investments recorded at fair value have quoted prices in active markets for identical assets and are classified as Level 1. The Company classified securities with observable inputs as Level 2 and without a quoted market price as Level 3.

The warrants associated with the warrant liability are classified as Level 3 derivatives. Consequently, the estimated fair value of the warrant liability is determined using the Black-Scholes pricing model. Until the warrants are exercised, expire, or other facts and circumstances lead the warrant liability to be reclassified to stockholders’ equity, the warrant liability (which relates to warrants to purchase shares of Common Stock) is marked-to-market each reporting period with the change in fair value recorded as the change in fair value of warrant liability within the consolidated statements of loss and comprehensive loss. Any significant adjustments to the unobservable inputs disclosed in the table below would have a direct impact on the fair value of the warrant liability.

A portion of the consideration to be paid in connection with the Company’s acquisition of Montauk Brewing Company (“Montauk”) is contingent upon the achievement of certain financial measures as of December 2025. If achieved, such contingent consideration is payable in cash. During ~~The~~the three months ended August 31, 2025, the contingent consideration amount was estimated by applying a probability of achievement of ~~100~~0% on the $15,000 sales earn-out component and 0% on the remaining criteria, which is not expected to be achieved and as such resulted in a corresponding change in fair value of $15,000 for the contingent consideration liability recognized. During the three months ended August 31, 2024, the contingent consideration amount was estimated by applying a probability of achievement of 100% on the $15,000 sales earn-out component and 0% on the remaining criterion, which is not expected to be achieved. The unobservable inputs into the future expected cash outflows result in a fair value measurement classified as Level 3.

~~During~~The ~~the~~balances ~~nine months ended February 28, 2025, a decrease in fair value~~ of ~~$nil~~assets ~~was~~and ~~recognized~~liabilities ~~compared~~categorized towithin ~~a decrease~~ Level 3 of the fair value ofhierarchy ~~$13,493 in~~measured ~~the~~at ~~period ended February 29, 2024, inclusive of changes in foreign exchange. The decrease was comprised of a decrease of~~ fair value ofon ~~$16,218 for the contingent consideration from the Sweetwater Brewing Company acquisition as~~ a ~~result~~recurring ~~of not achieving~~basis ~~the~~are ~~incentive targets and the settlement of $4~~reconciled,~~181 of~~ ~~contingent consideration~~as ~~liability~~follows ~~from the Truss acquisition in cash~~ for ~~$760 (CAD~~the ~~$1,041), which was offset by~~period anended August ~~increase in fair value of $3~~31,~~111 for~~ ~~the contingent consideration from the Montauk acquisition as a result of a higher probability of achieving the incentive targets.~~ 2025:

The balances of assets and liabilities categorized within Level 3 of the fair value hierarchy measured at fair value on a recurring basis are reconciled, as follows for the period ended February 28, 2025:

													APHA 24
	Equity			Warrant			Contingent
	Convertible			Equity			Warrant			Contingent			Convertible
	Investments			Liability			Consideration
	notes receivable			Investments			Liability			Consideration			Debt
Balance, May 31, 2025	$	8,160		$	(1,092	)	$	(15,000	)
Balance, May 31, 2024	$	32,000		$	5,500		$	(3,253	)	$	(15,000	)	$	(330	)
Unrealized gain (loss) on fair value		—			(3,670	)		15,000
Additions/(disposals)		(12,000	)		8,160			—			—			330
Balance, August 31, 2025	$	8,160		$	(4,762	)	$	—
Redemption		—			—			—			—			—
Unrealized gain (loss) on fair value		—			(5,500	)		2,896			—			—
Impairments		(20,000	)		—			—			—			—
Balance, February 28, 2025	$	—		$	8,160		$	(357	)	$	(15,000	)	$	—

													APHA 24
	Convertible			Equity			Warrant			Contingent			Convertible
	notes receivable			Investments			Liability			Consideration			Debt
Balance, May 31, 2023	$	103,401		$	5,651		$	(1,817	)	$	(27,107	)	$	(120,568	)
Balance, May 31, 2024	$	32,000		$	5,500		$	(3,253	)	$	(15,000	)	$	(330	)
Additions/(Repayments)		—			—			—			~~(4,181~~—	)		~~50,710~~330
Redemption		(28,720	)		—			—			760			—
Unrealized gain (loss) on fair value		—			—			696			—			—
Unrealized gain (loss) on fair value		—			(151	)		(1,365	)		16,528			(13,493	)
Balance, August 31, 2024	$	32,000		$	5,500		$	(2,557	)	$	(15,000	)	$	—
Impairments		(42,681	)		—			—			—			—
Balance, February 29, 2024	$	32,000		$	5,500		$	(3,182	)	$	(14,000	)	$	(83,351	)

The unrealized gain (loss) on fair value for the convertible debenture, the warrant liability, contingent consideration, and debt securities classified under available-for-sale method is recognized in the consolidated statements of loss and comprehensive loss using the following inputs:

		Significant
	Valuation	unobservable
Financial asset / financial liability	technique	input	Inputs
Warrant liability	Black-Scholes	Volatility,	50%
		expected life (in years)	0.605
Contingent consideration	Discounted cash flows	~~Discount~~Probability ~~rate,~~of achievement	110%
		Probability of achievement	100% and 0%
Equity investments	Discounted cash flows	Probability of achievement	70%

Items measured at fair value on a non-recurring basis

The Company's prepaids and other current assets, long lived assets, including property and equipment, goodwill and intangible assets are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There have been no changes to the Company’s capital management approach in the period. The Company considers its cash and cash equivalents and marketable securities as capital.

Note 2625. Segment reporting

~~Information~~Our ~~reported~~Company’s ~~to the~~ Chief Operating Decision Maker (“CODM”) ~~for~~is the ~~purpose~~Chairman of ~~resource~~the ~~allocation~~Board of Directors and ~~assessment~~Chief ofExecutive Officer. The CODM uses segment ~~performance~~gross ~~focuses~~profit onfor the ~~nature~~purpose of ~~the~~resource ~~operations.~~allocation, ~~The~~assessment ~~Company~~of ~~operates~~segment ~~in four~~performance ~~reportable~~against ~~segments: (1)~~determined ~~beverage operations~~targets, ~~which~~and ~~encompasses~~in ~~the~~deciding ~~production,~~whether ~~marketing~~to ~~and~~implement ~~sale~~cost ofsaving ~~beverage~~targets. ~~and~~The ~~beverage products,~~Company (2operates in four segments. 1) cannabis operations, which encompasses the ~~cultivation,~~ production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis, (as well as, produce operations which are managed by the cannabis team, 2) beverage operations, which encompasses the production, marketing and sale of beverage products, 3) distribution operations, which encompasses the purchase and resale~~/distribution~~ of pharmaceuticals products to ~~wholesale and pharmacy~~ customers, and ( 4) wellness products, which encompasses ~~hemp~~wellness ~~foods~~ and ~~hemp~~better-~~derived consumer~~for-you ~~products~~foods and beverages. This structure is in line with how our CODM assesses our performance and allocates resources.

Operating segments have not been aggregated and no asset information byis ~~segment~~provided isfor ~~not~~the ~~disclosed~~segments because ~~such information is not reported to or used by~~ the Company’s CODM ~~for~~does not receive ~~the~~asset ~~purposes~~information ofby ~~assessing~~ segment ~~performance~~on ora ~~allocating~~regular ~~resources~~basis.

The following tables reconcile the Company’s segment gross profit to consolidated U.S. GAAP results:

Segment gross profit from external customers:

	*For the three months ended*
	*August 31,*		*August 31,*
	*2025*		*2024*
Beverage
Net beverage revenue	$	55,739	$	55,972
Beverage costs		34,413		33,050
Beverage gross profit		21,326		22,922
Cannabis
Net cannabis revenue		64,511		61,249
Cannabis costs		41,241		37,054
Cannabis gross profit		23,270		24,195
Distribution
Distribution revenue		74,007		68,071
Distribution costs		66,008		60,138
Distribution gross profit		7,999		7,933
Wellness
Wellness revenue		15,244		14,752
Wellness costs		10,370		10,096
Wellness gross profit		4,874		4,656
Total
Total revenue		209,501		200,044
Total costs		152,032		140,338
Total gross profit	$	57,469	$	59,706

	For the three months ended				For the nine months ended
	February 28,		February 29,		February 28,		February 29,
	2025		2024		2025		2024
Beverage
Net beverage revenue	$	55,921	$	54,688	$	174,974	$	125,355
Beverage costs		35,986		35,836		106,961		77,615
Beverage gross profit		19,935		18,852		68,013		47,740
Cannabis
Net cannabis revenue		54,274		63,432		181,175		200,879
Cannabis costs		32,275		42,518		111,804		139,507
Cannabis gross profit		21,999		20,914		69,371		61,372
Distribution
Distribution revenue		61,493		56,794		197,175		193,174
Distribution costs		55,936		51,231		175,281		172,846
Distribution gross profit		5,557		5,563		21,894		20,328
Wellness
Wellness revenue		14,092		13,426		43,450		39,652
Wellness costs		9,572		9,359		29,791		28,091
Wellness gross profit	$	4,520	$	4,067	$	13,659	$	11,561

Segment costs are comprised of cost of goods sold, which include product costs, salaries and an allocation of overhead costs.

The following table reconciles the total segment gross profit to the Company’s consolidated totals:

	*For the three months ended*
	*August 31,*			*August 31,*
	*2025*			*2024*
Gross profit	$	57,469		$	59,706
Operating expenses:
General and administrative		41,053			44,113
Selling		12,923			11,690
Amortization		3,929			21,804
Marketing and promotion		10,155			11,566
Research and development		41			105
Change in fair value of contingent consideration		(15,000	)		—
Litigation costs, net of recoveries		1,007			1,595
Restructuring costs		869			4,247
Transaction costs (income), net		400			1,156
Total operating expenses		55,377			96,276
Operating income (loss)		2,092			(36,570	)
Interest expense, net		(6,696	)		(9,842	)
Non-operating income (expense), net		3,832			12,646
Loss before income taxes		(772	)		(33,766	)
Income tax expense (recovery), net		(2,285	)		886
Net income (loss)	$	1,513		$	(34,652	)

Channels of Cannabis revenue were as follows:

For the three months ended

~~For the nine months ended~~

February 28,

February 29,

February 28,

February 29,

August 31,

2025

2024

~~2025~~

~~2024~~

Revenue from Canadian medical cannabis

56,~~839~~146

6,~~363~~261

~~18,773~~

~~18,793~~

Revenue from Canadian adult-use cannabis

4964,~~315~~067

6257,~~107~~235

~~165,627~~

~~205,350~~

Revenue from wholesale cannabis

34,~~893~~155

25,~~764~~507

~~15,993~~

~~12,348~~

Revenue from international cannabis

13,~~935~~367

1412,~~002~~191

~~40,991~~

~~40,185~~

Less excise taxes

(1823,~~708~~224

)

(2119,~~804~~945

)

~~(60,209~~

)

~~(75,797~~

)

Total

5464,~~274~~511

6361,~~432~~249

~~181,175~~

~~200,879~~

There were no advisory services revenue associated with the HEXO commercial transaction agreements for the three and nine months ended February 28, 2025. There were $nil and $1,500 in advisory services revenue associated with the HEXO commercial transaction agreements for the three and nine months ended February 29, 2024.

Geographic net revenue:

For the three months ended

~~For the nine months ended~~

February 28,

February 29,

February 28,

February 29,

August 31,

2025

2024

~~2025~~

~~2024~~

USA

6463,~~420~~961

6263,~~384~~880

~~200,053~~

~~147,247~~

Canada

4558,~~930~~167

55,~~140~~905

~~158,555~~

~~178,417~~

EMEA

7285,~~386~~253

6777,~~143~~672

~~229,312~~

~~222,139~~

Rest of World

32,~~044~~120

32,~~673~~587

~~8,854~~

~~11,257~~

Total

~~185~~209,~~780~~501

~~188~~200,~~340~~044

~~596,774~~

~~559,060~~

Geographic capital assets:

	February 28,		May 31,
	August 31,		May 31,
	2025		~~2024~~2025
USA	$	~~199~~195,~~539~~436	$	~~141~~200,~~314~~003
Canada		~~244~~262,~~091~~114		~~313~~267,~~359~~458
EMEA		9099,~~740~~109		9997,~~921~~371
Rest of World		3,~~430~~498		3,~~653~~601
Total	$	~~537~~560,~~800~~157	$	~~558~~568,~~247~~433

Major customers are defined as customers that are materially significant to the Company’s annual revenues. For the three ~~and nine~~ months ended ~~February~~August 2831, 2025 and 2024, there were no major customers representing a material contribution to our quarterly revenues.

Note 2726. Subsequent Events

~~From~~Between ~~March~~September 5 and 15, 2025, ~~to March~~certain ~~17,~~holders ~~2025,~~elected ~~Tilray~~to ~~issued~~exercise an aggregate of 226,~~802~~209,~~671~~000 ~~shares~~ of the Company’s ~~common~~issued ~~stock~~and inoutstanding ~~exchange~~warrants ~~for~~in ~~$15,000 aggregate~~accordance ~~principal~~with ~~amount~~their ofterms. Pursuant to the ~~TLRY~~exercise 27of ~~Notes.~~such ~~The~~warrants, ~~remaining~~Tilray received $2,108 ~~principal~~of ~~outstanding~~cash asconsideration aand ~~result~~delivered 6,209,000 shares of ~~these~~common ~~transactions~~stock ~~was~~to ~~$114,400~~such holders.

On October 9, 2025, Tilray entered into an assignment and assumption agreement with Double Diamond Holdings Ltd. (“DDH”), an Ontario corporation, pursuant to which, among other things, Tilray acquired from DDH a promissory note in the amount of $14,821 (the “Note”) payable by Aphria Diamond Inc. (“Aphria Diamond”). DDH is a joint venturer with Aphria Inc. (Tilray’s wholly-owned subsidiary) in Aphria Diamond. As consideration for the Note, Tilray issued 8,617,068 shares of its Common Stock to DDH.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the Unaudited Interim Consolidated Financial Statements and the related Notes thereto for the three month period ended ~~February~~August 2831, 2025 contained in this Quarterly Report on Form 10-Q (“Form 10-Q”) and the Audited Consolidated Financial Statements and the related Notes thereto contained in our Annual Report on Form 10-K for the fiscal year ended May 31, ~~2024~~2025, as well as in conjunction with the sections entitled “Item 1A. Risk Factors” and “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended May 31, ~~2024~~2025 and in the section entitled “Item 1A. Risk Factors” in this ~~Quarterly Report on~~ Form 10-Q. Forward looking statements in this Form 10-Q are qualified by the cautionary statement included in this Form 10-Q under the sub-heading “Cautionary Note Regarding Forward-Looking Statements” in the introduction of this Form 10-Q.

Company Overview

Tilray Brands, Inc., a Delaware corporation (collectively, along with its subsidiaries, the “Company”, “Tilray”, “we”, “us” and “our”) , is a leading global lifestyle consumer products company, which was incorporated on January 24, 2018 and is headquartered in Leamington and New York, with operations in Canada, the United States, Europe, Australia and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy, wellness and create memorable experiences.

Our overall strategy is to leverage our brands, infrastructure, expertise and capabilities to drive revenue growth in the industries in which we compete, achieve industry-leading profitability and build sustainable, long-term shareholder value. In order to ensure the long-term sustainable growth of our Company, we continue to focus on developing strong capabilities in data analytics and consumer insights, drive category management leadership and assess opportunities for the introduction of new categories, products and entries into new geographies. In addition, we are relentlessly focused on managing our cost structure and expenses in order to maintain our strong financial position. Finally, our experienced leadership team provides a strong foundation to accelerate our growth. Our management team is complemented by experienced operators, cannabis industry experts, veteran beer and beverage industry leaders and leaders that are well-established in wellness ~~foods~~and better-for-you products, all of whom apply an innovative and consumer-centric approach to our businesses.

Trends and Other Factors Affecting Our Business

Beverage market trends:

Within the beverage category, we expect the following key trends to shape the near-term outlook in this segment:

- Beverage Distribution. In furtherance of our strategic vision, we remain focused on enhancing our relevance within home markets on mission critical ~~items~~SKUs, focusing on our core brands in their core markets. Through targeted efforts, we continue to strategically ~~adjust~~optimize our portfolio mix and distribution ~~geography~~network ~~through our distributor consolidation program~~ to refine our craft beer strategy, enhancing our relevance and focusing resources on our core markets as part of our portfolio ~~rationalization~~optimization initiatives. ~~Distributor~~Spring ~~chain~~retail ~~spring~~ product resets ~~have~~demonstrated ~~indicated~~ improvements ofin the distribution ~~for~~of our core brands and key innovation initiatives, including Shock Top, Runner’s High ~~Non~~non-~~Alcoholic~~alcoholic, and SweetWater Brewing’s newly launched Day Trip and Dive Beer. We expect to begin to see the impact of these gains ~~during the fourth quarter ended May 31, 2025 and~~ throughout fiscal year 2026.

- Innovation. Recognizing the evolving consumer landscape and the burgeoning demand for alternative beverage options, we have prioritized innovation and portfolio diversification. Our recent endeavors include launching a lineup of Hemp Derived Delta-9 (HD-D9) products, Non-Alcoholic beverages, water through our Liquid Love brand, flavored malt beverages, and clean label Energy drinks. These strategic innovations underscore our commitment to offering high-quality options across a diverse range of beverage categories, positioning us for sustained growth and differentiation in the competitive beverage segment.

- Brew Pubs. Following our recent Craft Acquisition I on September 29, 2023 and the Craft Acquisition II effective September 1, 2024, we operate 2016 brew pubs including our Breckenridge Distillery restaurant in geographic regions across the U.S. that are located in close proximity to the production of our craft brands. An important part of our strategic plan for our beverage operations centers on brew pubs to promote and showcase the distinct, regional positioning of our craft beer brands and enhance brand recognition to help drive revenue growth. We believe that our brew pub strategy allows us to curate unique small batch product offerings in targeted test markets to help drive effective product innovation.

In the spirits category, Breckenridge Distillery stands out as a beacon within the bourbon industry, making notable strides in vodka and gin markets while offering a comprehensive hospitality experience through its world-class restaurant and retail location. Our primary growth objective centers on expanding market share across the United States. To fuel future expansion, we prioritize showcasing our exceptional product quality and introducing innovative new offerings. Recent accolades, including Double Gold awards at prestigious competitions such as Breckenridge Reserve Port Cask Finish being named the World’s best finished Bourbon at the 2024 World Whiskies Awards, we believe underscore our brand's growing recognition and appeal. Despite prevailing challenges within the overall spirits market, we believe our focus on whiskey—a resilient segment— positions us for continued growth fueled by innovative product introductions and expanded market presence.

Canadian cannabis market trends:

The cannabis industry in Canada continues to evolve given how nascent the industry is with federal legalization of adult-use cannabis occurring just over five years ago. Through analysis of the current market conditions, the following key trends have emerged and are anticipated to influence the near-term future in the Canadian cannabis industry:

- Market share. During the quarter, Tilray continued to lead the Canadian market with the highest cannabis revenue in Canada. ~~However~~Additionally, during the quarter, we experienced a marginal ~~dip~~increase in market share in Canada from 9.43% to 9.34% from the immediately preceding quarter as reported by Hifyre data for all provinces, excluding Quebec where Weedcrawler was deemed more accurate. The current period ~~decrease~~increase in market share reflects our ~~efforts~~strength toin ~~preserve~~flower ~~margin~~and non-infused pre-roll categories which offset our lower participation in specific categories experiencing the most price compression. ~~and~~Additionally, we continue to enhance our ~~shift~~global insupply ~~strategy~~chain toand ~~redirect~~increase ~~inventories~~our tocultivation ~~international~~footprint ~~cannabis~~to ~~markets~~support ~~which~~the ~~provides~~growing demand for ~~higher~~our ~~margin~~product ~~sales~~in both Canadian and international cannabis markets. WeIn ~~intend~~the meantime, we continue to ~~enhance~~opportunistically ~~our~~redirect ~~global~~certain ~~supply~~inventories ~~chain~~to ~~and~~international ~~increase~~cannabis ~~our~~markets, ~~cultivation~~which ~~footprint~~is expected to ~~support~~generate ~~this~~higher ~~growing~~margin ~~demand~~sales.

Price compression. Historical price compression in specific categories is expected to persist in the market, intensified by fierce competition among the approximately 1,000 Licensed Producers in Canada. The fixed impact of excise per gram, notwithstanding the decline in average selling prices, further compounds these challenges, and has promoted ongoing industry lobbying efforts.

International cannabis trends:

We are a global leader in the development, production, distribution, marketing and sale of pharmaceutical-grade medical cannabis products. The cannabis industry in Europe is still in its early stages of development and countries within Europe are at different stages of medical and adult-use cannabis legalization. The most meaningful progress to date has been the legalization and regulation of cannabis for medical purposes, which has now taken place in more than 15 19 countries representing a population of more than ~~350~~ 477 million people (Germany, UK, Italy, Poland, Netherlands, Czech Republic, Greece, Portugal, Austria, Switzerland, Denmark, Croatia, Malta, Luxembourg, Ukraine, Sweden, Norway, Türkiye, Ireland, and Israel). Beyond this, some countries have expressed a clear political ambition to legalize adult-use cannabis (~~Germany,~~ Portugal~~, Luxembourg~~ and ~~Czech Republic~~Luxembourg), some are engaging in experiments for adult-use legalization (Germany, Netherlands, Malta, Czech Republic and Switzerland) and some are debating regulations for cannabinoid-based medicine (France and Spain). In Europe, we believe that, despite continuing recessionary economic conditions, political uncertainty in various countries and the continuing Russian conflict with Ukraine, cannabis legalization (both medicinal and adult-use) will continue to gain traction albeit more slowly than originally expected. This is evidenced by the cannabis regulations in Germany adopted on April 1, 2024, which we believe will serve as a catalyst for continued changes in drug policy throughout Europe. Outside of Europe and North America, the cannabis industry is also in its early stages of development with Australia representing one of the larger markets and with some Latin American countries also growing their respective medical cannabis markets, such as Argentina, Panama, Colombia and Brazil.

We continue to believe that Tilray remains uniquely positioned to maintain and gain significant market share in the markets in which we participate. We benefit from our end-to-end vertically-integrated infrastructure and well-placed investments, which are comprised of two EU-GMP cultivation facilities located in Portugal and Germany; our fully owned route-to-market encompassing sales, marketing and distribution infrastructure in Germany, Australia and Italy; a network of leading distributors who we work with in the various other countries in which we participate; and, our extensive genetics portfolio and demonstrated commitment and expertise related to the cultivation and production of high-quality, safe cannabis products. Tilray’s International business also benefits from the depth and breadth of knowledge, experience, relationships and infrastructure we have gleaned from our leading participation and investment into the Canadian medical and adult-use markets. Tilray is proudly pioneering the effort to further understand the therapeutic value of cannabis through the guidance of its independent Medical Advisory board and through partnerships with leading research institutions globally, Tilray is currently supporting clinical trials around the world studying the efficacy of cannabis in treading various indications. We believe that these assets and attributes, combined with our ability to navigate complex regulatory environments, will continue to drive our leadership in international medical markets and allow us to successfully enter new markets as they adopt medical cannabis and potentially adult-use regulations and may also serve to support a potential U.S. participation in the event of federal legalization.

Germany. Today, Germany remains the largest medical cannabis market in Europe.

On April 1, 2024, the Cannabis Act, consisting of two parts, the CanG and MedCanG, was signed into law by the Office of the Federal President and decriminalization and MedCanG portions of the Cannabis Act became effective. The MedCanG provides for several important medical cannabis reforms including the reclassification of medical cannabis from a narcotic to non-narcotic and the abolishment of the tender for domestic production, which has been replaced with a regular licensing scheme under the authority of the Federal Institute for Drugs and Medical Devices (the “BfArM”). Three licenses for domestic cultivation have been issued, with Tilray receiving the first one. The foreseen enhanced accessibility to medical cannabis due to non-narcotic prescriptions has had the desired effect. The prescription numbers have risen since April 1, 2024 and, accordingly, we have seen a significant increase in our business in Germany where we supply the market with a wide range of medical cannabis extracts and whole flower. In addition, the Federal Joint Committee (the “G-BA”) which issues directives for the German health insurance funds, enacted a resolution in July 2024 allowing for a significant reduction of reservation of approval. This is expected to have a positive market effect, allowing more doctors and specialists to be able to prescribe medical cannabis without receiving prior approval from statutory insurers. Tilray is well positioned to benefit from this change given our leading market share within the medical cannabis extracts segment that tends to have high levels of insurance coverage.

We continue to believe that Tilray is well-positioned in Germany, especially considering the enactment of MedCanG and given that we are one of only three manufacturers of medical cannabis in Germany since our wholly owned subsidiary, Aphria RX, was awarded the first license for the cultivation of medical cannabis in Germany by the BfArM under the liberalized regime. Said license will improve our ability to meet the needs of patients and provide cannabis of the utmost quality and enhanced availability to a broader market.

~~Poland. In~~As ~~Poland,~~the ~~cannabis~~market ~~was~~continues ~~legalized for medical use in 2018 and is prescribed~~ to ~~patients by a physician and dispensed by pharmacies. Today~~mature, ~~all~~we ~~doctors~~have inseen ~~Poland~~increased ~~are~~demands ~~allowed to prescribe medical cannabis~~ and itdifferentiation isspecifically awith ~~self-pay market as~~ medical cannabis ~~is not refundable by the Polish health service~~flowers. In ~~November 2024~~response, ~~Poland~~we ~~implemented strict restrictions on telemedicine, which~~ have ~~significantly~~launched ~~impacted~~ the ~~growth~~Tilray ofCraft, ~~the~~Redecan ~~market~~and ~~with~~Good ~~prescription~~Supply ~~numbers~~brands ~~decreasing~~and ~~from~~related ~~68,000~~medical incannabis ~~October 2024 to 28~~products,~~000~~ inwhich ~~December~~provides ~~2024.~~the ~~Tilray~~patient iswith a ~~leading~~segmented ~~supplier~~portfolio of ~~medical~~products ~~cannabis~~while inwe ~~Poland~~continue ~~through~~to ~~our~~deliver ~~network~~on ofthe ~~distributor~~trust, ~~partnerships. We~~safety ~~predominantly~~and ~~supply~~consistency ~~the~~that ~~market~~has ~~with~~become ~~whole~~expected ~~flower~~from ~~medical~~our ~~cannabis~~Tilray ~~products~~Medical brand.

~~United Kingdom~~Poland. ~~Since~~In ~~November~~Poland, cannabis was legalized for medical use in 2018 and is prescribed to patients by a physician and dispensed by pharmacies. Today, all doctors in ~~the~~Poland UKare ~~have~~allowed ~~been able~~ to prescribe medical cannabis ~~for~~and ~~medicinal~~it ~~use~~is ~~for~~a ~~patients~~self-pay market ~~with~~as medical ~~conditions~~cannabis ~~that~~is ~~had~~not ~~failed~~refundable toby ~~respond~~the toPolish ~~first-line~~health ~~medications~~service. ~~The~~ ~~market~~Tilray ~~today~~ is ~~predominantly~~a ~~all~~leading ~~self-pay~~supplier ~~and~~of ~~prescriptions~~medical ~~are~~cannabis ~~facilitated~~in byPoland ~~private~~through ~~clinics~~our network of distributor partnerships. ~~Today,~~ We wepredominantly supply the UK market with ~~mainly~~ whole flower ~~products~~medical ~~through~~cannabis ~~our distributor partners~~products.

United Kingdom. Since November 2018, doctors in the UK have been able to prescribe medical cannabis for medicinal use for patients with medical conditions that had failed to respond to first-line medications. The market today is predominantly all self-pay and prescriptions are facilitated by private clinics. Today, we supply the UK market with mainly whole flower products from both the Tilray Medical and Broken Coast brands through our distributor partners.

Ireland. In June 2019, the Minister for Health signed legislation allowing for the operation of the Medical Cannabis Access Programme (“MCAP”) on a pilot basis for five years. The MCAP allows a medical consultant to prescribe a cannabis-based treatment for a narrow set of specified medical conditions, where the patient has failed to respond to standard treatment. Reimbursement is available for products which have received the appropriate approvals. Tilray was one of the first players to enter the Irish market and is one of a few suppliers which has received approval for its products to be prescribed and to have been granted reimbursement status. Today, we supply our approved extract product to Ireland through our distribution partner.

Italy. In May 2023, Tilray Medical received authorization from Italy’s Ministry of Health to distribute three new medical cannabis compounds. These medical cannabis compounds are distributed by FL Group, our wholly-owned subsidiary, to pharmacies across Italy. With FL Group, we have an established broad national pharmaceutical distribution network in Italy, where medical cannabis is prescribed by doctors and reimbursed by the healthcare system to eligible patients. In 2025, Tilray has received additional cannabis flower and extract product authorizations and has formed a strategic partnership with Molteni Farmaceutici with the commitment to broaden the availability of Tilray Medical products for patients across Italy.

Australia. In 2016, the Australian Government legalized medicinal cannabis, which is regulated by the Therapeutic Goods Administration. Medical cannabis is prescribed by a doctor but there is no coverage under the Pharmaceutical Benefits Scheme. Tilray Medical ~~suppliers~~supplies the market with wide portfolio of medical cannabis extracts as well as whole flower products. We As ~~see~~the ~~increased~~market ~~differentiation~~continues ~~between~~to ~~the~~mature, ~~physician-led~~we have seen increased demands and ~~the~~differentiation ~~patient-led~~specifically ~~channels~~with medical cannabis flowers. In response, we launched the Broken Coast, Redecan and Good Supply brands and products, which provides the patient with a segmented portfolio of products while we continue to deliver on the trust, safety and consistency that has become expected from our Tilray Medical brand.

Wellness market trends:

Tilray Wellness’s branded business continues to grow across brick-and-mortar retail as well as ecommerce, further establishing its leading market share position in better -for -you categories. The Company continues to focus on value-added innovation within ~~the~~natural ~~wellness~~and ~~space with~~organic ~~the~~food ~~launch~~and ofbeverages across branded ~~Whole Flaxseed~~ and ~~Ground~~ingredient ~~Flaxseed~~sales. ~~and~~We ~~Superseed~~continue ~~Snack Clusters~~ to participate in ~~partnership~~multiple ~~with~~growing ~~Whole~~categories ~~Foods~~including ~~Market~~super-seeds, asbetter ~~well~~for asyou ~~continued~~breakfast, ~~emphasis~~better onfor ~~The~~you ~~Humble Seed~~snacking, aand ~~seed-forward~~natural ~~cracker~~energy ~~brand which was purchased earlier this year~~drinks.

Acquisitions, Strategic Transactions and Synergies

We strive to continue to expand our business, on a consolidated basis, through a combination of organic growth and acquisition. While we continue to execute against our strategic initiatives that we believe will result in long-term, sustainable growth and value to our stockholders, we continue to evaluate potential acquisitions and other strategic transactions of businesses that we believe complement our existing portfolio, infrastructure and capabilities or provide us with the opportunity to enter attractive new geographic markets and product categories as well as expand our existing capabilities. In addition, we have exited certain businesses and continue to evaluate certain businesses within our portfolio that are dilutive to profitability and cash flow. As a result, we incur transaction costs in connection with identifying and completing acquisitions and strategic transactions, as well as ongoing integration and restructuring costs as we combine acquired companies and continue to achieve synergies, which is offset by income generated in connection with the execution of these transactions. For the ~~nine~~three months ended ~~February~~August 2831, 2025, we incurred $20.64 million of transaction expenses, as discussed further below.

Effective September 1, 2024, Tilray acquired a portfolio of four craft brands and breweries comprised of Atwater Brewery, Hop Valley Brewing Company, Terrapin Beer Co., and Revolver Brewing from Molson, see Note 7 (Business Acquisition). We expect this acquisition to further the execution of our beverage strategy, which we believe will have positive impacts on our beverage segment leading to increased revenues and whitespace penetration.

Beverage segment Project 420:

In November 2020, we entered the beverage category with the acquisition of SweetWater Brewing Company, one of the largest independent craft brewers in the U.S. by volume, with the vision of creating a larger and more diversified global lifestyle consumer products company.

This initial acquisition provided us with a foundation to pursue additional acquisitions in the beverage category and scale our business on a national basis. We acquired Alpine Beer Company, Green Flash and Breckenridge Distillery in December 2021, Montauk Brewing Company in November 2022, Craft Acquisition I in October 2023 and Craft Acquisition II in September 2024.

With Craft Acquisition I and Craft Acquisition II, we capitalized on opportunities to acquire additional beverage businesses that consisted of strong brands in decline and in need of investment in order to promote growth at a significantly reduced price. To support the growth of these acquired brands and establish a clear path to profitability, we implemented Project 420, which is a comprehensive plan covering (i) SKU rationalization; (ii) Geographic rationalization; (iii) Distributor rationalization; and (iv) synergy optimization plan through which we expect to invest in the acquired brands for growth and improve profitability:

- SKU rationalization – In response to the declining growth in the craft beer industry and consolidation of distributors, we are working with our distributors in various markets to streamline our portfolio by eliminating duplicative, lower margin and slower growth products, which ~~had~~has the immediate effect of reducing revenue. However, by eliminating these slower ~~growing~~moving and lower margin SKUs, we are able to focus our attention and resources on our higher growth SKUs and the introduction of new innovation, which we expect will accelerate our revenue growth in future quarters. Going forward, we will continue to manage SKU performance within our portfolio on a “one in and one out basis” to maximize SKU productivity.

- Geographic rationalization – ~~Our~~On ~~brands~~a consolidated basis, we generate sales in all states however, ~~their~~our ~~results~~brands are significantly stronger in their home markets. For example, SweetWater is located in Georgia and, as a result, its revenues are stronger in Georgia, Alabama, North Carolina and Florida, while 10 Barrel, which is located in Oregon has stronger revenue in Oregon, Washington, Idaho and Wyoming. In away markets, like Oregon for SweetWater, and Georgia for 10 Barrel, the brands are not as strong in the away states. Our geographic rationalization works to concentrate our efforts in individual states with our strongest brands in those states. As we reduce the distribution of away markets brands in those states, we are working to increase the distribution and shelf space of home market brands. This initiative is consistent with our Regional Jewel strategy developed in conjunction with the Boston Consulting Group.

- Distributor rationalization – As a result of our various acquisitions in the last five years, we have over 750 distributors and 975 distributor shipping locations. As a result, we are shipping to multiple distributors in the same geography as well as splitting the allocation of local brands between multiple distributors. The goal of the distributor rationalization is to reduce our distributor footprint down to between 450 and 500 distributors, concentrating those distributor’s effort on our brands and SKUs, while minimizing logistical complexities.

- Synergy optimization plan – We previously announced a $2533 million synergy plan focused on optimizing our production footprint and eliminating redundancies in manufacturing and warehouse assets. By integrating the newly acquired facilities into our existing footprint, we are optimizing capacities, utilization and better absorbing fixed overheads. This in turn is improving our gross margins. InAs ~~the~~of ~~current~~August ~~quarter~~31, 2025, we ~~increased the synergy plan by $8 million to $33 million and~~ have achieved $2025.61 million of those savings to date. We expect to complete the synergy optimization plan in the third quarter of fiscal 2026.

Brand and business investment – We have been and are continuing to increase our investment in the marketing, promotion and infrastructure of our recently acquired brands in order to reestablish their dominance in their core markets. Our intention is to fund this investment through the cost savings and synergies achieved through Project 420.

For the nine months ended February 28, 2025, our SKU and geographic rationalization resulted in a reduction in net sales of approximately $14.0 million. For the fiscal year ended May 31, 2025, it is anticipated that the cumulative impact of these initiatives will result in a reduction of approximately $20.0 million in net sales, which we believe will be offset by the growth of our new product innovation, including in new beverage categories, and brand extensions over the next 12 months. This revenue reduction has a corresponding decrease in our Adjusted EBITDA for the three and nine months ended February 28, 2025, of $1.0 million and $4.2 million, respectively.

It is important to note, however, that there is a lag between the discontinuation of the SKUs and the associated reduction in revenue, which has an immediate effect, and the acceleration of the growth of our existing SKUs and the introduction of new innovation and the associated increase in revenue, which takes time due to retailer resets. We also expect these efforts will lead to improved sales and margins, with benefits realized through lower selling costs, as well as reduced requirements for working capital through inventory reductions and an improvement in our cash conversion cycle.

Political and Economic Environment

Our results of operations may continue to be affected by economic, political, legislative, regulatory, legal actions, global volatility and general market disruption resulting from geopolitical tensions, such as Russia's continued incursion into Ukraine, the ongoing events in the Middle East and political uncertainty in certain countries in Europe. Economic conditions, such as recessionary trends, inflation, supply chain disruptions, interest and monetary exchange rates, government fiscal policies, and the recent economic uncertainties resulting from certain changes in U.S. global economic policy, including changes on global trade policies can have a significant effect on operations. More specifically, there are no expected impacts on revenue from the recently enacted U.S. tariffs and foreign enacted retaliatory tariffs (“Tariffs”). From a cost perspective, we believe the recently enacted ~~tariffs~~Tariffs could impact input materials such as aluminum, hops, barley, malt and vape componentry , which are partially imported but ~~will~~we beintend ~~mitigated~~to mitigate these impacts to the extent possible.

Results of Operations

Our consolidated results, in thousands except for per share data, are as follows:

	For the three months ended												~~For the nine months ended~~
	February 28,			February 29,			Change			% Change			February 28,			February 29,			Change			% Change
	August 31,			August 31,			Change			% Change
(in thousands of U.S. dollars)	2025			2024			2025 vs. 2024						~~2025~~			~~2024~~			~~2025 vs. 2024~~
Net revenue	$	~~185~~209,~~780~~501		$	~~188~~200,~~340~~044		$	(29,~~560~~457	)		(15	)%	$	~~596,774~~		$	~~559,060~~		$	~~37,714~~			7	%
Cost of goods sold		~~133~~152,~~769~~032			~~138~~140,~~944~~338			(511,~~175~~694	)		(48	)%		~~423,837~~			~~418,059~~			~~5,778~~			1	%
Gross profit		5257,~~011~~469			4959,~~396~~706			(2,~~615~~237	)		5(4	)%		~~172,937~~			~~141,001~~			~~31,936~~			23	%
Operating expenses:
General and administrative		3941,~~246~~053			3944,~~940~~113			(~~694~~3,060	)		(27	)%		~~129,356~~			~~123,769~~			~~5,587~~			5	%
Selling		1312,~~905~~923			911,~~995~~690			31,~~910~~233			3911	%		~~41,757~~			~~24,437~~			~~17,320~~			71	%
Amortization		233,~~182~~929			21,~~558~~804			1(17,~~624~~875	)		8(82	)%		~~67,913~~			~~65,700~~			~~2,213~~			3	%
Marketing and promotion		610,~~793~~155			11,~~191~~566			(41,~~398~~411	)		(3912	)%		~~28,079~~			~~28,934~~			~~(855~~	)		(3	)%
Research and development		8541			~~106~~105			(2164	)		(2061	)%		~~250~~			~~241~~			9			4	%
Change in fair value of contingent consideration		—(15,000	)		~~(5,983~~—	)		5(15,~~983~~000	)		~~(100~~NM	)%		—			~~(16,790~~	)		~~16,790~~			~~(100~~	)%
Impairments		699,235			—			699,235			NM			699,235			—			699,235			NM
Litigation costs, net of recoveries		1,007			1,595			(588	)		(37	)%
Other than temporary change in fair value of convertible notes receivable		20,000			42,681			(22,681	)		(53	)%		20,000			42,681			(22,681	)		(53	)%
Restructuring costs		869			4,247			(3,378	)		(80	)%
Litigation costs, net of recoveries		2,758			3,363			(605	)		(18	)%		5,254			8,439			(3,185	)		(38	)%
Transaction costs (income), net		400			1,156			(756	)		(65	)%
Restructuring costs		6,133			5,178			955			18	%		17,249			8,748			8,501			97	%
Total operating expenses		55,377			96,276			(40,899	)		(42	)%
Transaction costs (income), net		605			3,465			(2,860	)		(83	)%		2,563			13,061			(10,498	)		(80	)%
Operating income (loss)		2,092			(36,570	)		38,662			(106	)%
Total operating expenses		811,942			131,494			680,448			517	%		1,011,656			299,220			712,436			238	%
Interest expense, net		(6,696	)		(9,842	)		3,146			(32	)%
Operating loss		(759,931	)		(82,098	)		(677,833	)		826	%		(838,719	)		(158,219	)		(680,500	)		430	%
Non-operating (expense) income, net		3,832			12,646			(8,814	)		(70	)%
Interest expense, net		(8,378	)		(8,517	)		139			(2	)%		(25,986	)		(26,977	)		991			(4	)%
Loss before income taxes		(772	)		(33,766	)		32,994			(98	)%
Non-operating (expense) income, net		(24,022	)		(17,239	)		(6,783	)		39	%		(44,631	)		(20,820	)		(23,811	)		114	%
Income tax expense (recovery), net		(2,285	)		886			(3,171	)		(358	)%
Loss before income taxes		(792,331	)		(107,854	)		(684,477	)		635	%		(909,336	)		(206,016	)		(703,320	)		341	%
Net income (loss)	$	1,513		$	(34,652	)	$	36,165			(104	)%
Income tax expense (recovery), net		1,203			(2,871	)		4,074			(142	)%		4,125			1,013			3,112			307	%
Net loss	$	(793,534	)	$	(104,983	)	$	(688,551	)		656	%	$	(913,461	)	$	(207,029	)	$	(706,432	)		341	%

Use of Non-GAAP Measures

Throughout this Management's Discussion and Analysis of Financial Condition and Results of Operations in this Quarterly Report on Form 10-Q, we discuss non-GAAP financial measures, including references to:

● adjusted gross profit (excluding purchase price ~~accounting~~allocation (“PPA”) ~~fair value~~ step up) consolidated and for each reporting segment (Cannabis, Beverage, Distribution and Wellness) ~~as applicable~~,

● adjusted gross margin (excluding PPA ~~fair value~~ step up) consolidated and for each reporting segment (~~Beverage~~Cannabis, ~~Cannabis~~Beverage, Distribution and Wellness) ~~as applicable~~,

●

adjusted EBITDA,

●

cash and marketable securities, and

● constant currency presentation of net revenue (by segment and consolidated).

These non-GAAP financial measures should be considered in addition to, and not in lieu of, the financial measures calculated and presented in accordance with generally accepted accounting principles in the United States of America, (“GAAP”). These financial measures, which may be different than similarly titled financial measures used by other companies, are presented to help investors' overall understanding of our financial performance and should not be considered a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. Please see “Reconciliation of Non-GAAP Financial Measures to GAAP Measures” below for reconciliation of such non-GAAP financial measures to the most directly comparable GAAP financial measures, as well as a discussion of our adjusted gross margin, adjusted gross profit and adjusted EBITDA measures and the calculation of such measures.

Constant Currency Presentation

We believe that this financial measure provides useful information to investors because it eliminates the effect that foreign currency exchange rate fluctuations may have on period-to-period comparability given the volatility in foreign currency exchange markets and therefore, provides greater transparency to the underlying performance of our consolidated net sales. To present this information for historical periods, current period net sales for entities reporting in currencies other than the U.S. Dollar are translated into U.S. Dollars at the average monthly exchange rate in effect during the corresponding period of the prior fiscal year rather than at the actual average monthly exchange rate in effect during the current period of the current fiscal year. As a result, the foreign currency impact is equal to the current year results in local currencies multiplied by the change in average foreign currency exchange rate between the current fiscal period and the corresponding period of the prior fiscal year.

Cash and Marketable Securities

The Company combines the Cash and cash equivalent financial statement line item and the Marketable securities financial statement line item as an aggregate total as reconciled in the liquidity and capital resource section below. The Company’s management believes that this presentation provides useful information to management, analysts and investors regarding certain additional financial and business trends relating to its short-term liquidity position by combining these two GAAP metrics.

Operating Metrics and Non-GAAP Measures

We use the operating metrics and non-GAAP measures set forth in the table below to evaluate our business and operations, measure our performance, identify trends affecting our business, project our future performance, and make strategic decisions. Other companies, including companies in our industry, may calculate operating metrics and non-GAAP measures with similar names differently which may reduce their usefulness as comparative measures. Certain variances are labeled as not meaningful ("“NM"”) throughout management's discussion and analysis.

For the three months ended

~~For the nine months ended~~

February 28,

February 29,

February 28,

February 29,

August 31,

(in thousands of U.S. dollars)

2025

2024

~~2025~~

~~2024~~

Net beverage revenue

55,~~921~~739

5455,~~688~~972

~~174,974~~

~~125,355~~

Net cannabis revenue

5464,~~274~~511

6361,~~432~~249

~~181,175~~

~~200,879~~

Distribution revenue

6174,~~493~~007

5668,~~794~~071

~~197,175~~

~~193,174~~

Wellness revenue

1415,~~092~~244

1314,~~426~~752

~~43,450~~

~~39,652~~

Beverage costs

3534,~~986~~413

3533,~~836~~050

~~106,961~~

~~77,615~~

Cannabis costs

3241,~~275~~241

4237,~~518~~054

~~111,804~~

~~139,507~~

Distribution costs

5566,~~936~~008

5160,~~231~~138

~~175,281~~

~~172,846~~

Wellness costs

910,~~572~~370

910,~~359~~096

~~29,791~~

~~28,091~~

Adjusted gross profit (excluding PPA step-up) (1)

5257,~~070~~469

5159,~~643~~881

~~174,547~~

~~153,055~~

Beverage adjusted gross margin (excluding PPA step-up) (1)

3638

3841

Cannabis adjusted gross margin (excluding PPA step-up) (1)

4136

3340

Distribution gross margin

911

1012

Wellness gross margin

3032

Adjusted EBITDA (1)

910,~~040~~181

109,~~154~~334

~~27,391~~

~~30,974~~

Cash and marketable securities (1) as at the period ended:

~~248~~264,~~414~~828

~~225~~280,~~858~~055

~~248,414~~

~~225,858~~

Working capital as at the period ended:

~~424~~433,~~115~~508

~~302~~432,~~111~~334

~~424,115~~

~~302,111~~

⁽¹⁾Adjusted EBITDA, adjusted gross profit (excluding PPA step-up) and adjusted gross margin (excluding PPA step-up) for each of our segments, and cash and marketable securities are non-GAAP financial measures. See “Use of Non-GAAP Measures” above for a discussion of these Non-GAAP measures and “Reconciliation of Non-GAAP Financial Measures to GAAP Measures” below for a reconciliation of these Non-GAAP Measures to our most comparable GAAP measure and the discussion above captioned “Cash and Marketable Securities.”

Segment Reporting

~~Our~~For the three months ended August 31, 2025 and August 31, 2024, respectively, our reporting segments net revenue is was comprised of net revenues from our beverage, cannabis, distribution, and wellness operations, as follows:

	For the three months ended										~~For the nine months ended~~
	February 28,		February 29,		Change			% Change			February 28,		February 29,		Change			% Change
	August 31,		August 31,		Change			% Change
(in thousands of U.S. dollars)	2025		2024		2025 vs. 2024						~~2025~~		~~2024~~		~~2025 vs. 2024~~
Beverage business	$	55,~~921~~739	$	5455,~~688~~972	$	1,(233	)		2(0	)%	$	~~174,974~~	$	~~125,355~~	$	~~49,619~~			40	%
Cannabis business		5464,~~274~~511		6361,~~432~~249		(93,~~158~~262	)		~~(14~~5	)%		~~181,175~~		~~200,879~~		~~(19,704~~	)		~~(10~~	)%
Distribution business		6174,~~493~~007		5668,~~794~~071		45,~~699~~936			89	%		~~197,175~~		~~193,174~~		~~4,001~~			2	%
Wellness business		1415,~~092~~244		1314,~~426~~752		~~666~~492			53	%		~~43,450~~		~~39,652~~		~~3,798~~			10	%
Total net revenue	$	~~185~~209,~~780~~501	$	~~188~~200,~~340~~044	$	(29,~~560~~457	)		(15	)%	$	~~596,774~~	$	~~559,060~~	$	~~37,714~~			7	%

~~Our~~For the three months ended August 31, 2025 and August 31, 2024, respectively, our reporting segment net revenue on a constant currency(1) basis iswas as follows:

	For the three months ended										~~For the nine months ended~~
	as reported in constant currency										~~as reported in constant currency~~
		February 28,		February 29,		Change			% Change			February 28,		February 29,		Change		% Change
	August 31,		August 31,		Change			% Change
(in thousands of U.S. dollars)	2025		2024		2025 vs. 2024						~~2025~~		~~2024~~		~~2025 vs. 2024~~
Beverage business	$	55,~~921~~739	$	5455,~~688~~972	$	1,(233	)		2(0	)%	$	~~174,974~~	$	~~125,355~~	$	~~49,619~~		40	%
Cannabis business		5764,~~475~~049		6361,~~432~~249		(52,~~957~~800	)		(95	)%		~~186,120~~		~~200,879~~		~~(14,759~~	)	(7	)%
Distribution business		6569,~~054~~706		5668,~~794~~071		81,~~260~~635			152	%		~~204,861~~		~~193,174~~		~~11,687~~		6	%
Wellness business		1415,~~499~~281		1314,~~426~~752		~~1,073~~529			84	%		~~44,068~~		~~39,652~~		~~4,416~~		11	%
Total net revenue	$	~~192~~204,~~949~~775	$	~~188~~200,~~340~~044	$	4,~~609~~731			2	%	$	~~610,023~~	$	~~559,060~~	$	~~50,963~~		9	%

~~Our~~For the three months ended August 31, 2025 and August 31, 2024, respectively, our geographic net revenue is was as follows:

For the three months ended

~~For the nine months ended~~

February 28,

February 29,

Change

% Change

February 28,

February 29,

Change

% Change

August 31,

Change

% Change

(in thousands of U.S. dollars)

2025

2024

2025 vs. 2024

~~2025~~

~~2024~~

~~2025 vs. 2024~~

USA

6463,~~420~~961

6263,~~384~~880

~~2,036~~81

~~200,053~~

~~147,247~~

~~52,806~~

Canada

4558,~~930~~167

55,~~140~~905

(92,~~210~~262

)

~~(17~~4

~~158,555~~

~~178,417~~

~~(19,862~~

)

~~(11~~

EMEA

7285,~~386~~253

6777,~~143~~672

57,~~243~~581

810

~~229,312~~

~~222,139~~

~~7,173~~

Rest of World

32,~~044~~120

32,~~673~~587

(~~629~~467

)

(1718

~~8,854~~

~~11,257~~

~~(2,403~~

)

~~(21~~

Total net revenue

~~185~~209,~~780~~501

~~188~~200,~~340~~044

(29,~~560~~457

)

(15

~~596,774~~

~~559,060~~

~~37,714~~

~~Our~~For the three months ended August 31, 2025 and August 31, 2024, respectively, our geographic net revenue on a constant currency(1) basis is was as follows:

For the three months ended

~~For the nine months ended~~

as reported in constant currency

~~as reported in constant currency~~

February 28,

February 29,

Change

% Change

February 28,

February 29,

Change

% Change

August 31,

Change

% Change

(in thousands of U.S. dollars)

2025

2024

2025 vs. 2024

~~2025~~

~~2024~~

~~2025 vs. 2024~~

USA

6463,~~420~~961

6263,~~384~~880

~~2,036~~81

~~200,053~~

~~147,247~~

~~52,806~~

Canada

4958,~~208~~436

55,~~140~~905

(52,~~932~~531

)

~~(11~~5

~~163,695~~

~~178,417~~

~~(14,722~~

)

EMEA

7580,~~735~~008

6777,~~143~~672

82,~~592~~336

133

~~231,706~~

~~222,139~~

~~9,567~~

Rest of World

32,~~586~~370

32,~~673~~587

(87217

)

(28

~~14,569~~

~~11,257~~

~~3,312~~

Total net revenue

~~192~~204,~~949~~775

~~188~~200,~~340~~044

4,~~609~~731

~~610,023~~

~~559,060~~

~~50,963~~

~~Our~~For the three months ended August 31, 2025 and May 31, 2025, respectively, our geographic capital assets ~~are~~ were as follows:

		February 28,		May 31,		Change			% Change
	August 31,		May 31,		Change			% Change
(in thousands of U.S. dollars)	2025		~~2024~~2025		2025 vs. 2024
USA	$	~~199~~195,~~539~~436	$	~~141~~200,~~314~~003	$	58(4,~~225~~567	)		41(2	)%
Canada		~~244~~262,~~091~~114		~~313~~267,~~359~~458		(695,~~268~~344	)		(222	)%
EMEA		9099,~~740~~109		9997,~~921~~371		(91,~~181~~738	)		(92	)%
Rest of World		3,~~430~~498		3,~~653~~601		(~~223~~103	)		(63	)%
Total capital assets	$	~~537~~560,~~800~~157	$	~~558~~568,~~247~~433	$	(208,~~447~~276	)		(41	)%

Beverage revenue

~~Revenue~~Net revenue from our Beverage segment ~~increased~~decreased to $55.97 million ~~and to~~ ~~$175.0 million~~ for the three ~~and nine~~ months ended ~~February~~August 2831, 2025, compared to revenue of $5456.70 million ~~and~~ ~~$125.4 million~~ for the prior year period. The ~~three and nine months increase~~ decrease in beverage net revenue was primarily driven by ~~our~~industry ~~newly~~trends ~~launched~~within ~~innovation~~the incraft ~~the~~beer ~~HD-D9~~segment ~~product~~as ~~category~~well ~~and~~as our ~~recent~~portfolio ~~Craft~~optimization ~~Acquisition~~efforts ~~II,~~in ~~effective~~connection ~~September~~with our 1,ongoing ~~2024,~~Project ~~which~~420 ~~included~~initiatives. ~~the~~These ~~brands~~impacts ~~and~~were ~~breweries~~offset ofby ~~Hop Valley Brewing Company, Terrapin Beer Company, Revolver Brewing, and Atwater Brewery. Further,~~ the ~~prior~~inclusion ~~year period did not reflect a full period~~ of ~~revenue~~sales from ~~the initial~~ Craft Acquisition II, effective ~~completed on~~ September 291, ~~2023. These impacts to beverage revenue were offset by the SKU rationalization implemented in connection with Project 420~~2024, ~~which~~as ~~resulted in a reduction of revenue of $6.0 million and $14.0 million for~~ the ~~three~~prior ~~and~~year ~~nine~~fiscal ~~months~~quarter ~~ended~~did ~~February~~not ~~28,~~reflect ~~2025,~~this ~~respectively~~transaction.

Cannabis revenue

~~Cannabis~~For the three months ended August 31, 2025 and August 31, 2024, respectively, cannabis net revenue based on market channel was as follows:

For the three months ended

~~For the nine months ended~~

February 28,

February 29,

Change

% Change

February 28,

February 29,

Change

% Change

August 31,

Change

% Change

(in thousands of US dollars)

2025

2024

2025 vs. 2024

~~2025~~

~~2024~~

~~2025 vs. 2024~~

Revenue from Canadian medical cannabis

56,~~839~~146

6,~~363~~261

(~~524~~115

)

(82

~~18,773~~

~~18,793~~

~~(20~~

)

Revenue from Canadian adult-use cannabis

4964,~~315~~067

6257,~~107~~235

~~(12~~6,~~792~~832

)

~~(21~~12

~~165,627~~

~~205,350~~

~~(39,723~~

)

~~(19~~

Revenue from wholesale cannabis

34,~~893~~155

25,~~764~~507

(1,~~129~~352

)

41(25

~~15,993~~

~~12,348~~

~~3,645~~

Revenue from international cannabis

13,~~935~~367

1412,~~002~~191

~~(67~~1,176

)

(010

~~40,991~~

~~40,185~~

~~806~~

Total cannabis revenue

7287,~~982~~735

8581,~~236~~194

~~(12~~6,~~254~~541

)

~~(14~~8

~~241,384~~

~~276,676~~

~~(35,292~~

)

~~(13~~

Excise taxes

(1823,~~708~~224

)

(2119,~~804~~945

)

(3,~~096~~279

)

~~(14~~16

~~(60,209~~

)

~~(75,797~~

)

~~15,588~~

~~(21~~

Total cannabis net revenue

5464,~~274~~511

6361,~~432~~249

(93,~~158~~262

)

~~(14~~5

~~181,175~~

~~200,879~~

~~(19,704~~

)

~~(10~~

~~Cannabis~~For the three months ended August 31, 2025 and August 31, 2024, respectively, cannabis net revenue based on market channel on a constant currency(1) basis was as follows:

	For the three months ended												~~For the nine months ended~~
	as reported in constant currency												~~as reported in constant currency~~
		February 28,			February 29,			Change			% Change			February 28,			February 29,			Change		% Change
	August 31,			August 31,			Change			% Change
(in thousands of US dollars)	2025			2024			2025 vs. 2024						~~2025~~			~~2024~~			~~2025 vs. 2024~~
Revenue from Canadian medical cannabis	$	6,~~259~~174		$	6,~~363~~261		$	(~~104~~87	)		(21	)%	$	~~19,398~~		$	~~18,793~~		$	~~605~~		3	%
Revenue from Canadian adult-use cannabis		5264,~~815~~359			6257,~~107~~235			(97,~~292~~124	)		~~(15~~12	)%		~~170,967~~			~~205,350~~			~~(34,383~~	)	~~(17~~	)%
Revenue from wholesale cannabis		4,~~170~~173			25,~~764~~507			(1,~~406~~334	)		51(24	)%		~~16,525~~			~~12,348~~			~~4,177~~		34	%
Revenue from international cannabis		1412,~~264~~674			1412,~~002~~191			~~262~~483			24	%		~~41,411~~			~~40,185~~			~~1,226~~		3	%
Total cannabis revenue		7787,~~508~~380			8581,~~236~~194			(76,~~728~~186	)		(98	)%		~~248,301~~			~~276,676~~			~~(28,375~~	)	~~(10~~	)%
Excise taxes		(2023,~~033~~331	)		(2119,~~804~~945	)		1(3,~~771~~386	)		(817	)%		~~(62,181~~	)		~~(75,797~~	)		~~13,616~~		~~(18~~	)%
Total cannabis net revenue	$	5764,~~475~~049		$	6361,~~432~~249		$	(52,~~957~~800	)		(95	)%	$	~~186,120~~		$	~~200,879~~		$	~~(14,759~~	)	(7	)%

(1)

The constant currency presentation of our Cannabis revenue based on market channel is a non-GAAP financial measure. See “Use of Non-GAAP Measures –Constant Currency Presentation” above for a discussion of these Non-GAAP Measures.

Revenue from Canadian medical cannabis: Gross revenue from Canadian medical cannabis decreased to $56.81 million ~~and remained consistent at~~ ~~$18.8 million~~ for the three ~~and nine~~ months ended ~~February~~August 2831, 2025 compared to gross revenue of $6.43 million ~~and $18.8 million~~ for the prior year period. On a constant currency basis, gross revenue from Canadian medical cannabis was $6.32 million ~~and~~ ~~$19.4 million~~ for the three ~~and nine~~ months ended ~~February~~August 2831, 2025 ~~compared to gross revenue of $6~~.4 ~~million and $18.8 million for the prior year period.~~ The ~~nine~~decrease ~~months increase~~ in gross revenue from medical cannabis, on a constant currency basis, was primarily driven by ~~growth~~uninsured ~~in the insured~~ patient ~~category exceeding the decline in un-insured patient~~ attrition to the adult-use recreational market, which was partially offset by new insured patient acquisition.

Revenue from Canadian adult-use cannabis: During the three ~~and nine~~ months ended ~~February~~August 2831, 2025, our gross revenue from Canadian adult-use cannabis ~~decreased~~increased to $4964.31 million ~~and $165.6 million~~, compared to gross revenue of $6257.12 million ~~and $205.4 million~~ for the prior year period. ~~Gross revenue in the prior year period included $1.5 million in advisory fees, which did not repeat during the three and nine months ended February 28, 2025.~~ On a constant currency basis, our gross revenue from Canadian adult-use cannabis ~~decreased~~increased to $5264.84 million ~~and~~ ~~$171.0 million~~ for the three ~~and nine~~ months ended ~~February~~August 2831, 2025. The ~~decrease~~ increase in gross adult-use revenue was ~~driven~~primarily attributed byto ~~our~~sales ~~renewed~~growth ~~focus~~in onour ~~preserving~~flower ~~gross margin~~ and ~~maintaining~~non-infused apre-roll ~~higher~~categories ~~average~~where ~~selling~~we ~~price~~have inbegun ~~growing~~to ~~categories such~~see aspositive ~~vapes~~results ~~that~~from ~~have~~our ~~experienced~~continued ainnovation ~~high~~and ~~degree~~enhanced ofcultivation ~~price compression~~capacity. We ~~expect~~Additionally, towe behave ~~able~~ started to ~~increase~~re-enter ~~our~~price-compressed ~~participation in these~~ categories asthat awere ~~result~~previously ofmargin ~~our~~prohibitive ~~capex~~but ~~investments~~are innow ~~the~~generating ~~fourth~~positive ~~quarter~~gross ~~ended~~margins ~~May~~due ~~31, 2025,~~ to our ~~improve~~ongoing ~~these~~cost ~~trends~~savings initiatives. ~~Additionally~~Lastly, we have ~~shifted~~continued ~~our strategic focus~~ to ~~redirect inventories~~invest ~~to international~~in ~~cannabis~~our ~~markets~~cultivation footprint to ~~take~~support ~~advantage~~the growing ofdemand ~~the~~in ~~higher~~both ~~margin~~the ~~sales~~Canadian ~~available in~~and ~~these~~international markets. WeGiven ~~expect these inventories to be sold during~~ the ~~fourth~~higher ~~fiscal~~margin ~~quarter~~that ~~ended~~can ~~May~~be ~~31,~~earned ~~2025,~~on ~~however~~international ~~this caused a temporary decline in gross adult-use~~ cannabis ~~revenue~~sales, ~~and~~we ~~cannabis~~may, ~~revenue~~when ~~overall~~advantageous ~~until their~~to ~~eventual~~do ~~sale.~~so, Wecontinue ~~intend~~ to ~~enhance~~redirect ~~our~~inventories ~~global~~to ~~supply~~international ~~chain~~markets, ~~through~~which ~~Phase~~may IInegatively ofimpact ~~our~~Canadian ~~accelerated~~adult-use ~~growth~~sales ~~plan and increase our cultivation footprint to support the growing demand~~ in ~~both~~future ~~the Canadian and international markets~~periods.

Wholesale cannabis revenue: Gross revenue from wholesale cannabis ~~increased~~decreased to $34.92 million ~~and~~ ~~$16.0 million~~ for the three ~~and nine~~ months ended ~~February~~August 2831, 2025 , compared to gross revenue of $25.85 million ~~and~~ ~~$12.3 million~~ for the prior year period. On a constant currency basis, gross revenue from wholesale cannabis ~~increased~~decreased to $4.2 million ~~and $16.5 million~~ for the three ~~and nine~~ months ended ~~February~~August 2831, 2025 ~~compared to gross revenue of $2~~.~~8 million~~ ~~and $12.3~~Due ~~million for~~to the ~~prior~~transition ~~year~~by ~~period. Due~~many tolicensed producers in the ~~transition~~Canadian market to asset-light business models, the Canadian cannabis industry has experienced a reduction in excess inventory resulting in price increases in the B2B market. ~~This~~As a result of this shift in market dynamics and demand, ~~enabled~~we uscontinue to ~~strategically sell~~evaluate ~~inventory~~the ~~that~~market ~~was~~and ~~sought~~may ~~after in~~opportunistically ~~the~~sell into the wholesale market ~~during~~where ~~the~~it ~~quarter but~~makes ~~does~~sense. Specifically, ~~not~~during ~~meet~~this ~~the~~fiscal ~~high~~quarter, ~~standards~~our ~~required~~wholesale ~~for~~cannabis ~~our~~revenue ~~branded~~was ~~product.~~lower Inthan the ~~near-term,~~prior weyear ~~anticipate~~fiscal ~~continued~~quarter ~~volatility~~due ~~and~~to ~~fluctuation~~our instrategic ~~the~~decision ~~wholesale~~to ~~market,~~channel ~~and~~more weof ~~will~~our ~~assess~~volume ~~market~~into ~~conditions~~the onother amarkets ~~quarterly~~in ~~basis~~which we participate.

International cannabis revenue: Net revenue from International cannabis ~~was consistent~~ ~~at $13.9 million and~~ increased to $4113.04 million for the three ~~and nine~~ months ended ~~February~~August 2831, 2025 , compared to net revenue of $1412.~~0 million and $40.~~2 million for the prior year period. On a constant currency basis, given the ~~changes~~strengthening in of the Euro against the U.S. Dollar when compared to the prior year quarter, net revenue from international cannabis increased to $1412.37 million ~~and $41.4 million~~for ~~compared to $14.0 million and $40.2 million in~~ the ~~prior~~three ~~year period. The~~months ~~increase~~ended ~~during~~August ~~the period was primarily driven by higher sales in Germany~~31, ~~attributed to the expanding German medical market~~2025. ~~This~~ International ~~growth~~cannabis ~~was~~net ~~partially offset by lower~~ revenue in Poland driven by the timing of export/import permits and lower prescriptions due to restrictions placed on telemedicine in November 2024 as well as lower revenue in Australia and the strategic decision to exit the New Zealand medical market. Net international cannabis revenue may fluctuate from quarter to quarter based upon the timing of the receipt of export/import permits as well as the timing of shipments from one quarter to the next. WeDespite ~~anticipate~~increasing ~~that~~international cannabis revenue in the ~~redirected~~fiscal ~~product~~quarter, ~~from~~we ~~the~~continued ~~Canadian~~to ~~cannabis~~experience extensive ~~market~~delays ~~will~~in bethe ~~sold~~receipt inof ~~our~~import/export ~~fourth~~permits that ~~fiscal~~prevented ~~quarter~~us ~~through~~from ~~these~~shipping medical ~~international~~cannabis ~~markets~~flowers to their intended destination.

Distribution revenue

~~Revenue~~Net revenue from our Distribution segment increased to $6174.50 million ~~and~~ ~~$197.2 million~~ for the three ~~and nine~~ months ended ~~February~~August 2831, 2025, compared to revenue of $5668.81 million ~~and $193.2 million~~ for the prior year period. On a constant currency basis, given the change in the Euro and Argentine Peso against the U.S. Dollar in the quarter, revenue from Distribution increased to $6569.17 million ~~and~~ ~~$204.9 million~~ for the three ~~and nine~~ months ended ~~February~~August 2831, 2025~~, compared to $56~~.~~8 million~~ ~~and $193.2 million for the prior year period.~~ The increase in distribution revenue ~~for~~in ~~both~~ the ~~three~~period ~~and nine months periods~~ was driven by a change in product mix ~~offset~~and by the impacts of foreign exchange ~~and that, during the prior year period, there were IT infrastructure outages and weather complications that negatively impacted our sales activities~~.

Wellness revenue

Our Wellness segment ~~revenue~~net revenue increased to $1415.12 million ~~and~~ ~~$43.5 million~~ for the three ~~and nine~~ months ended ~~February~~August 2831, 2025 compared to $1314.48 million ~~and~~ ~~$39.7 million~~ from the prior year period. On a constant currency basis for the three ~~and nine~~ months ended ~~February~~August 2831, 2025, Wellness segment net revenue increased to $1415.53 million ~~and $44~~.~~1 million~~ ~~from $13.4 million and $39.7 million.~~ The increase in revenue was ~~primarily attributed~~drive to by our strategic focus on ~~continued~~value-add innovations, including ~~the~~high ~~relaunch of HiBall~~protein ~~Energy~~super-seeds, ~~and~~better-for-you ~~organic~~breakfast ~~growth~~products, ~~within~~better-for-you ~~our~~snacking, ~~branded~~and ~~hemp~~clean ~~food~~energy ~~business related to higher consumption~~drinks.

Gross profit, gross margin and adjusted gross margin⁽¹⁾ for our reporting segments

~~Our~~For ~~gross profit and gross margin for~~ the three ~~and nine~~ months ended ~~February~~August 2831, 2025 and ~~February~~August 2931, 2024, respectively, ~~was~~our gross profit and gross margin were as follows:

	For the three months ended												~~For the nine months ended~~
(in thousands of U.S. dollars)	~~February~~August 2831,			~~February~~August 2931,			Change			% Change			~~February 28,~~			~~February 29,~~			~~Change~~			~~% Change~~
Beverage	2025			2024			2025 vs. 2024						~~2025~~			~~2024~~			~~2025 vs. 2024~~
Net revenue	$	55,~~921~~739		$	5455,~~688~~972		$	1,(233	)		2(0	)%	$	~~174,974~~		$	~~125,355~~		$	~~49,619~~			40	%
Cost of goods sold		3534,~~986~~413			3533,~~836~~050			~~150~~1,363			04	%		~~106,961~~			~~77,615~~			~~29,346~~			38	%
Gross profit		1921,~~935~~326			1822,~~852~~922			(1,~~083~~596	)		6(7	)%		~~68,013~~			~~47,740~~			~~20,273~~			42	%
Gross margin		3638	%		3441	%		2(3	)%		6(7	)%		39	%		38	%		1	%		3	%
Purchase price accounting step-up		59—			~~2,073~~175			(~~2,014~~175	)		(97100	)%		~~1,610~~			~~4,426~~			~~(2,816~~	)		~~(64~~	)%
Adjusted gross profit (1)		1921,~~994~~326			2023,~~925~~097			(~~931~~1,771	)		(48	)%		~~69,623~~			~~52,166~~			~~17,457~~			33	%
Adjusted gross margin (1)		3638	%		3841	%		(23	%)%		(57	%)%		40	%		42	%		(2	%)		(5	%)
Cannabis
Net revenue		5464,~~274~~511			6361,~~432~~249			(93,~~158~~262	)		~~(14~~5	)%		~~181,175~~			~~200,879~~			~~(19,704~~	)		~~(10~~	)%
Cost of goods sold		3241,~~275~~241			4237,~~518~~054			~~(10~~4,~~243~~187	)		~~(24~~11	)%		~~111,804~~			~~139,507~~			~~(27,703~~	)		~~(20~~	)%
Gross profit		2123,~~999~~270			2024,~~914~~195			~~1,085~~(925	)		5(4	)%		~~69,371~~			~~61,372~~			~~7,999~~			13	%
Gross margin		4136	%		3340	%		8(4	)%		24(10	)%		38	%		31	%		7	%		23	%
Purchase price accounting step-up		—			174			(174	)		(100	)%		—			7,628			(7,628	)		(100	)%
Distribution
Adjusted gross profit (1)		21,999			21,088			911			4	%		69,371			69,000			371			1	%
Net revenue		74,007			68,071			5,936			9	%
Adjusted gross margin (1)		41	%		33	%		8	%		24	%		38	%		34	%		4	%		12	%
Cost of goods sold		66,008			60,138			5,870			10	%
Distribution
Gross profit		7,999			7,933			66			1	%
Net revenue		61,493			56,794			4,699			8	%		197,175			193,174			4,001			2	%
Gross margin		11	%		12	%		(1	)%		(8	)%
Cost of goods sold		55,936			51,231			4,705			9	%		175,281			172,846			2,435			1	%
Wellness
Gross profit		5,557			5,563			(6	)		(0	)%		21,894			20,328			1,566			8	%
Net revenue		15,244			14,752			492			3	%
Gross margin		9	%		10	%		(1	)%		(10	)%		11	%		11	%		0	%		0	%
Cost of goods sold		10,370			10,096			274			3	%
Wellness
Gross profit		4,874			4,656			218			5	%
Net revenue		14,092			13,426			666			5	%		43,450			39,652			3,798			10	%
Gross margin		32	%		32	%		0	%		0	%
Cost of goods sold		9,572			9,359			213			2	%		29,791			28,091			1,700			6	%
Total
Gross profit		4,520			4,067			453			11	%		13,659			11,561			2,098			18	%
Net revenue		209,501			200,044			9,457			5	%
Gross margin		32	%		30	%		2	%		7	%		31	%		29	%		2	%		7	%
Cost of goods sold		152,032			140,338			11,694			8	%
Total
Gross profit		57,469			59,706			(2,237	)		(4	)%
Net revenue		185,780			188,340			(2,560	)		(1	)%		596,774			559,060			37,714			7	%
Gross margin		27	%		30	%		(3	)%		(10	)%
Cost of goods sold		133,769			138,944			(5,175	)		(4	)%		423,837			418,059			5,778			1	%
Purchase price accounting step-up		—			175			(175	)		(100	)%
Gross profit		52,011			49,396			2,615			5	%		172,937			141,001			31,936			23	%
Adjusted gross profit (1)		57,469			59,881			(2,412	)		(4	)%
Gross margin		28	%		26	%		2	%		8	%		29	%		25	%		4	%		16	%
Adjusted gross margin (1)		27	%		30	%		(3	)%		(10	)%
Purchase price accounting step-up		59			2,247			(2,188	)		(97	)%		1,610			12,054			(10,444	)		(87	)%
Adjusted gross profit (1)		52,070			51,643			427			1	%		174,547			153,055			21,492			14	%
Adjusted gross margin (1)		28	%		27	%		1	%		4	%		29	%		27	%		2	%		7	%

(1)

Adjusted gross profit is our Gross profit (adjusted to exclude purchase price accounting valuation step-up) and adjusted gross margin is our Gross margin (adjusted to exclude purchase price accounting valuation step-up) and are non-GAAP financial measures. See “Use of Non-GAAP Measures” above for additional discussion regarding these non-GAAP measures. The Company’s management believes that adjusted gross profit and adjusted gross margin are useful to our management to evaluate our business and operations, measure our performance, identify trends affecting our business, project our future performance, and make strategic decisions. We do not consider adjusted gross profit and adjusted gross margin in isolation or as an alternative to financial measures determined in accordance with GAAP.

Beverage gross margin: ~~Gross margin of~~ ~~36% and 39%~~For ~~for~~ the three ~~and nine~~ months ended ~~February~~August 2831, 2025, ~~increased~~our ~~from 34% and 38%~~beverage ~~in the prior~~segment ~~year~~generated ~~period. Adjusted~~ gross margin ~~of 36%~~ and ~~40%~~ ~~for~~adjusted ~~the~~gross ~~three and nine months ended February 28, 2025 decreased~~margin ~~from~~of 38%, which ~~and~~decreased from 4241% generated in the prior year period. The change in the beverage gross margin and adjusted beverage gross margin ~~during~~for the three ~~and nine~~ months ended ~~February~~August 2831, 2025 was driven by several factors., ~~Our~~including ~~continued integration efforts of~~ our Craft Acquisition II, ~~increased~~which ~~utilization~~historically ofhas ~~our~~operated ~~facilities~~at ~~and~~a ~~improvements~~lower ingross ~~our product~~margin ~~mix~~ as ~~part~~well ofas ~~our~~timing ~~strategic~~delays ~~initiatives~~in ~~under~~realizing ~~Project~~the ~~420~~full ~~have~~benefits ~~had~~of ~~favorable impacts on~~ our ~~adjusted~~Project ~~gross~~420 ~~margin.~~cost ~~However,~~savings ~~these improvements were partially offset by the impacts from the Craft Acquisition II, which has lower margins than our historical business~~initiatives.

Cannabis gross margin: ~~Gross~~For ~~margin increased during~~ the three ~~and nine~~ months ended ~~February~~August 2831, 2025, toour ~~41% and 38%~~cannabis ~~from 33%~~segment ~~and 31%~~generated ~~in the prior year period. Excluding the impact of the non-cash fair value purchase price accounting step-up, adjusted~~ gross margin ~~during~~ ~~the three and nine months ended February 28~~of 36%, ~~2025~~which ~~increased~~decreased ~~to 41% and 38%~~ from 33 40% ~~and 34%~~generated in the prior year period. The ~~improvement~~ decrease in gross margin ~~and adjusted gross margin~~ for the three ~~and nine~~ months ended ~~February~~August 2831, 2025 was driven by our increased ~~international~~participation ~~cannabis~~in ~~revenue~~lower ~~as a proportion of total cannabis revenue given its higher~~ margin, ~~as well as a continued focus on maintaining a higher average selling price and favorable~~ product ~~mix~~categories ~~to improve gross margins~~ in ~~Canada despite lower sales in~~ the Canadian adult-use ~~market.~~cannabis ~~Additionally~~market, as ~~the~~we ~~prior~~lower ~~year~~our ~~period~~cost ~~also~~structure ~~included~~to ~~$1.5~~eliminate ~~million~~negative ~~of HEXO advisory services revenue, which did not recur in the current year period~~margins.

Distribution gross margin: ~~Gross~~For ~~margin decreased~~the ~~to 9% and~~three ~~remained~~months ~~consistent~~ended ~~at 11%~~August ~~for~~31, ~~the~~2025, ~~three~~our ~~and~~distribution ~~nine~~segment ~~months~~generated ~~ended~~gross ~~February~~margin 28of 11%, ~~2025~~which decreased from 1012% ~~and 11%~~generated ~~for~~ in the prior year period, which was attributed to ~~shortages~~a change in ~~key pharmaceutical~~ product ~~lines as well as price reductions~~mix.

Wellness gross margin: ~~Gross~~For ~~margin increased to 32% and 31% for~~ the three ~~and nine~~ months ended ~~February~~August 2831, 2025 ~~from 30% and 29% from the prior year period~~, ~~which~~ ~~was~~our awellness ~~result~~segment ofgenerated ~~strong~~gross ~~operational~~margin ~~efficiencies~~of 32%, ~~lower~~which ~~input~~was ~~costs~~consistent ~~and the~~with ~~culmination of a change in sales mix towards~~the ~~higher~~prior ~~margin~~year ~~product offerings including HiBall energy drinks~~period.

Operating expenses

	For the three months ended											For the nine months ended
	February 28,		February 29,			Change			% Change			February 28,		February 29,			Change			% Change
(in thousands of US dollars)	2025		2024			2025 vs. 2024						2025		2024			2025 vs. 2024
General and administrative	$	39,246	$	39,940		$	(694	)		(2	)%	$	129,356	$	123,769		$	5,587			5	%
Selling		13,905		9,995			3,910			39	%		41,757		24,437			17,320			71	%
Amortization		23,182		21,558			1,624			8	%		67,913		65,700			2,213			3	%
Marketing and promotion		6,793		11,191			(4,398	)		(39	)%		28,079		28,934			(855	)		(3	)%
Research and development		85		106			(21	)		(20	)%		250		241			9			4	%
Change in fair value of contingent consideration		—		(5,983	)		5,983			(100	)%		—		(16,790	)		16,790			(100	)%
Impairments		699,235		—			699,235			NM			699,235		—			699,235			NM
Other than temporary change in fair value of convertible notes receivable		20,000		42,681			(22,681	)		(53	)%		20,000		42,681			(22,681	)		(53	)%
Litigation costs, net of recoveries		2,758		3,363			(605	)		(18	)%		5,254		8,439			(3,185	)		(38	)%
Restructuring costs		6,133		5,178			955			18	%		17,249		8,748			8,501			97	%
Transaction costs (income), net		605		3,465			(2,860	)		(83	)%		2,563		13,061			(10,498	)		(80	)%
Total operating expenses	$	811,942	$	131,494		$	680,448			517	%	$	1,011,656	$	299,220		$	712,436			238	%

During the three months ended August 31, 2025 and August 31, 2024, respectively, the changes in operating expenses were as follows:

Operating expenses are comprised of general and administrative, selling, amortization, marketing and promotion, research and development, change in fair value of contingent consideration, impairments, other than temporary change in fair value of convertible notes receivable, litigation costs, net of recoveries, restructuring costs and transaction costs (income), net. These costs increased by $680.4 million and $712.4 million to $811.9 million and $1,011.7 million for the three and nine months ended February 28, 2025 compared to $131.5 million and $299.2 million for the prior year period. This nine months increase was primarily a result of the non-cash impairments recorded in the period described in detail below. Additionally, of the $680.4 million and $712.4 million increase recognized during the three and nine months ended February 28, 2025, $1.0 million and $19.8 million was attributed to the inclusion of expenses from our recent Craft Acquisition II, effective September 1, 2024, and the prior year period did not reflect a full period of results from the initial Craft Acquisition, completed on September 29, 2023. These changes period over period are described below.

	For the three months ended
	August 31,			August 31,		Change			% Change
(in thousands of US dollars)	2025			2024		2025 vs. 2024
General and administrative	$	41,053		$	44,113	$	(3,060	)		(7	)%
Selling		12,923			11,690		1,233			11	%
Amortization		3,929			21,804		(17,875	)		(82	)%
Marketing and promotion		10,155			11,566		(1,411	)		(12	)%
Research and development		41			105		(64	)		(61	)%
Change in fair value of contingent consideration		(15,000	)		—		(15,000	)		NM
Litigation costs, net of recoveries		1,007			1,595		(588	)		(37	)%
Restructuring costs		869			4,247		(3,378	)		(80	)%
Transaction costs (income), net		400			1,156		(756	)		(65	)%
Total operating expenses	$	55,377		$	96,276	$	(40,899	)		(42	)%

Operating expenses are comprised of general and administrative, selling, amortization, marketing and promotion, research and development, change in fair value of contingent consideration, litigation costs, net of recoveries, restructuring costs and transaction costs (income), net. For the three months ended August 31, 2025, operating expenses decreased by $40.9 million to $55.4 million when compared to $96.3 million for the prior year period. This decrease was primarily attributed to the lower amortization expense in the current period, which resulted from the intangible asset reduction recorded during the fiscal quarter ended May 31, 2025, as well as, a gain from the change in fair value of the Montauk contingent consideration, and, to a lesser extent, a reduction in non-recurring litigation, restructuring and transaction cost charges as well as general and administrative costs.

General and administrative costs

During the three ~~and nine~~ months ended ~~February~~August 2831, 2025 and August 31, 2024, respectively, the changes in general and administrative costs when compared to the prior year period ~~are~~were as follows:

	For the three months ended												~~For the nine months ended~~
	February 28,			February 29,			Change			% Change			February 28,			February 29,		Change			% Change
	August 31,			August 31,			Change			% Change
(in thousands of US dollars)	2025			2024			2025 vs. 2024						~~2025~~			~~2024~~		~~2025 vs. 2024~~
Salaries and wages	$	21,~~908~~736		$	21,~~173~~567		$	~~735~~169			31	%	$	~~66,201~~		$	~~57,067~~	$	~~9,134~~			16	%
Office and general		78,~~385~~697			49,~~190~~260			~~3,195~~(563	)		76(6	)%		~~26,103~~			~~20,423~~		~~5,680~~			28	%
Stock-based compensation		45,~~035~~052			86,~~059~~917			(41,~~024~~865	)		(5027	)%		~~18,189~~			~~24,517~~		~~(6,328~~	)		~~(26~~	)%
Insurance		2,~~942~~393			32,~~569~~455			(~~627~~62	)		(183	)%		~~8,552~~			~~9,917~~		~~(1,365~~	)		~~(14~~	)%
Professional fees		1,~~352~~218			~~656~~1,178			~~696~~40			~~106~~3	%		~~3,656~~			~~4,658~~		~~(1,002~~	)		~~(22~~	)%
(Gain) loss on sale of capital assets		(202	)		23			(225	)		(978	)%		(733	)		3		(736	)		(24,533	)%
Gain on sale of capital assets		(241	)		(26	)		(215	)		827	%
Travel and accommodation		1,~~100~~312			1,~~246~~493			(~~146~~181	)		(12	)%		~~4,347~~			~~3,727~~		~~620~~			17	%
Rent		~~726~~886			1,~~024~~269			(~~298~~383	)		(2930	)%		~~3,041~~			~~3,457~~		~~(416~~	)		~~(12~~	)%
Total general and administrative costs	$	3941,~~246~~053		$	3944,~~940~~113		$	(~~694~~3,060	)		(27	)%	$	~~129,356~~		$	~~123,769~~	$	~~5,587~~			5	%

Salaries and wages increased by 31% ~~and 16%~~ during the three ~~and nine~~ months ended ~~February~~August 2831, 2025 when compared to the prior year period. The increase during the three ~~and nine~~ months ended ~~February~~August 2831, 2025 was primarily due to to the inclusion of of employees from our ~~recent~~ Craft Acquisition II, which was effective as of September 1, 2024, and ~~the~~therefore, ~~prior~~its ~~year~~salaries ~~period~~and ~~did~~wages were not ~~reflect~~included ain ~~full~~the ~~period~~prior ofyear ~~results~~quarter. ~~from~~In addition, the ~~initial~~current ~~Craft~~period ~~Acquisition,~~included ~~completed~~$1.3 onmillion ~~September~~of ~~29,~~retention ~~2023.~~payments compared ~~Additionally,~~to ~~included~~$0.2 in million the ~~nine months~~prior ~~period~~year fiscal quarter ended ~~February~~ 28August 31, ~~2025~~2024, ~~there~~which was ~~$3.2~~ ~~million~~offset ofby ~~retention~~our ~~payments~~ongoing ~~that~~cost ~~did~~saving ~~not occur in the prior year period~~initiatives.

Office and general ~~increased~~decreased by 766% ~~and 28%~~ during the three ~~and nine~~ months ended ~~February~~August 2831, 2025. ~~The~~when ~~increase~~compared ~~was primarily due~~ to the ~~inclusion of bad debt recoveries of $4.4 million in the~~ prior year period ended February 29, 2024, that did not recur and expenses from our recent Craft Acquisition II, effective September 1, 2024, and the prior year period did not reflect a full period of results from the initial Craft Acquisition, completed on September 29, 2023. ~~These~~The ~~impacts~~decrease ~~were~~was ~~partially~~driven ~~offset~~ by our ~~continued~~ongoing cost saving initiatives.

The Company recognized stock-based compensation expense of $45.01 million ~~and~~ ~~$18.2 million~~ for the three ~~and nine~~ months ended ~~February~~August 2831, 2025 compared to $86.19 million ~~and $24.5 million~~ for the prior year period. Stock-based compensation expense is based on the time-based vesting schedules and varies according to the assumptions used in the vesting model. During the three ~~and nine~~ months ended ~~February~~August 2831, 2025, stock-based ascompensation adecreased ~~result~~ due to the vesting of previously issued stock options, restricted stock units (“RSUs”) and stock appreciation rights (“SARs”) under Tilray 2018 Equity Incentive Plan and Original Plan~~, as described in the Annual Report on Form 10-K for the fiscal year ended May 31, 2024, that have fully vested, stock-based compensation decreased period over period~~. ~~Additionally, the decrease for the three months ended February 28, 2025 was driven by the cancellation of certain performance-based RSUs.~~

Insurance expense decreased by 183% ~~and decreased by 14%~~ for the three ~~and nine~~ months ended ~~February~~August 2831, 2025 to $2.94 million ~~and $8.6 million~~ from $32.65 million ~~and~~ ~~$9.9 million~~ for the prior year period~~. The~~ ~~change~~due ~~for the three and nine months ended February 28, 2025~~to ~~was driven by~~ lower premiums~~, offset by the additional polices required for our newly acquired beverage business portfolio for both the Craft Acquisition and Craft Acquisition II~~. ~~For the~~ three and nine months ended February 28, 2025, as a percentage of revenue insurance was 2% and 1% compared to 2% and 2% in the prior year period, demonstrating our ability to manage our policy costs despite growing the business.

Rent expense decreased by 2930% ~~and 12%~~ for the three ~~and nine~~ months ended ~~February~~August 2831, 2025 to $0.79 million ~~and $3.0 million~~compared ~~from~~to $1.~~0 million and $~~3.5 million for the prior year period, driven by ongoing cost saving initiatives. Rent expense is predominantly comprised of operating lease ~~costs~~expenses for our brew pubs and office spaces. The decrease was driven by the exit from the Truss lease in the current year and a reduction in lease payments, which was previously included in the prior period results, offset by the inclusion of expenses from our recent Craft Acquisition II, effective September 1, 2024, and the prior year period did not reflect a full period of results from the initial Craft Acquisition, completed on September 29, 2023.

Selling costs

For the three ~~and nine~~ months ended ~~February~~August 2831, 2025, the Company incurred selling costs of $1312.9 million ~~and~~ ~~$41.8 million~~ or 76.52% ~~and 7.0%~~ of net revenue as compared to $1011.07 million ~~and $24.4 million~~ or 5.38% ~~and 4.4%~~ of net revenue in the prior year period. These costs relate to third-party shipping costs for all segments, in addition to distributor commission incurred by the cannabis segment, Health Canada cannabis fees, and patient acquisition and maintenance costs. The increase for the three ~~and nine~~ months ended ~~February~~August 2831, 2025, is predominately due to ~~the~~ higher freight costs ~~experienced~~incurred in the beverage segment~~. Additionally,~~ ~~during~~as ~~the~~they ~~three~~continue ~~and~~to ~~nine~~integrate ~~months~~operations ~~period ended~~and ~~February 29, 2024,~~ the ~~Company~~higher ~~received~~proportion ~~a refund~~ of ~~$2.1~~ ~~million~~medical ~~and $3.3~~cannabis ~~million~~sales onwithin ~~cannabis~~Germany ~~selling fees related to an amended fee calculation and a commission refund~~ that ~~did~~have ~~not~~higher ~~recur~~distribution ~~in the current period~~costs.

Amortization

The Company incurred non-production related amortization charges of $233.29 million ~~and $67.9 million~~ for the three ~~and nine~~ months ended ~~February~~August 2831, 2025, compared to $21.68 million ~~and~~ ~~$65.7 million~~ in the prior year period based on depreciable capital and intangible assets useful lives. The decrease in the amortization expense is due to the lower carrying value of intangible assets as a result of the impairment charges recognized during the fiscal year ended May 31, 2025.

Marketing and promotion costs

For the three ~~and nine~~ months ended ~~February~~August 2831, 2025, the Company incurred marketing and promotion costs of $610.82 million ~~and~~ ~~$28.1 million~~ as compared to $11.26 million ~~and $28.9 million~~ for the prior year period. The ~~current~~decrease ~~period change~~ was ~~primarily~~driven ~~due~~by toless ~~the~~expense ~~inclusion of~~relating ~~expenses~~to ~~from~~discretionary ~~our~~marketing ~~recent~~in ~~Craft~~the ~~Acquisition~~quarter ~~II,~~when ~~effective~~compared ~~September~~to ~~1, 2024, and that~~ the prior year period ~~did not reflect a full period of results from the initial Craft Acquisition, completed on September 29, 2023, offset by the quarterly variability in discretionary marketing expenses~~.

Research and development

Research and development costs were $0.~~1 million and $~~0.3 million during the three ~~and nine~~ months ended ~~February~~August 2831, 2025, compared to $0.1 million ~~and~~ ~~$0.2 million~~ in the prior year period. These relate to external costs associated with the development of new products.

Change in fair value of contingent consideration

The Company measures contingent consideration at fair value classified as Level 3, as discussed in Note 2524 (~~Fair~~Financial ~~value~~risk ~~measurements~~management and financial instruments). During the three ~~and nine~~ months ended ~~February~~August 2831, 2025, the Company recognized $~~nil~~15.0 ~~and~~million ~~$nil~~of change in the fair value of contingent consideration as ~~there were no changes to~~ the likelihood of achievement ~~for~~decreased ~~Montauk Brewing compared~~ to ~~a gain of $6.~~0% ~~million and a gain~~ of ~~$16.8~~such ~~million in the prior period from the conclusion of the Sweetwater obligation, the favorable cash settlement for the Truss~~ contingent consideration~~, and was offset by an increase~~ related to the ~~increased probability of achieving the contingent consideration from the~~ Montauk Brewing acquisition.

Impairments

Based upon a combination of factors including a sustained decline in the Company’s market capitalization stemming from the uncertainty resulting from certain changes in U.S. global economic policy, including slower than anticipated progress in global cannabis legalization and overall declines in the craft beer industry sector, the Company concluded that it is more likely than not, that the fair value of our reporting units were less than their carrying amounts as of February 28, 2025. Accordingly, the Company utilized the income approach, which uses future discounted cash flows, to determine the fair value of each reporting unit. As a result, the Company recorded non-cash impairment charges of $570.0 million of cannabis goodwill, $100.0 million of beverage goodwill, $25.0 million of wellness goodwill and $4.2 million of distribution goodwill for the three and nine months ended February 28, 2025. The non-cash impairment charge had no impact on the Company’s compliance with debt covenants, its cash flows or available liquidity.

In the Company's cannabis goodwill assessment, the Company used a discount rate of 12.00%, a terminal growth rate of 5%, and an average revenue growth rate of 34% over 5 years, based on an 88% and 40% average probability of anticipated EU and U.S. cannabis legalization, respectively and/or changes in drug policy in various countries within the next 5 years. A 1% increase in the discount rate would result in an additional $285.0 million in impairment, a 1% decrease in the terminal growth rate would result in an additional $210.0 million in impairment, a 5% decrease in the average growth rate would result in an additional $170.0 million in impairment, a 5% decrease in the probability of EU cannabis legalization would result in an additional $80.0 million in impairment and a 5% decrease in the probability of US cannabis legalization would result in an additional $7.0 million in impairment. Changes to those probabilities resulting in continued delays in or cessation of legalization of cannabis within the United States and internationally, or adverse regulatory changes to existing legislation, could have an unfavorable impact on the estimated future cash flows, and ultimately, the fair value of the cannabis reporting unit, which may result in a material impairment expense recognized in future reporting periods.

In the Company's beverage goodwill assessment, the Company used a discount rate of 9.25%, a terminal growth rate of 2%, and an average revenue growth rate of 12% over 5 years. A 1% increase in the discount rate would result in an additional $70.0 million in impairment, a 1% decrease in the terminal growth rate would result in an additional $50.0 million in impairment and a 1% decrease in the average growth rate would result in an additional $40.0 million in impairment.

In the Company's wellness goodwill assessment, the Company used a discount rate of 10.50%, a terminal growth rate of 2%, and an average revenue growth rate of 7% over 5 years. A 1% increase in the discount rate would result in an additional $5.0 million in impairment, a 1% decrease in the terminal growth rate would result in an additional $3.0 million in impairment and a 1% decrease in the average growth rate would result in an additional $2.0 million in impairment.

In the Company's distribution goodwill assessment, the Company recorded $4.2 million of impairments which brought the remaining distribution goodwill balance to $nil.

Other than temporary write-down of convertible notes receivable

During the three and nine months ended February 28, 2025, the Company recognized an other-than-temporary change in fair value, which resulted in a non-cash expense of $20.0 million and $20.0 million compared to $42.7 million and $42.7 million for the prior year period. The MedMen Convertible Note was valued based upon the estimated fair value of the collateral assets net of estimated disposal costs and has been reduced to reflect recent developments in restructuring efforts. See Note 8, (Convertible notes receivable) for additional transactions related to the MedMen Convertible Note which occurred during the period ended February 28, 2025.

Litigation costs, net of recoveries

For the three ~~and nine~~ months ended ~~February~~August 2831, 2025, the Company recorded $21.80 million ~~and~~ ~~$5.3 million~~ of litigation settlements costs and third-party fees incurred in defending these claims, net of favorable recoveries compared to $31.46 million ~~and $8.4 million~~ in the prior year period. The decrease is related to period-to-period variability as litigation and settlement costs are non-recurring in nature.

Restructuring costs

In connection with the ~~execution~~integration of ~~our~~certain ~~acquisition~~acquisitions ~~strategy~~ and strategic transactions, the Company has incurred ~~non-recurring~~ restructuring and exit costs ~~associated~~in ~~with~~ the ~~integration~~amount ~~efforts~~ of ~~these transactions~~ $0.9 million for ~~In connection with these efforts, during~~ the three ~~and nine~~ months ended ~~February~~August 2831, 2025, ~~the Company incurred $6.1 million and $17.2 million of restructuring charges~~ compared to $54.2 ~~million and~~ ~~$8.7~~ million for the prior year period. All restructuring plans are approved at the executive level, and their associated expenses are recognized in the period in which the plan is committed. ~~All~~or ~~amounts~~otherwise incurred ~~as of February 28, 2025 have been paid~~.

Within the Cannabis segment, ~~our restructuring costs predominantly related to~~ ~~the~~during ~~HEXO acquisition, which are expected to be completed within 24 months from~~ the ~~original~~three ~~acquisition, which occurred June 2023. In the nine~~ months ended ~~February~~August 2831, 2025, we the Company recognized $70.9 7 million of expenses related to employee termination severance and benefits and other costs related to the conversion of the HEXO Quebec cultivation facility from cannabis to produce (which is currently held for sale), the optimization of our Redecan facilities, and $0.8 million of restructuring charges related to the remaining costs of exiting the Truss facility following its sale to a third party in the fiscal year ended May 31, 2024. Additionally, the Company recognized $1.1 million of cost associated with the ~~winding~~reorganization ~~down~~ of ~~our Avanti facility,~~ the ~~closure~~Canadian ofcannabis ~~which~~commercial ~~was announced during the quarter ended November 30, 2024~~function. ~~Lastly~~Additionally, the Company recognized $0.32 million of restructuring charges related to our decision to exit ~~from~~ the New Zealand medical cannabis market announced during the ~~quarter~~fiscal year ended ~~February~~May 2831, 2025.

~~Within~~During the ~~Beverage segment,~~fiscal ~~the~~year ~~Company~~ended ~~recognized $1.0 million of~~May ~~expenses~~31, ~~related~~2025, tothe ~~employee~~Company ~~termination~~accrued ~~severance and benefits and~~ $2.8.5 million of ~~costs associated with the consolidation~~restructuring ofcharges ~~production~~related ~~sites through~~to the ~~integration~~closure of ~~the~~Hop ~~Craft~~Valley ~~Acquisition~~ and ~~the~~other ~~Craft~~Project ~~Acquisition~~420 initiatives ~~II.~~within ~~Additionally,~~ the ~~Company~~Beverage ~~recognized~~segment, ~~$0.8 million~~ of ~~restructuring~~which ~~charges related to terminating a legacy storage agreement from the Craft Acquisition~~$1.2 Wemillion ~~expect~~was torecognized ~~transition to a new storage facility~~ in the ~~fourth~~three ~~quarter~~months ofended ~~fiscal~~August ~~year ending May~~ 31, 2025 thereby, ~~consistent~~reducing ~~with~~the ~~our announced~~accrual ~~cost~~to ~~savings~~$7.3 ~~initiatives~~million.

Within the Distribution segment, the Company recognized $0.4 million of restructuring charges related to the divestiture of its retail pharmacy location in Argentina.

Lastly, for the nine months ended February 28, 2025, the Company recognized $2.1 million of costs associated with the investment held in Superhero Acquisition Corp. as a result of MedMen’s ongoing restructuring and liquidation undertakings.

Transaction (income) costs, net

Transaction (income) costs, net, ~~includes~~include non-recurring acquisition related income and expenses, related legal, financial advisor and due diligence cost and expenses and transaction related compensation. ~~The~~For the three ~~and nine~~ months ended ~~February~~August 2831, 2025 ~~decrease~~, oftransaction ~~83%~~(income) costs, decreased by ~~and 80~~65% from the prior year ~~period~~fiscal ~~was~~quarter adue ~~result~~to ofthe ~~HEXO,~~fact ~~Truss~~that ~~and~~we ~~the~~incurred ~~Craft~~more ~~Acquisition taking~~expense ~~place~~ in the ~~previous~~prior year ~~which~~period ~~did not recur. The expenses incurred~~ in ~~the~~connection ~~current~~with ~~period largely related to~~ the Craft Acquisition ~~II, for~~ ~~the four craft beer brands and breweries from Molson, which was effective September 1, 2024~~II.

Non-operating (expense) income, net

~~Non~~During the three months ended August 31, 2025 and August 31, 2024, respectively, the changes in non-operating (expense), net income ~~was~~ were comprised of:

	For the three months ended												~~For the nine months ended~~
	February 28,			February 29,			Change			% Change			February 28,			February 29,			Change			% Change
	August 31,			August 31,			Change			% Change
(in thousands of US dollars)	2025			2024			2025 vs. 2024						~~2025~~			~~2024~~			~~2025 vs. 2024~~
Change in fair value of convertible debenture payable	$	—		$	(6,311	)	$	6,311			(100	)%	$	—		$	(12,352	)	$	12,352			(100	)%
Change in fair value of warrant liability		(3,670	)		696			(4,366	)		(627	)%
Change in fair value of warrant liability		1,338			586			752			128	%		2,896			(1,365	)		4,261			(312	)%
Foreign exchange gain (loss)		6,928			11,881			(4,953	)		(42	)%
Foreign exchange gain (loss)		(22,290	)		(3,302	)		(18,988	)		575	%		(44,206	)		1,941			(46,147	)		(2,377	)%
Loss on long-term investments		39			(39	)		78			(200	)%
Loss on long-term investments		(5,474	)		33			(5,507	)		(16,688	)%		(5,540	)		383			(5,923	)		(1,546	)%
Unrealized loss on digital assets		(8	)		—			(8	)		NM
Other non-operating (losses) gains, net		~~2,404~~543			~~(8,245~~108	)		~~10,649~~435			~~(129~~403	)%		~~2,219~~			~~(9,427~~	)		~~11,646~~			~~(124~~	)%
Total non-operating income (expense)	$	~~(24~~3,~~022~~832	)	$	~~(17~~12,~~239~~646	)	$	(68,~~783~~814	)		39(70	)%	$	~~(44,631~~	)	$	~~(20,820~~	)	$	~~(23,811~~	)		~~114~~	%

For the three ~~and nine~~ months ended ~~February~~August 2831, 2025, the Company recognized a ~~change~~loss inon ~~fair value of its convertible debentures payable of $0.0 million and $0.0 million compared to ($6.3) million and ($12.4) million in~~ the ~~prior year period. The~~ change ~~was~~ ~~driven primarily by the exchange of APHA 24 convertible debenture prior to and upon maturity. Additionally, for the three and nine months ended February 28, 2025, the Company recognized a change~~ in fair value of its warrants, ~~resulting in a gain~~ of ~~$1.3 million~~ ~~and~~ $23.97 million, compared to a gain of $0.67 million ~~and~~in athe ~~loss~~prior ~~of ($1.4) million~~year period as a result of the change in our share price and the exercise price of the ~~instrument~~warrants. For the three ~~and nine~~ months ended ~~February~~August 2831, 2025, the Company recognized a ~~loss~~ gain of ($226.3)9 million ~~and ($44.2) million~~ resulting from the changes in foreign exchange rates during the period compared to a ~~loss~~gain of ($311.3)9 million ~~and a gain of~~ ~~$1.9 million~~ for the prior year period. For the three ~~and nine~~ months ended ~~February~~August 2831, 2025, the Company recognized a ~~loss~~gain of $0.04 million on long-term investments, compared ~~resulting~~to a loss of ~~($5.5) million and~~ ($50.5) 04 million asfor athe ~~result~~prior ofyear aperiod. ~~change~~For inthe three ~~fair~~months ~~value~~ended ofAugust ~~certain~~31, ~~long-term~~2025, ~~investments compared~~the toCompany recognized a ~~gain~~loss of $0.001 million ~~and~~on adigital ~~gain~~assets from the unrealized change in fair value of Bitcoin compared to $~~0.4~~ nil million for the prior year period. The other non-operating (losses) gains, net were ~~$2.4 million~~gains ~~and~~ of $20.25 million for the three ~~and nine~~ months ended ~~February~~August 2831, 2025, compared to ~~loss~~a gain of ($80.2) 1 million ~~and ($9.4) million,~~ for the prior year period, and was mainly comprised of a the gain of $20.45 million resulting from the exchange transaction of the TLRY 27 ~~Notes~~ Note, ~~see~~as described in Note 17 12 (Convertible debentures payable).

Reconciliation of Non-GAAP Financial Measures to GAAP Measures

Adjusted EBITDA

Adjusted EBITDA is a non-GAAP financial measure that does not have any standardized meaning prescribed by GAAP and may not be comparable to similar measures presented by other companies. The Company calculates adjusted EBITDA as net loss/net income before income taxes, net interest expense, depreciation and amortization, ~~equity in net loss of equity-method investees,~~ purchase price accounting step-up on inventory, stock-based compensation, impairments, other than temporary change in fair value of convertible notes receivable, restructuring costs, transaction (income) costs net, litigation costs net of recoveries, change in fair value of contingent consideration, project 420 cost savings initiatives, unrealized currency gains and losses and other adjustments.

We believe that this presentation provides useful information to management, analysts and investors regarding certain additional financial and business trends relating to ~~its~~the Company’s results of operations and financial condition. In addition, management uses this measure for reviewing the financial results of the Company and as a component of performance-based executive compensation.

We do not consider adjusted EBITDA in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of adjusted EBITDA is that it excludes certain expenses and income that are required by U.S. GAAP to be recorded in our consolidated financial statements. In addition, adjusted EBITDA is subject to inherent limitations as this metric reflects the exercise of judgment by management about which expenses and income are excluded or included in determining adjusted EBITDA. In order to compensate for these limitations, management presents adjusted EBITDA in connection with GAAP results.

For three ~~and nine~~ months ended ~~February~~August 2831, 2025, adjusted EBITDA ~~decreased~~increased to $910.02 million ~~and~~ ~~$27.4 million~~ compared to $109.23 million ~~and~~ ~~$31.0 million~~ for the prior year period as wea ~~continue~~result toof ~~integrate~~ our ~~recent~~organic ~~craft~~growth ~~beverage~~combined ~~acquisitions~~with ongoing cost savings initiatives.

	For the three months ended												~~For the nine months ended~~
	February 28,			February 29,			Change			% Change			February 28,			February 29,			Change			% Change
	August 31,			August 31,			Change			% Change
Adjusted EBITDA reconciliation:	2025			2024			2025 vs. 2024						~~2025~~			~~2024~~			~~2025 vs. 2024~~
Net loss	$	(793,534	)	$	(104,983	)	$	(688,551	)		656	%	$	(913,461	)	$	(207,029	)	$	(706,432	)		341	%
Net income (loss)	$	1,513		$	(34,652	)	$	36,165			(104	)%
Income tax expense (recovery), net		1(2,~~203~~285	)		~~(2,871~~886	)		4(3,~~074~~171	)		(~~142~~358	)%		~~4,125~~			~~1,013~~			~~3,112~~			~~307~~	%
Interest expense, net		86,~~378~~696			89,~~517~~842			(~~139~~3,146	)		(232	)%		~~25,986~~			~~26,977~~			~~(991~~	)		(4	)%
Non-operating income (expense), net		24(3,~~022~~832	)		17(12,~~239~~646	)		68,~~783~~814			39(70	)%		~~44,631~~			~~20,820~~			~~23,811~~			~~114~~	%
Amortization		3315,~~546~~561			3231,~~842~~814			~~704~~(16,253	)		2(51	)%		~~99,410~~			~~95,183~~			~~4,227~~			4	%
Stock-based compensation		45,~~035~~052			86,~~059~~917			(41,~~024~~865	)		(5027	)%		~~18,189~~			~~24,517~~			~~(6,328~~	)		~~(26~~	)%
Change in fair value of contingent consideration		—(15,000	)		~~(5,983~~—	)		5(15,~~983~~000	)		~~(100~~NM	)%		—			~~(16,790~~	)		~~16,790~~			~~(100~~	)%
Impairments		~~699,235~~—			—			~~699,235~~—			NM			~~699,235~~			—			~~699,235~~			NM
Other than temporary change in fair value of convertible notes receivable		~~20,000~~—			~~42,681~~—			~~(22,681~~—	)		~~(53~~NM	)%		~~20,000~~			~~42,681~~			~~(22,681~~	)		~~(53~~	)%
Project 420 business optimization		~~2,600~~200			—			~~2,600~~200			NM			~~2,600~~			—			~~2,600~~			NM
Purchase price accounting step-up		59—			~~2,247~~175			(~~2,188~~175	)		(97100	)%		~~1,610~~			~~12,054~~			~~(10,444~~	)		~~(87~~	)%
Facility start-up and closure costs		—			~~400~~—			~~(400~~—	)		~~(100~~NM	)%		—			~~1,300~~			~~(1,300~~	)		~~(100~~	)%
Litigation costs, net of recoveries		21,~~758~~007			31,~~363~~595			(~~605~~588	)		(1837	)%		~~5,254~~			~~8,439~~			~~(3,185~~	)		~~(38~~	)%
Restructuring costs		~~6,133~~869			54,~~178~~247			~~955~~(3,378	)		18(80	)%		~~17,249~~			~~8,748~~			~~8,501~~			97	%
Transaction costs (income), net		~~605~~400			31,~~465~~156			(~~2,860~~756	)		(8365	)%		~~2,563~~			~~13,061~~			~~(10,498~~	)		~~(80~~	)%
Adjusted EBITDA	$	910,~~040~~181		$	109,~~154~~334		$	~~(1,114~~847	)		~~(11~~9	)%	$	~~27,391~~		$	~~30,974~~		$	~~(3,583~~	)		~~(12~~	)%

Adjusted EBITDA should not be considered in isolation from, or as a substitute for, net income (loss). There are a number of limitations related to the use of Adjusted EBITDA as compared to net income (loss), the closest comparable GAAP measure. Adjusted EBITDA adjusts for the following:

●

Non-cash amortization expenses and, although these are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future;

●

Stock-based compensation expenses, a non-cash expense and are an important part of our compensation strategy;

●

Non-cash impairment charges, as the charges are not expected to be a recurring business activity;

● Non-cash other than temporary write-down of convertible notes receivable, as the charges are not expected to be a recurring business activity;

●

Non-cash foreign exchange gains or losses, which accounts for the effect of both realized and unrealized foreign exchange transactions. Unrealized gains or losses represent foreign exchange revaluation of foreign denominated monetary assets and liabilities;

●

Non-cash change in fair value of warrant liability;

●

Non-cash change in fair value of contingent consideration;

●

Project 420 business optimization costs;

●

Interest expense, net;

●

Costs incurred to start up new facilities, and to fund emerging market operations;

●

Transaction (income) costs, net which includes acquisition related income and expenses, related legal, financial advisor and due diligence cost and expenses and transaction related compensation, which vary significantly by transaction and are excluded to evaluate ongoing operating results;

●

Restructuring charges;

● Litigation costs, net of favorable recoveries and the third party fees associated with defending these claims, ~~includes~~including costs related to legacy and non-operational litigation matters, legal settlements and recoveries;

●

Amortization of purchase accounting fair value step-up in inventory value included in costs of goods sold; and

●

Current and deferred income tax expenses and recoveries, which could be a significant recurring expense or recovery in our business in the future and reduce or increase cash available to us.

Adjusted Gross Profit and Adjusted Gross Margin

Adjusted gross profit and adjusted gross margin are non-GAAP financial measures and may not be comparable to similar measures presented by other companies. Adjusted gross profit is our Gross profit (adjusted to exclude PPA valuation step-up) and adjusted gross margin is our Gross margin (adjusted to exclude PPA valuation step-up) and are non-GAAP financial measures. The Company’s management believes that adjusted gross profit and adjusted gross margin are useful to our management to evaluate our business and operations, measure our performance, identify trends affecting our business, project our future performance, and make strategic decisions. We do not consider adjusted gross profit and adjusted gross margin percentage in isolation or as an alternative to financial measures determined in accordance with GAAP.

Liquidity and Capital Resources

We actively manage our cash and investments in order to internally fund operating needs, make scheduled interest and principal payments on our borrowings, and complete acquisitions. We believe that existing cash, cash equivalents, marketable securities and cash generated by operations, together with access to external sources of funds, will be sufficient to meet our domestic and foreign capital needs for the short and long term outlook.

For the Company's short-term liquidity requirements, we are focused on generating positive cash ~~flows~~flow from operations and being free cash flow positive. As Certain aof ~~result~~our ofbusiness ~~delays~~segments, insuch ~~legalization~~as ~~across~~cannabis, ~~multiple~~are ~~markets~~working capital intensive and have longer cash conversion cycles. In order to mitigate these effects, management continues to optimize our ~~operating structure~~infrastructure, headcount, as well as the elimination of other discretionary operational costs. Additionally, the Company continues to work on improvements to the cash conversion cycles across its businesses and invest our excess cash in ~~the~~ short-term in marketable securities, which are comprised of U.S. treasury bills and term deposits with major Canadian, European and Australian banks as well as in digital assets.

For the Company's long-term liquidity requirements, we are focused on funding operations through profitable organic growth and ~~inorganic growth~~ through acquisitions of businesses that are accretive to earnings and are less working capital intensive. We may need to take on additional debt or equity financing arrangements in order to achieve these ~~ambitions~~target goals on a long-term basis.

On May 17, 2024, the Company entered into an equity distribution agreement with TD Securities (USA) LLC and Jefferies LLC in connection with an aggregate offering value of up to $250 million from time to time through an at-the-market equity program (“ATM Program”). During the ~~nine~~three months ended ~~February~~August 2831, 2025, the Company issued 93 34,~~610~~443,~~801~~799 shares under the ATM Program generating gross proceeds of $~~143~~23.4 0 million. The Company paid $30.75 million in commissions and other fees associated with these issuances generating net proceeds of $~~139~~22.75 million. The Company intends to use the net proceeds from the ATM Program to fund strategic and accretive acquisitions or investments in businesses and capital expenditures for acquired businesses, including potential acquisitions of assets ~~in the U.S. and internationally in order~~ to capitalize on expected regulatory advancements or expansion opportunities. As of ~~February~~August 2831, 2025, $9651.6 million of gross proceeds remain available ~~through~~under the ATM program.

Additionally, we are committed to optimizing our capital structure and enhancing financial flexibility as we intend to continue to opportunistically purchase or exchange equity for the TLRY 27 Notes prior to their underlying maturity date in June 2027, subject to market conditions.

The following table sets forth the major components of our statements of cash flows for the periods presented:

For the three months ended

~~For the nine months ended~~

February 28,

February 29,

February 28,

February 29,

August 31,

2025

2024

~~2025~~

~~2024~~

Net cash provided by (used in) operating activities

(51,~~761~~341

)

(1535,~~361~~307

)

~~(81,792~~

)

~~(61,612~~

)

Net cash provided by (used in) investing activities

~~(119~~24,467

)

28(49,~~086~~395

)

~~(60,239~~

)

~~83,293~~

Net cash provided by financing activities

1819,~~071~~848

~~(10~~60,~~909~~590

)

~~116,864~~

~~(82,257~~

)

Effect on cash of foreign currency translation

~~(1,933~~188

)

~~(512~~958

)

~~(3,217~~

)

~~197~~

Cash and cash equivalents, beginning of period

~~189~~221,~~698~~666

~~144~~228,~~949~~340

~~228,340~~

~~206,632~~

Cash and cash equivalents, end of period

~~199~~264,~~956~~828

~~146~~205,~~253~~186

~~199,956~~

~~146,253~~

Marketable securities

~~48,458~~—

7974,~~605~~869

~~48,458~~

~~79,605~~

Cash and marketable securities(1)

~~248~~264,~~414~~828

~~225~~280,~~858~~055

~~248,414~~

~~225,858~~

(1)

Cash and marketable securities are non-GAAP financial measures. See “Use of Non-GAAP Measures” above for additional discussion regarding these non-GAAP measures. The Company combines the Cash and cash equivalent financial statement line item, and the Marketable securities financial statement line item as an aggregate total as reconciled in the liquidity and capital resource section below. The Company’s management believes that this presentation provides useful information to management, analysts and investors regarding certain additional financial and business trends relating to its short-term liquidity position by combing these three GAAP metrics.

Cash flows from operating activities

The change in net cash used in operating activities was ($51.83) million ~~and~~ ~~($81.8) million~~ for three ~~and nine~~ months ended ~~February~~August 2831, 2025, compared to ($1535.43) million ~~and~~ ~~($61.6) million~~ for the prior year period. ~~and~~The ~~was~~prior ayear ~~result~~period ofwas ~~additional~~impacted ~~working capital requirements as we continued to scale up our operations, including~~ by the integration Craft Acquisition I, IIwhich inrequired ~~September~~working ~~2024~~capital investments.

Cash flows from investing activities

The change in net cash provided by (used in ) investing activities was ($024.1)5 million ~~and~~ ~~($60.2) million~~ for three ~~and nine~~ months ended ~~February~~August 2831, 2025 , compared to ($2849.14) million ~~and $83.3 million~~ for the prior year period, and was a result of the ~~purchase~~sale of marketable securities in the current year compared to the ~~sale~~purchase of marketable securities in the prior ~~period, and the differences in cash paid for the Craft Acquisition II in the current~~ year ~~compared~~ ~~to HEXO, Truss and the Craft Acquisition in the prior~~ period.

Cash flows from financing activities

The change in cash provided by financing activities was $1819.18 million ~~and $116.9 million~~ for three ~~and nine~~ months ended ~~February~~August 2831, 2025 , compared to ($1060.9)6 million ~~and ($82.3) million~~ for the prior year period. Indue ~~the~~to ~~current~~variability in ~~period,~~funds ~~cash was~~ provided byunder ~~funds from~~ the ATM Program ~~that did not occur in the prior period~~. In the prior period ended February 29 2024, the Company received proceeds of $21.6 million for the overallotment issuance of the TLRY 27 Notes and proceeds from the delayed draw on the ABC credit facility, offset by the $107.3 million repayment of the TLRY 23 Notes and the APHA 24 Notes.

Subsequent Events

Refer to Part I, Financial Information, Note 27 Subsequent Events.

Contingencies

In addition to the litigation described in the Part II, Item 1 - Legal Proceedings, the Company is and may be a defendant in lawsuits from time to time in the normal course of business. While the results of litigation and claims cannot be predicted with certainty, the Company believes the reasonably possible losses of such matters, individually and in the aggregate, are not material. Additionally, the Company believes the probable final outcome of such matters will not have a material adverse effect on the Company’s consolidated results of operations, financial position, cash flows or liquidity.

Critical Accounting Estimates

Our financial statements are prepared in accordance with accounting principles generally accepted in the United States. The accounting principles we use require us to make estimates and assumptions that ~~affect~~may impact the reported amounts of assets and liabilities atas of the date of the financial statements and amounts of income and expenses during the reporting periods presented. We believe in the quality and reasonableness of our critical accounting policies, however, materially different amounts may be reported under different conditions or using assumptions different from those that we have applied. The accounting estimates that have been identified as critical to our business operations and to understanding the results of our operations pertain to revenue recognition, valuation of inventory, valuation of long-lived assets, goodwill and intangible assets, stock-based compensation and valuation allowances for deferred tax assets. The application of each of these critical accounting policies and estimates is discussed in Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, ofset forth in, our Annual Report on Form 10-K for the fiscal year ended May 31, ~~2024~~2025.

Recently Issued Accounting Pronouncements

A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in “Part I, Item 1. Note 1 – Basis of presentation and summary of significant accounting policies” to our financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

~~There~~During the three months ended August 31, 2025, there have been no material changes in market risk from those addressed in the Company’s Annual Report on Form 10-K for the fiscal year ended May 31, ~~2024 during the nine months ended February 28,~~ 2025. See the information set forth in Part II, Item 7A, Quantitative and Qualitative Disclosures About Market Risk, ofset forth in the Company’s Annual Report on Form 10-K for the fiscal year ended May 31, ~~2024~~2025.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, and summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. An evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report was made under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer.

Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of ~~February~~August 2831, 2025, our disclosure controls and procedures (a) are effective to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is timely recorded, processed, summarized and reported and (b) include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Consistent with guidance issued by the SEC, the scope of management’s assessment of the effectiveness of our disclosure controls and procedures did not include the internal controls over financial reporting of our recently acquired businesses from the Craft Acquisition II, which was effective on September 1, 2024. The acquired businesses represented 01.73% of our consolidated assets and 3.4.2% of our consolidated net revenues as of and for the ~~nine~~three months ended ~~February~~August 2831, 2025.

Changes in Internal Control over Financial Reporting

There have been no changes in our “internal control over financial reporting” (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this Quarterly Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. As mentioned above, the Company acquired four craft brands in connection with Craft Acquisition II on September 1, 2024. The Company is in the process of reviewing the internal control structure of those brands and their associated businesses and, if necessary, will make appropriate changes as it integrates them into the Company’s overall internal control over financial reporting process. ~~Additionally, beginning~~ ~~June 1, 2024, the Company fully integrated the initial Craft Acquisition entities into the Company’s overall internal control over financial reporting processes.~~

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

In the ordinary course of business, we are at times subject to various legal proceedings and disputes, including the proceedings specifically discussed below. We assess our liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that we will incur a loss and the amount of the loss can be reasonably estimated, we record a liability in our consolidated financial statements. These legal reserves may be increased or decreased to reflect any relevant developments on a quarterly basis. Where a loss is not probable or the amount of loss is not estimable, we do not accrue legal reserves. While the outcome of legal proceedings is inherently uncertain, based on information currently available, our management believes that it has established appropriate legal reserves. Any liabilities arising from pending legal proceedings are not expected to have a material adverse effect on our consolidated financial position, consolidated results of operations, or consolidated cash flows. However, it is possible that the ultimate resolution of these matters, if unfavorable, may be material to our consolidated financial position, consolidated results of operations, or consolidated cash flows.

“Item 3. Legal Proceedings” of our Annual Report on Form 10-K for the fiscal year ended May 31, ~~2024~~2025 includes a discussion of our legal proceedings. There have been no material changes from the legal proceedings described in our Form 10-K, ~~except with respect to the matters~~ as disclosed and incorporated herein by reference to Note 19 (Commitments and contingencies), ~~in the Notes~~ to the Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.

Item 1A. Risk Factors.

“Item 1A. Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended May 31, ~~2024~~2025 includes a discussion of our known material risk factors, other than risks that could apply to any issuer or offering. A summary of our risk factors is included below. Except for the below risk factors, there have been no material changes from the risk factors described in our Form 10-K.

● We may not achieve the expected revenue or other benefits from the craft beer operations we acquired in fiscal years 2024 and 2025.

● We may experience difficulties integrating operations and realizing the expected benefits of recent acquisitions, including the ~~HEXO arrangement and the~~ Craft brands acquisitions.

● ~~Additional~~Our ~~impairments~~cannabis ofbusiness ~~our~~is ~~goodwill,~~dependent ~~impairments~~upon ofregulatory ~~our~~approvals ~~intangible~~ and ~~other~~licenses, ~~long-lived~~ongoing ~~assets,~~compliance and ~~changes~~reporting inobligations, ~~the~~and ~~estimated~~timely ~~useful lives of intangible assets could have a material adverse impact on our financial results~~renewals.

● ~~Our~~Government ~~business~~regulation is ~~dependent~~evolving, ~~upon~~including potential regulatory ~~approvals~~developments ~~and~~in ~~licenses~~the United States to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act or revise the current federal framework under the 2018 Farm Bill for hemp-derived cannabis, ~~ongoing~~including ~~compliance~~Delta-9. In addition, we are subject to potential modifications to existing regulatory frameworks outside of North America, as well as uncertainties and ~~reporting~~potential ~~obligations~~delays in receiving required export/import permits in Europe and Australia. Any unfavorable changes to or lack of commercial legalization, or extended delays in receipt of required permits, could negatively impact our businesses and ~~timely~~the ~~renewals~~potential planned expansion of our business.

● ~~Government~~We ~~regulation~~face isintense ~~evolving~~competition, ~~and~~including ~~unfavorable~~from ~~changes~~the orillicit ~~lack~~cannabis ofmarket, ~~commercial~~and ~~legalization~~anticipate ~~could~~competition ~~impact~~will ~~our~~increase, ~~ability~~which tocould ~~carry~~hurt on our business ~~as currently conducted and the potential expansion of our business~~.

●

Our production and processing facilities are integral to our business and adverse changes or developments affecting our facilities may have an adverse impact on our business.

● We face intense competition, and anticipate competition will increase, which could hurt our business.

●

Regulations constrain our ability to market and distribute our products in Canada.

● United States regulations relating to hemp-derived CBD products, ~~including~~ Delta -9 ~~beverages~~products, and medical cannabis products are new and rapidly evolving, and changes may not develop in the timeframe or manner most favorable to our business objectives.

● Changes in consumer preferences or public attitudes about alcohol could decrease demand for our beverage ~~alcohol~~ products.

● SweetWater ~~Brewing~~, Breckenridge ~~Distillery~~, Montauk ~~Brewing~~ and our recently-acquired craft beer brands each face substantial competition in the beer industry or the broader market for ~~alcoholic~~ beverage products, which could impact our business and financial results.

● We have a limited operating history and a history of net losses, and we may not achieve or maintain profitability in the future.

●

We are subject to litigation, arbitration and demands, which could result in significant liability and costs, and impact our resources and reputation.

●

Our business may be materially adversely affected by the imposition of duties and tariffs and other trade barriers and retaliatory countermeasures implemented by the U.S. and other governments.

●

Additional impairments of our goodwill and impairments of our long-lived assets could have a material adverse impact on our financial results.

●

We have a limited operating history and a history of net losses, and we may not achieve or maintain profitability in the future

●

Our strategic alliances and other third-party business relationships may not achieve the intended beneficial impact and expose us to risks.

●

We may not be able to successfully identify and execute future acquisitions, dispositions or other equity transactions or to successfully manage the impacts of such transactions on our operations.

●

We are subject to risks inherent in an agricultural business, including the risk of crop failure.

● We depend on ~~significant~~recurring customers for a substantial portion of our revenue. If we fail to retain or expand our customer relationships or ~~significant~~these customers reduce their purchases, our revenue could decline significantly.

●

Our products may be subject to recalls for a variety of reasons, which could require us to expend significant management and capital resources.

●

Significant interruptions in our access to certain supply chains for key inputs such as raw materials, supplies, electricity, water and other utilities may impair our operations.

●

Management may not be able to successfully establish and maintain effective internal controls over financial reporting.

● ~~The~~There ~~price~~is ofuncertainty ~~our~~regarding ~~Common~~the ~~Stock~~impact inof ~~public~~our ~~markets~~implementation ~~has~~of ~~experienced~~a ~~and~~reverse ~~may~~stock ~~continue to experience severe volatility and fluctuations~~split.

●

The price of our common stock in public markets has experienced and may continue to experience severe volatility and fluctuations.

●

The volatility of our stock and the stockholder base may hinder or prevent us from engaging in beneficial corporate initiatives.

● The terms of our outstanding warrants may limit our ability to raise additional equity capital or pursue acquisitions, which may impact funding of our ongoing operations and cause significant dilution to existing stockholders.

●

We may not have the ability to raise the funds necessary to settle conversions of the convertible securities in cash or to repurchase the convertible securities upon a fundamental change.

●

Our cryptocurrency strategy faces high risk and uncertainty in light of market volatility and an evolving regulatory landscape.

●

We are subject to other risks generally applicable to our industry and the conduct of our business.

The Company’s business may be materially adversely affected by the imposition of duties and tariffs and other trade barriers and retaliatory countermeasures implemented by the U.S. and other governments.

Recently there have been significant changes to U.S. trade policies, sanctions, legislation, treaties and tariffs, including, but not limited to, trade policies and tariffs affecting products from outside of the U.S. For example, in early 2025, the current U.S. presidential administration announced significant new tariffs on foreign imports into the U.S., specifically from Mexico and Canada, and has proposed additional new tariffs that may be implemented in the future. The extent and duration of increased tariffs and the resulting impact on general economic conditions and on our business are uncertain and depend on various factors, such as negotiations between the U.S. and affected countries, the responses of other countries or regions, exemptions or exclusions that may be granted, availability and cost of alternative sources of supply, and demand for our products in affected markets. Any new or additional tariffs on goods imported to the U.S. from Mexico, Canada, or other countries, or products imported into the European Union or other non-U.S. markets, could also increase the cost of some of our products and reduce our margins. In response to the tariffs, the Company may seek to increase prices to its customers, which may diminish demand for its products. The imposition of additional tariffs or other trade barriers could increase our costs in certain markets and may cause our customers to find alternative sourcing or could make it more difficult for us to sell our products in some markets. Other countries where we operate or sell our products have changed, and may continue to change, their own policies on trade as well as business and foreign investment in their respective countries. Additionally, it is possible that U.S. policy changes and uncertainty about such changes could increase market volatility and currency exchange rate fluctuations. As a result of these dynamics, we cannot predict the impact to our business of any future changes to the U.S.’s or other countries’ trading relationships or the impact of new laws or regulations adopted by the U.S. or other countries.

Our failure to meet the continued listing requirements of Nasdaq could result in a delisting of our securities.

On March 25, 2025, the Company received written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Select Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The Notice does not impact the listing of the Company’s common stock on The Nasdaq Global Select Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of ten consecutive business days before September 21, 2025. In the event that the Company does not regain compliance within this 180-day period, the Company may be eligible to transfer from the Nasdaq Global Select Market to the Nasdaq Capital Market and seek an additional compliance period of 180 calendar days if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and provides written notice to Nasdaq of its intent to cure the deficiency during this second compliance period by effecting a reverse stock split if necessary. However, if it appears to the Nasdaq staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice to the Company that its common stock will be subject to delisting. The Company is actively monitoring the closing bid price of its common stock and evaluating available options to regain compliance with the minimum bid price requirement. There can be no assurance that the Company will regain compliance with Nasdaq’s minimum bid price requirements.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Recent Sales of Unregistered Equity Securities

~~Between~~On ~~January~~June 2816, 2025 ~~and February 28~~, ~~2025,~~the ~~Tilray~~Company issued an aggregate of 2712,~~136~~591,~~770~~816 shares of the Company’s ~~common~~Common ~~stock~~Stock, in exchange for $265.60 million ~~aggregate~~ principal amount of the Company’s 5.20% Convertible Senior Notes due June 1, 2027 ~~(the “Exchange Transactions”)~~. The shares of Common Stock issued in the Exchange Transactions were issued without registration under the Securities Act, as amended, in reliance on the exemption provided by Section 3(a)(9) of the Securities Act as securities exchanged by the Company with an existing security holder where no commission or other remuneration was paid or given directly or indirectly for soliciting such exchange.

The shares of Common Stock issued in the foregoing transaction were issued without registration under the Securities Act of 1933, as amended, in reliance on the exemption provided by Section 3(a)(9) thereunder as securities exchanged by the Company with an existing security holder where no commission or other remuneration was paid or given directly or indirectly for soliciting such exchange.

Item 3. Defaults Upon Senior Securities.

Not applicable.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

On ~~February~~October 217, 2025, ~~Aphria~~the ~~Diamond~~Company ~~Inc~~entered into Amendment No. 1 (the “~~Borrower~~Amendment”), ato ~~majority-owned~~the ~~subsidiary~~Employment ~~of Tilray~~Agreement, ~~refinanced~~originally ~~its~~dated July ~~existing~~27, ~~term~~2021, ~~loan~~with byits ~~entering~~Chief ~~into~~Executive aOfficer, ~~new~~Irwin ~~Credit~~D. ~~Agreement~~Simon (the “~~Credit Agreement~~Executive”),. byThe ~~and~~Amendment ~~among~~modifies ~~Tilray~~certain ~~and~~compensation ~~certain~~benefit ~~other~~provisions. Effective ~~affiliates~~as of the ~~Borrower~~start ~~and~~of ~~Canadian~~the ~~Imperial~~Company’s ~~Bank~~Fiscal ofYear ~~Commerce~~2026, asthe ~~Lender~~Company ~~and~~will ~~Administrative~~pay ~~Agent (~~the ~~“Lender”~~Executive (i). ~~The Credit Agreement provides for term loans in~~ an ~~aggregate~~after-tax ~~principal~~ amount equal to ~~CAD~~ $535,000~~,000~~ ~~(the~~per ~~“Term~~month ~~Loans”). The~~for ~~Borrower~~participation ~~used~~in ~~CAD~~all ~~$48,171,221~~employee ofretirement ~~the~~and ~~proceeds~~welfare ~~from~~benefit ~~the~~plans ~~Credit~~and ~~Agreement~~(ii) toan ~~repay~~additional in$500 ~~full~~per ~~all~~month ~~outstanding~~as ~~obligations~~a ~~under~~car ~~that~~allowance. The ~~certain~~foregoing ~~Amended~~summary ~~and~~does ~~Restated~~not ~~Credit~~purport ~~Agreement,~~to ~~dated~~be ascomplete ~~of November~~and ~~28,~~is ~~2022,~~qualified in its entirety by ~~and~~reference ~~among~~to the ~~Borrower,~~full ~~Bank~~text of ~~Montreal~~the Amendment, aswhich ~~agent,~~is ~~and~~filed aas ~~syndicate~~Exhibit of10.2 to ~~lenders~~this ~~(the~~Quarterly ~~“Prior~~Report ~~Credit~~on ~~Agreement”)~~Form 10-Q.

On ~~March~~October 259, 2025, ~~the~~Tilray ~~Company~~entered ~~received~~into ~~written~~an ~~notice~~assignment ~~(the~~and ~~“Notice”)~~assumption ~~from~~agreement ~~the~~with Double ~~Nasdaq~~Diamond Holdings ~~Listing~~Ltd. ~~Qualifications Department of the Nasdaq Stock Market, LLC~~ (“~~Nasdaq~~DDH”), ~~notifying~~an ~~the~~Ontario ~~Company~~corporation, ~~that~~pursuant itto iswhich, ~~not~~among inother ~~compliance~~things, ~~with~~Tilray ~~the~~acquired ~~minimum~~from ~~bid~~DDH ~~price~~a ~~requirement~~promissory ~~set~~note ~~forth~~ in ~~Nasdaq~~the ~~Listing~~amount ~~Rule~~of ~~5450~~$14,821,356 (athe “Note”)~~(1)~~ ~~for~~payable ~~continued~~by ~~listing~~Aphria onDiamond ~~The Nasdaq Global Select Market~~Inc. ~~Nasdaq Listing Rule 5450~~(a“Aphria Diamond”)~~(1)~~. ~~requires~~DDH ~~listed~~is ~~securities to maintain~~ a ~~minimum~~joint ~~bid~~venturer ~~price~~with ofAphria $1Inc.00 ~~per~~(Tilray’s ~~share,~~wholly-owned ~~and Listing Rule 5810(c~~subsidiary)~~(3)(A)~~ ~~provides~~in ~~that~~Aphria aDiamond. ~~failure~~As toconsideration ~~meet~~for the ~~minimum~~Note, ~~bid~~Tilray ~~price~~issued ~~requirement~~8,617,068 ~~exists~~shares ~~if the deficiency continues for a period~~ of 30its ~~consecutive~~Common ~~business~~Stock ~~days.~~to ~~The Notice does not impact the listing of the Company~~DDH. DDH’s ~~common~~management ~~stock~~team onprovides ~~The~~a ~~Nasdaq~~range ~~Global~~of ~~Select~~additional ~~Market~~services atto ~~this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A),~~ the Company ~~has~~at ~~180~~no ~~calendar~~incremental ~~days~~cost. toThese ~~regain~~additional ~~compliance~~services ~~with~~include ~~the~~expert ~~minimum~~advice ~~bid~~on ~~price~~maximizing ~~requirement.~~vegetable Tocultivation ~~regain~~and ~~compliance,~~cannabis ~~the~~yields for ~~closing bid price of~~ the Company’s ~~common~~Quebec ~~stock~~cultivation ~~must~~facility; bemaximizing atcultivation ~~least~~yields ~~$1.00 per share~~ for athe ~~minimum~~Company’s ofCayuga ~~ten~~outdoor ~~consecutive business days before September 21, 2025.~~grow ~~The~~facility; ~~Company is actively monitoring the closing bid price of its common stock~~ and ~~evaluating~~cannabis ~~available~~cultivation ~~options~~insights tofor ~~regain compliance with~~ the ~~minimum~~Company’s ~~bid~~facility ~~price~~in ~~requirement~~Cantanhede, Portugal.

The consideration shares were issued to DDH in reliance on the exemption provided by Regulation S (“Regulation S”) of the Securities Act of 1933, as amended (the “Securities Act”), which permits offers or sales of securities by Tilray outside of the United States that are not made to “U.S. Persons” or for the account or benefit of a “U.S. Person”, as that term is defined in Rule 902 of Regulation S. No underwriter participated in the offer and sale of the consideration shares, and no commission or other remuneration was paid or given directly or indirectly in connection therewith.

Item 6. Exhibits.

Exhibit Number		Description
3.1		Credit Agreement, dated February 21, 2025, by and among Aphria Diamond Inc., Canadian Imperial Bank of Commerce and the other parties thereto (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on February 26, 2025).
10.1		Fifth Amendment to Credit Agreement, dated as of July 25, 2025, by and among American Beverage Crafts Group, Inc., Bank of America, N.A. and the other parties thereto (incorporated by reference to Exhibit 10.20 to the Current Report on Form 10-K filed with the U.S. Securities and Exchange Commission on July 28, 2025).
10.2*		Amendment No. 1 to Employment Agreement, dated as of October 7, 2025, by and between the Company and Irwin D. Simon.
10.3*		Promissory note in the amount of $14,821,356, made by Aphria Diamond Inc. in favor of Double Diamond Holdings Ltd.
31.1*		Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*		Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Exhibit Number		Description
32.2**		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101*		The following financial statements from the Company's Quarterly Report on Form 10-Q for the quarter ended ~~February~~August 2831, 2025, formatted in Inline XBRL: (i) Consolidated Statements of Financial Position, (ii) Consolidated Statements of Loss and Comprehensive Loss , (iii) Consolidated Statements of Stockholders' Equity, (iv) Consolidated Statements of Cash Flows, and (v) Notes to Condensed Interim Consolidated Financial Statements, tagged as blocks of text and including detailed tags.
104*		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

* Filed herewith.

** Furnished herewith.

† Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Tilray Brands, Inc.
Date: April 8, 2025	By:	/s/ Irwin D. Simon
Date: October 9, 2025	By:	/s/ Irwin D. Simon
		Irwin D. Simon
		Chairman and Chief Executive Officer
Date: April 8, 2025	By:	/s/ Carl Merton
Date: October 9, 2025	By:	/s/ Carl Merton
		Carl Merton
		Chief Financial Officer

Filing Compare · Tilray Brands, Inc.